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Malaria remains a huge public health concern, affecting millions of people from all around 
the world. The widespread resistance by Plasmodium parasites to previously effective 
quinoline-based drugs and the emerging resistance to current antimalarial therapies, stresses 
the urgent need for the exploration and development of diverse new classes of compounds. 
Amongst other requirements, these diverse new compound classes should target resistant 
strains in particular. In this regard, benzimidazoles have been identified as promising potential 
drug candidates, displaying potent antiplasmodial activity. Furthermore, benzimidazoles can 
be chemically transformed into metal-containing organometallic complexes that elevate 
generally flat benzimidazoles to the third dimension. To date, examples of metal-containing 
benzimidazoles are extremely limited, with only two reported as having antiplasmodial 
activity. Thus, we report the syntheses of a series of substituted 2-phenylbenzimidazole 
ligands, from the cyclo-condensation of o-phenylenediamines and benzaldehyde, as well as 
the synthesis of Ru(II) and Ir(III) cyclometallated benzimidazole complexes. All of the 
compounds synthesised were fully characterised by 1H and 13C{1H} Nuclear Magnetic 
Resonance (NMR) Spectroscopy, Elemental Analysis and Mass Spectrometry.  
The synthesised 2-phenylbenzimidazoles and metal complexes were screened in vitro against 
the chloroquine-sensitive NF54 strain and selected complexes were screened against the 
chloroquine-resistant K1 strain of P. falciparum. In addition, selected compounds were also 
tested against the Chinese Hamster Ovarian (CHO) mammalian cell-line to evaluate their 
selectivity. 
The 2-phenylbenzimidazoles generally displayed weak to moderate antiplasmodial activity 
against the chloroquine-sensitive NF54 strain, where IC50 values ranged from  
3.27 – 32.97 µM. Furthermore, it was demonstrated that the antiplasmodial activities of the 
2-phenylbenzimidazoles increased significantly upon metal complexation, using Ru and Ir 
metals. In general, the antiplasmodial activity of the Ru(II) complexes were significantly better 
compared to the Ir(III) complexes. The cyclometallated benzimidazole complexes were much 
more active across both parasite strains (0.12 < IC50 < 4.31), compared to the corresponding 
ligands tested. The unsubstituted Ru(II) and Ir(III) cyclometallated benzimidazole complexes 





displaying IC50 values of 0.12 and 0.19 µM, respectively. In most cases, the resistance indices 
obtained for the select compounds tested were significantly lower compared to chloroquine, 
which suggested that the compounds are not cross-resistant with chloroquine. Furthermore, 
cytotoxicity studies indicated that the synthesised compounds had low cytotoxicity and were 
selective towards the malaria parasites. Additional studies which involved testing the 
aqueous solubility of selected compounds in PBS buffer at pH 6.5 showed that the 
introduction of water-solubilising groups improved the compounds solubility significantly. 
Preliminary mechanistic studies suggested that the synthesised benzimidazoles may have a 
different mode of action to chloroquine as the compounds did not inhibit β-haematin 
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1          Chapter 1: Introduction 
Chapter 1: Introduction 
 
1.1 Malaria 
1.1.1 History and Prevalence 
Malaria is a mosquito-borne infectious disease caused by parasitic protozoa of the genus 
Plasmodium. Five different Plasmodium species have been identified to infect humans, 
namely; Plasmodium falciparum (P. falciparum), P. vivax, P. ovale, P. malariae and  
P. knowlesi.1, 2 The most severe and fatal of the five species is P. falciparum, which constitutes 
close to 90% of all reported malaria cases. Malaria remains infamous as one of the top three 
killers among communicable diseases. It is largely prevalent in the tropical areas of 
sub-Saharan Africa, Southeast Asia and Latin America (Figure 1.1), where conditions are ideal 
for mosquitos to survive and multiply.3, 4  
 
Figure 1.1: Global distribution of malaria cases.3 
In 2016, the World Health Organisation (WHO) estimated 216 million cases of malaria; and a 
resultant 445 000 deaths of which are mostly pregnant women and children under the age of 
five.5 Despite the general decrease, in mortality and morbidity rates associated with malaria 
(in recent years), malaria continues to negatively impact developing countries both socially 
and economically.5, 6   
The term malaria was first derived from the Italian term mala’aria which translates to bad air, 
due to its early association with swamps and marshes. Throughout recorded history it has 
been one of the major health problems faced by humanity, in fact reference to this disease 
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documentation on malaria, scientists only began to understand this disease towards the end 
of the 19th century. The discovery that the cause of malaria is a protozoan was first made in 
1880 by Nobel Prize winner, Charles Louis Alphonse Laveran.8 Later, in 1897, Ronald Ross, a 
British officer in the Indian Medical Service, discovered that transmission of malaria was 
caused by mosquitos. The complete parasite life cycle was also established by Ronald Ross, 
who later in 1902 was also awarded a Nobel Prize.9, 10 
 
1.1.2 Biology of the disease 
The severity associated with malaria is a result of the complex molecular and cellular events 
that take place during the parasite’s life cycle (Figure 1.2). It is necessary to look at the life 
cycle of the parasite in order to understand some of the current antimalarial chemotherapies. 
The parasite’s life cycle is dependent on two hosts: a vector host and human host for sexual 
reproduction and asexual reproduction, respectively, which are essential for the parasite to 
survive and propagate.11  
 
Figure 1.2: Life cycle of the malaria parasite.12 
Unicellular parasites called sporozoites are found in the salivary glands of an infected female 
Anopheles mosquito. When a human is bitten by an infected mosquito, saliva containing these 
sporozoites are injected into the bloodstream of the human host. The exo-erythrocytic stage 
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the parasite may either stay dormant as hypnozoites causing relapses weeks or months later 
particularly in malaria caused by P. vivax; or they may multiply and mature into schizonts. 
Mature schizonts eventually rupture, releasing tens of thousands of merozoites per liver cell, 
back into the host’s bloodstream. The intra-erythrocytic stage begins once the merozoites 
invade the red blood cells and develop into ring forms and trophozoites, which later mature 
into schizonts. The red blood cells then rupture, resulting in merozoites and toxins being 
released into the bloodstream. At this point, clinical symptoms of malaria such as fever, 
headache, chills, diarrhoea and anaemia transpire. The merozoites released may then invade 
more red blood cells or a small portion may develop into male and female gametocytes. 
Further transmission of the parasite results when the infected host is bitten by an uninfected 
female Anopheles mosquito. Sexual reproduction occurs within the mosquito when the male 
and female gametocytes fuse and develop into ookinetes which then migrate into the midgut 
of the mosquito. In the external midgut, formation and maturation of oocysts occur. 
Rupturing of these mature oocysts results in the release of thousands of sporozoites, which 
migrate to the mosquito’s salivary glands, recommencing the cycle.11, 13 
 
1.1.3 Prevention and Treatment  
Owing to the complex nature of the multiple stages of the parasite’s lifecycle, the 
implementation of several preventative and chemotherapeutic strategies is required in order 
to control and eliminate malaria.  
Since there is no effective vaccination available, a first-line approach is to reduce the number 
of infectious mosquitos by vector control. Vector control may be achieved through the use of 
insecticide-treated nets (ITNs) or indoor residual spraying (IRS).14 The WHO recently reported 
a decrease in the number of malaria cases between 2001 and 2015, is largely a result of 
malaria control interventions such as ITNs and IRS.15 This strategy, however, has been 
hampered due to the widespread development of resistance to insecticides by the malaria 
parasite.5   
Chemotherapy has historically played a key role in controlling and treating malaria. Over 
many years, several families of antimalarial drugs, which aim to target the lifecycle and 
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erythrocytic/liver stage is the first site where replication of the parasite occurs, it is an ideal 
stage for drugs to target. However, during the exo-erythrocytic stage, no malaria-like 
symptoms are evident. Consequently, treatment during this stage is understandably 
challenging, as patients are often unaware that they are infected. The intra-
erythrocytic/blood stage of the lifecycle, where symptoms are evident, is therefore the main 
target site of many antimalarial drugs. A general strategy in the development of antimalarial 
drugs involves the identification of important biological pathways that are either specific to 
the parasite or that have sufficient differences from the host. Major organelles involved in 
parasite growth and survival include: the parasite food vacuole, apicoplast and 
mitochondrion, all of which are considered to be prime targets for potential antimalarial 
drugs.11 The design and synthesis of an antimalarial drug which targets all stages of the 
parasite’s life cycle is in fact key for the elimination and eradication of this disease. 
 
It is for this reason that an international consortium sequenced the complete genome of   
P. falciparum.17 Subsequent proteomic studies based on the sequenced genome are now 
providing researchers with new potential drug and vaccine targets and also providing a better 
understanding of the parasites sophisticated molecular and cellular biology as well as its 
biochemistry.18, 19 The field of proteomics has also proved to be valuable with respect to 
investigations into the mechanism(s) of action of current and new antiplasmodial drugs.20, 21 
 
1.1.4 Quinoline and non-quinoline based antimalarial drugs 
Over many years, significant strides have been made regarding the development of 
antimalarial drugs, which are currently being used. Despite current trends in drug discovery, 
most of the currently used antimalarial drugs were in fact developed from natural products. 
Examples of such compounds include, but are not limited to, quinine and artemisinin.  
 
Quinine, a major alkaloid of the Cinchona plant and initially used by natives in South America 
to reduce fever, was first isolated in 1820.22 Later, through systematic modification of quinine, 
an array of quinoline antimalarial drugs with diverse substitutions around the quinoline ring 
were discovered. Chloroquine, a synthetic 4-aminoquinoline, was first chemically synthesised 
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chloroquine was due to it being cheap, very effective, and of relatively low toxicity.11, 24, 25 In 
most parts of the world however, chloroquine and some of its derivatives shown in Figure 1.3, 
have now become virtually ineffective due to the increase in resistant parasites.25 
            
     Quinine                                  Chloroquine                                      Mefloquine 
         
Amodiaquine                                                                      Piperaquine 
Figure 1.3: Selected quinoline-based antimalarial drugs 
By understanding the mechanism of drug action and the process associated with resistance, 
it becomes possible to unveil biological details that will lead to circumvention of drug 
resistance. The mechanism of action of quinoline-based antimalarial drugs has been well 
documented.23, 26 There is a general consensus that chloroquine along with, quinine, 
amodiaquine and mefloquine, inhibit haemozoin formation, a detoxification process specific 
to the parasite which occurs during the intra-erythrocytic stage of the parasites lifecycle.27 
Haemozoin is an insoluble material produced by the parasite. It has been reported that the 
survival of the parasite is dependent on its ability to form haemozoin. Formation of 
haemozoin prevents oxygen radical-mediated damage to the parasite. Thus, an attractive 
approach in drug development is to inhibit haemozoin formation or its synthetic counter-part, 
β-haematin. The quinoline methanols (quinine), 4-aminoquinolines (chloroquine, 
amodiaquine, and piperaquine) and the aryl alcohols (mefloquine) all form part of a group of 
drugs which are able to prevent the conversion of haematin (ferriprotoporphyrin IX) to 
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stacking of their planar aromatic groups.28 It is widely accepted that the site of action of 
chloroquine is within the acidic food vacuole of the malaria parasite, where haemoglobin is 
actively degraded by the parasite.29 Chloroquine diffuses across the vacuolar membrane 
against a pH-gradient, as a neutral species. However, once inside the food vacuole, 
protonation of the nitrogen atoms occur, preventing the resultant species from crossing the 
membrane again. This then leads to the accumulation of chloroquine within the food vacuole. 
The accumulated chloroquine may then form a complex with haematin via π-π stacking with 
the porphyrin ring system, resulting in further accumulation of the drug.30 The accumulation 
of toxic haematin and chloroquine-haematin adducts inevitably leads to parasite death and 
erythrocyte lysis, due to the inhibition of haemozoin formation and key enzymes.30 
Artemisinin, a sesquiterpene lactone containing an endoperoxide bridge, was first isolated in 
1970 from the Chinese plant, Artemisia annua. In 1983, the first complete chemical synthesis 
of artemisinin was reported.31 However, it was thought to be too expensive for commercial 
pharmaceutical production. Semi-synthetic artemisinin derivatives, artemether, artesunate 
and dihydroartemisinin were developed soon after the discovery of artemisinin. Artemisinin-
based drugs have been reported to be active against the asexual (exo-erythrocytic and intra-
erythrocytic) stages inside the host and the sexual stage (targeting gametocytes).31 
        
                    Artemisinin                           Artemether                                  Artesunate      
 
Dihydroartemisinin 
Figure 1.4: Artemisinin and derivatives 
The site and mechanism of action of artemisinins remain unclear. However, structure-activity 
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essential for antimalarial activity.31 It is reported that the endoperoxide bridge generates 
oxidative stress.31, 32 Oxidative stress is induced by reactive oxygen species (ROS). The 
generation of oxidative stress can trigger programmed cell death as a result of ROS causing 
irreparable damage to cell structures such as DNA, lipids and proteins. It has been reported 
that the Plasmodium parasite possesses internal defence mechanisms against ROS.33 
However, cell damage may occur if a given drug is able to sufficiently increase cellular 
oxidative potential, resulting in the parasites internal defence mechanisms being 
incapacitated.33 Artemisinin-based drugs may therefore act by impairing parasite redox 
homeostasis. There are many other proposed ACT drug targets, some of which include a 
PfATP6 enzyme, the P. falciparum ortholog of mammalian sarcoendoplasmic reticulum 
Ca21-ATPases (SERCAs), translational controlled tumor protein, and haem.21, 34 
Although artemisinin-based drugs are known to act faster than any other currently available 
antimalarial, the fact that artemisinins have a short half-life is of concern as there is increased 
risk of recrudescence or resistance. Thus, the current recommended treatment for malaria is 
artemisinin-based combination therapy (ACTs), which involves the use of a combination of 
artemisinin derivatives with other antimalarial drugs, possessing a longer half-life. The most 
frequently used ACTs are: artemether-lumefantrine, artesunate-amodiaquine, artesunate-
mefloquine and dihydroartemisin-piperaquine.32 
 
1.1.5 Challenges in treating malaria 
The rise in resistance against current antimalarial drugs is of notable concern. Over the last 
60 years, the parasite has managed to develop resistance to antimalarial drugs at a pace that 
exceeds the rate at which new antimalarial drugs were and are being developed. By definition, 
drug resistance occurs when the parasite is able to survive, and even multiply, despite the 
administration of a drug in doses, which are equal to or higher than the usual recommended 
dose, but are within the limits of tolerance of the subject.35 Resistance occurs generally 
through spontaneous mutations. In some cases, resistance may occur due to a single 
mutation, whereas in other cases, multiple mutations are required to lead to drug resistance.  
In recent years, our understanding of molecular mechanisms associated with drug resistance 
in P. falciparum has advanced substantially. For instance, polymorphisms in a gene called the 
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susceptibility to quinoline and quinoline-like antimalarial drugs.36 Pfcrt is localised at the 
membrane of the parasite’s acidic food vacuole and when this gene undergoes a key 
mutational change, key interactions with protonated quinoline antimalarials, that ensures 
their concentration in the food vacuole is maintained, are lost. This results in the drugs leaking 
out of the parasites digestive vacuole, thus rendering these drugs virtually ineffective.37, 38 
Resistance of P. falciparum to chloroquine has been reported as a gradual process. The 
emergence of chloroquine resistance was first reported in 1957, at the Thai-Cambodian 
border.39 Later, in 1960, chloroquine-resistant strains were reported in Venezuela and 
Colombia and in 1976 in Papua New Guinea. Finally, in 1978, chloroquine resistance emerged 
in Africa and by 1983 cases of chloroquine resistance was reported in Sudan, Uganda, Zambia 
and Malawi.35 Resistance to mefloquine (including other chloroquine derivatives) and 
alternative drugs introduced to treat chloroquine resistant strains, developed in some cases 
relatively rapidly over recent years. Decreased sensitivity of P. falciparum to artemisinins 
were recently reported in Southeast Asia, causing great alarm as ACTs are currently the most 
effective antimalarial treatment.34, 35 These reports of decreased efficacy and the known 
emergence of resistance to current drugs drive the need to develop new antimalarials which 
are effective against resistant strains.  
A possible solution to overcoming drug resistance may be to explore pharmacophores such 
as benzimidazoles for instance, which are structurally different to that of antimalarials 
currently in use.  
New drugs, however, are not so simple to develop. A general challenge often faced when a 
lead compound has been developed is that it rarely passes Phase I clinical trials, due to poor 
physicochemical/pharmacokinetic properties. It is therefore necessary that physicochemical 
properties be optimised as early as possible in the drug design and development process. 
A promising drug candidate should have a good ADMET profile, in order for it to be an efficient 
and effective drug. ADMET is an abbreviation for absorption, distribution, metabolism, 
excretion and toxicity. Solubility is often the first step in drug absorption processes. In fact, 
this physicochemical parameter is often linked to metabolism and bioavailability.40 There has 
been numerous reports of potential drug candidates having failed drug development phases 
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screening (HTS) systems has led to a change in the profile of many compound libraries. These 
compound libraries include compounds of higher hydrophobicity and higher molecular 
weights, resulting in a profile of lower solubility. Thus, improving the aqueous solubility of a 
compound continues to be a major and common issue in medicinal chemistry.41 
There are many strategies which can be employed in order to improve solubility. A classical 
approach is to introduce water solubilising groups into a molecule, such as, sulfones, 
sulfoxides, hydroxyls, tetrazoles or trifluoromethanes. Le Manach and co-workers recently 
reported several strategies which could improve aqueous solubility;42 replacement of phenyl 
rings with pyridyl rings was aimed at reducing lipophilicity and introduction of water-
solubilising H-bonding groups such as hydroxyl containing amides and piperazine sulfones 
resulted in an improvement in solubility. A significant increase in solubility was also observed 
upon replacement of a sulfone group with a sulfoxide.42 An alternative approach for 
improving aqueous solubility is by the disruption of molecular planarity and symmetry. 
Disruption of molecular planarity and symmetry may be achieved through the removal of 
aromaticity, the increase of dihedral angle, substitution of benzylic positions or the twisting 




The imidazole nucleus (Figure 1.5, a) is present in a number of important biological building 
blocks, such as histidine, histamine and purine. Benzimidazole (Figure 1.5, b), also known as 
benziminazole and 1,3-benzodiazole, is a benzo-fused derivative of imidazole and is well-
established in literature as an important biologically active nitrogen heterocycle.43, 44 
                                    
                                                        a                                                          b 
Figure 1.5: a) Imidazole and b) Benzimidazole 
Over many years, this compound class has become known to medicinal chemists as a 
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activities.43 Interest in benzimidazole chemistry however, was initiated, in the 1950s, by the 
discovery that the 5,6-dimethylbenzimidazole moiety is an integral component of vitamin 
B12.45 Since then, numerous efforts have been made in order to produce libraries of these 
compounds. In fact, the synthesis of many other drugs and anthelmitics such as albendazole, 
mebendazole and thiabendazole was a result of the optimisation of substituents around the 
benzimidazole nucleus.46 
 
In 1872, the very first benzimidazole (2,5 or 2,6-dimethylbenzimdiazole) was synthesised by 
Hobrecker, through the reduction of 2-nitro-4-methylacetanilide.47 Ladenburg later obtained 
the same compound by refluxing 2,4-diamino toluene with acetic acid.48 In very early 
literature, these compounds were called ‘anhydrobases’ due to their synthesis involving the 
loss of water.45 In the past years, several synthetic methods involving the synthesis of 
benzimidazoles have been developed. However, the most classical and common method of 
synthesising benzimidazoles involves the cyclo-condensation of o-phenylenediamine with 
aldehydes, carboxylic acids or their derivatives (nitriles, amidates, orthoesters), under harsh 
conditions, using strong acids such as hydrochloric acid, polyphosphoric acid (PPA) or 
p-toluenesulfonic acid (Scheme 1.1). By using milder reagents, for example Lewis acids, both 
the yield and purity of the reaction can be improved.49, 50 
 
 
Scheme 1.1: General scheme for the synthesis of benzimidazole, where R = Alkyl/Aryl; R’= OH, H, 
CN, NH2, OR’’ or OCO2R. Reagent: i) strong acids/ mild reagents/ oxidative reagent/ different 
catalyst. 
The synthesis of benzimidazoles via the abovementioned method, requires an oxidative 
reagent to generate the benzimidazole nucleus. Various oxidative reagents previously 
employed, include; nitrobenzene, benzoquinone, sodium metabisulfite, mercuric oxide, lead 
tetraacetate, iodine, copper(II) acetate, indium perfluorooctane sulfonates, ytterbium 
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1.2.2 Antiparasitic activity 
The benzimidazole scaffold is undoubtedly a useful structural motif, which may be used for 
the development of molecules with both pharmaceutical and biological interest. Several 
compounds recently synthesised, containing the benzimidazole moiety, have been reported 
to display interesting biological activity as antitumor agents, antiretrovirals and 
antimalarials.44, 51-53 
The first of many compounds containing the benzimidazole moiety, and displaying lethal 
parasitic effects in man, was mebendazole, a benzimidazole carbamate derivative (Figure 
1.6a).54, 55 There are now more than twenty benzimidazole derivatives currently available and 
used as anthelmintic drugs, examples include; albendazole (Figure 1.6b) and thiabendazole 
(Figure 1.6c). In 2011, Sawant and Kawade reported the synthesis and biological evaluation 
of 2-phenylbenzimidazole-1-acetamide derivatives for anthelmintic activity.56 In comparison 
to albendazole (the standard), compound d (Figure 1.6d) was the most potent with regard to 
paralysing and killing helminths.56 This SAR study also concluded that substitution of R with 
an electron-withdrawing polar group, increased the potency of the compound significantly.56 
        
a                                                                                   b 
                                                          
                                             c                                                                                  d 
Figure 1.6: Anthelmintic compounds, a) mebendazole, b) albendazole, c) thiabendazole and d) 
2-phenylbenzimidazole-1-acetamide derivative, where R= NO2 and R’= Et. 
 
A library of pyrido[1,2- a]benzimidazoles were recently synthesised and screened for 
antimalarial properties, by Ndakala et al.51 They report the synthesis of a pyrido[1,2- 
a]benzimidazole compound (Figure 1.7a), which exhibited antiplasmodial activity comparable 
to that of chloroquine (IC50 = 0.17 – 0.20 μM) in the chloroquine-sensitive NF54 strain.51 More 
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previously reported by Ndakala et al.57 They concluded that a key factor to improving in vitro 
activity against P. falciparum is through substitution on the benzimidazole phenyl. 
Furthermore, the synthesised compounds displayed significantly better in vivo activity in the 
mouse P. berghei model and against gametocytes.57 
                
                                      a                                                                              b 
Figure 1.7: a) Anti-malarial pyrido[1,2-a]benzimidazole (IC50: PfNF54= 0.11 μM; PfK1= 0.12 μM) 
and b) Astemizole. 
 
Roman et al. reported on the screening of a library of existing drugs, for inhibitors of   
P. falciparum.58 This screen led to the identification of astemizole, a drug that inhibits the 
proliferation of three parasite strains, which differ in chloroquine sensitivity. Astemizole 
(Figure 1.7b) contains a benzimidazole scaffold and is known as a non-sedating, selective 
H1-histamine receptor antagonist.58 They concluded that the benzimidazole core is an 
essential structural prerequisite for the exhibition of antiplasmodial activity. The substitution 
of various groups at positions 1 and 2 proved to have significant effects on their 
antiplasmodial activity. Replacement of the fluoro- group of astemizole with a trifluoromethyl 
group resulted in the antiplasmodial activity surpassing that of astemizole.58 
The above-mentioned selected examples of compounds containing the benzimidazole 
scaffold, confirms that this pharmacophore is worthy of further exploration. 
 
1.2.3 Proposed mode(s) of action of benzimidazole drugs 
Several benzimidazole containing compounds have been prepared and demonstrated 
significant antimalarial activity. However, the modes of action of these benzimidazole 
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Recently, a series of piperazine-based compounds were synthesised and upon linkage to a 
benzimidazole core (Figure 1.8), the compound displayed a chloroquine-like mechanism, 
concerning accumulation in the acidic food vacuole and inhibition of β-haematin formation.59 
 
Figure 1.8: A compound containing the benzimidazole core, displaying a chloroquine-like 
mechanism 
 
In addition, Saify et al. recently reported the synthesis of benzimidazole-acetophenone 
compounds, whereby various substitutions were made on the acetophenone ring.60 These 
compounds displayed antiplasmodial activity and proved to be plasmepsin inhibitors   
(Figure 1.9a).60 Plasmepsins are aspartic acid proteases which are produced by the   
P. falciparum parasite. There are ten plasmepsins which have been identified in the genome 
of P. falciparum. Four of these plasmepsins (plasmepsin-I, plasmepsin-II, plasmepsin-III and 
plasmepsin-IV/HAP) have been identified to participate in haemoglobin degradation.61 Ligand 
docking studies with plasmepsin-II, carried out by Saify et al., predicted binding of the 
benzimidazole compounds at the centre of the extended substrate-binding cleft.60  
 
Another known target site for antimalarial drugs, is the Plasmodium mitochondrial electron 
transport chain (ETC), which is believed to contain five hydrogenases; namely NADH: 
ubiquinone oxidoreductase (PfNDH2), succinate: ubiquinone oxidoreductase, glycerol-3-
phosphate dehydrogenase, the malate quinone oxidoreductase (MQO) and dihydroorotate 
dehydrogenase (DHODH).62 Although the function of these dehydrogenases to the ETC is not 
completely understood, PfNDH2 and MQO were identified as dehydrogenases, specific to the 
parasites mitochondria. The molecular structure of the parasites DHODH were also found to 
be different to that of the human homolog and it is said to be involved in de novo pyrimidine 
biosynthesis, which is an essential source of energy for the parasites survival.62, 63 It is for this 
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In 2011, Skerlj et al. reported on the synthesis and SAR studies of a series of  
5-(2-methylbenzimidazol-1-yl)-N-alkylthiophene-2-carboxamides.64 These benzimidazole 
derivatives were found to be potent inhibitors against DHODH of the P. falciparum parasite 
and displayed good activity against the P. falciparum 3D7 strain (Figure 1.9b).64 Later in 2015, 
Abdullah et al. also reported on the synthesis of benzimidazole analogues displaying 
inhibitory effects against DHODH.65 
                
                                           a                                                                            b 
Figure 1.9: a) Plasmepsin inhibitor b) DHODH inhibitor 
 
From literature, organic compounds containing the benzimidazole moiety clearly display 
multifaceted modes of action in the malaria parasite. Multiple modes of action coupled to the 
incorporation of chemical/structural diversity, may provide new drug leads and aid in 
combating resistance. In this regard, investigation of metal-based benzimidazoles is of 
interest.  
 
1.3 Metals in Medicine 
1.3.1 Metal-based drugs 
Despite the field of bioinorganic chemistry being relatively new, there is now a significant 
number of metal-based drugs currently in clinical trials. It is well-known that transition metals 
play essential roles in biological and biomedical processes.66 Consequently, there are many 
cases in medicine, where organic compounds do not have a purely organic mode of action. 
The activation or biotransformation of these organic compounds are often reliant on metal 
ions. Through the synthesis of metal coordination complexes, biological and chemical 
diversity, which is distinct from that of organic drugs, can be achieved. Synthetic diversity is 




15          Chapter 1: Introduction 
the ligands to which the metals are coordinated, as well as from the different coordination 
geometries of the metal.66, 67 In addition, organometallic species are relatively lipophilic 
compared to purely organic compounds and are capable of binding to biological targets.68 
Organometallic compounds are therefore considered as promising alternatives in medicinal 
chemistry.  
One of the first examples of a metallodrug used in medicine was Salvarsan, an arsenic-based 
antimicrobial agent, which was developed in 1912 by Paul Ehrlich.69 Preceding World War II, 
Salvarsan was known as the standard drug for the treatment of syphilis, after which it was 
replaced by penicillin.70 For many years the structure of Salvarsan was debatable. Salvarsan 
was assumed to have an As=As double bond (as shown in Figure 1.10a). However, it was 
recently discovered through extensive mass spectral analysis that salvarsan consists of single 
As-As bonds. Salvarsan was also found to consist of a mixture of cyclic species (Figure 1.10b 
and 1.10c).71 
 
                      a                                                   b                                                            c 
Figure 1.10: a) Initial proposed structure of Salvarsan. b) and c) cyclic species as models for 
Salvarsan 
  
The discovery of Salvarsan is often regarded as the beginning of modern chemotherapy and 
the development of metallodrugs. However, the serendipitous discovery of the anticancer 
drug cisplatin in 1965, led to a huge surge of interest in the field of bioinorganic medicinal 
chemistry.72 Platinum-based drugs; cisplatin, carboplatin and oxaliplatin (Figure 1.11), have 
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                                a                                               b                                                    c  
Figure 1.11: Platinum anticancer therapy agents: a) cisplatin, b) carboplatin and c) oxaliplatin 
 
Despite the success of these platinum-based drugs as anticancer agents, their use is often 
accompanied by undesirable side effects such as neurotoxicity. Other limitations of these 
traditional platinum-based drugs include; sensitivity to mechanisms of resistance, their 
inactivation by small biomolecules such as glutathione and efflux out of the cell.68 A wide 
range of transition-metal drug candidates are therefore currently under consideration for 
future development in order to overcome these limitations. 
 
A transition metal that has recently received immense attention is ruthenium. The synthesis 
of ruthenium-based drugs allows for access of various oxidation states [Ru(II), Ru(III) and 
Ru(IV)]. These ruthenium complexes are generally lower in toxicity, which may be due to their 
ability to mimic iron.68 Although no commercially available ruthenium-based drugs currently 
exist, ruthenium compounds have recently provided promising alternatives to platinum-
based drugs. As a result of the increase in research efforts in this field, two ruthenium 
coordination complexes (Figure 1.12) have reached clinical trials for cancer chemotherapy, 
namely; NAMI-A (developed by Alessio, Mestroni, Sava, and co-workers) and KP1019 
(developed by Keppler and co-workers).73-75 
 
          
                                              a                                                                        b 
Figure 1.12: Ruthenium anticancer therapy agents: a) NAMI-A and b) KP1019 
 
More recently the transition metals, iridium and rhodium, have provided fascinating 
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were initially regarded as chemically inert, it was discovered that upon complexation to a 
suitable auxiliary ligand, the reactivity and biological activity may be unlocked.76 The use of 
arene ligands such as pentamethylcyclopentadienyl (Cp*) for example has been reported to 
aid in stabilisation of the Ir(III) or Rh(III) metal center.76  
  
During the last decade, the synthesis and anticancer activity of Ru(II), Os(II), Ir(III) and Rh(III) 
arene complexes have been well-documented.77-80 The success of metallodrugs in cancer 
chemotherapy has therefore spurred further research interest in the use of coordination 
complexes in other areas such as anti-inflammatories, antifungal and antimalarial agents.81 
 
1.3.2 Metalloantimalarials 
The design and development of many metalloantimalarial compounds have been encouraged 
through the successful synthesis of a vast array of metal compounds displaying antitumor, 
antiarthritic and antibacterial properties. It has been reported that metal compounds show 
pronounced selectivity for selected biomolecules of parasites compared to that of the 
host’s.82  
The successful modification of chloroquine with metal-containing fragments has led to the 
development of other metalloantimalarials. RhCl(COD)CQ, a compound synthesised by 
Sanchez-Delgado et al., was one of the first organometallic complexes which was evaluated 
as an antiplasmodial agent.83 Sanchez-Delgado et al, also reported on the synthesis and 
antimalarial evaluation of ruthenium(II) chloroquine [RuCQCl2]2 and gold(I) chloroquine 
[Au(PPh3)CQ]PF6 (Figure 1.13). These metal complexes were found to be active against   
P. berghei and against chloroquine-resistant FcB1 and FcB2 P. falciparum strains. The authors 
concluded that the ruthenium complexes exhibited in vitro and in vivo activity against the 
rodent strain P. berghei and a 94% reduction of parasitaemia was observed.83 Coordination 
of ruthenium and gold significantly enhanced the activity of the parent drug, suggesting that 
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                                             a                                                                            b 
Figure 1.13: a) [RuCQCl2]2 and b) [Au(PPh3)CQ]PF6 
 
In addition, ferroquine, a successful metallodrug, has demonstrated excellent activity against 
malarial parasites, both in vitro and in vivo. Ferroquine is classified as a 4-aminoquinoline 
which contains a quinoline nucleus and a ferrocenyl group in its side chain. Excellent activity 
against chloroquine-resistant strains has also been displayed by this metalloantimalarial.82, 85  
 
Figure 1.14: Bioorganometallic drug candidate, ferroquine, under phase II clinical trials 
 
Following the success of ferroquine, several other analogues were synthesised. SAR studies 
revealed that the ferrocene moiety does not show any efficacy on its own. But when this 
moiety was covalently linked to the 4-aminoquinoline and the alkyl amine moieties, the 
potency of chloroquine was enhanced.86 On the other hand, Smith and co-workers have 
reported on the synthesis and anti-parasitic activity of a series of chelating (N,S-) cationic 
Ru(II)-arene complexes based on thiosemicarbazone scaffolds.87 The antiplasmodial activity 
of the p-cymene Ru(II) thiosemicarbazone complexes were significantly higher compared to 
the free thiosemicarbazone ligands.87 
These findings further provide data in support of the now proven hypothesis that 
incorporation of a transition metal onto a known pharmacophore may be a useful strategy in 
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1.4 Transition-metal based benzimidazoles 
Despite many reports on metal-based benzimidazoles displaying good anticancer activity, 
there is currently, very little research on transition-metal based benzimidazoles which display 
antimalarial activity. According to a recent literature search, there are only two known 
examples of metal-based benzimidazoles which have been synthesised and evaluated for 
antiplasmodial activity.88, 89 
Copper(II) nanohybrid solids [LCu(CH3COO)2 and LCuCl2] were recently synthesised using 
bis(benzimidazole)diamide as the capping ligand. The Cu(II) coordination complexes displayed 
antiplasmodial activity comparable to chloroquine, where IC50 values ranged from 0.048 – 
0.059 µM against the P. falciparum chloroquine-sensitive (MRC 2) strain.88  
More recently, a study which involved the conjugation of ferrocene and rhenium to a 
benzimidazole scaffold and the antimalarial evaluation showed promising results against the 
chloroquine-sensitive (3D7) and chloroquine-resistant (W2) strain.89 
                
a                                                                             b 
Figure 1.15: a) Cyrrhetrenyl and b) ferrocenyl benzimidazole complexes 
 
The cyrhetrenyl compound displayed better activity (IC50 = 10.4 – 26.5 μM) in both strains, 
compared to its ferrocenyl analogue (IC50 =23.9 – 48.0 μM). Increased antiplasmodial activity 
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1.5 Research Rationale and Motivation 
The increasing rise in resistant strains against antimalarial drugs, which has previously been 
known to be effective, remains a huge global concern. Thus, there is an urgent need to 
develop novel and effective anti-malarial drugs that are chemically and structurally diverse.  
 
Over the past decade, the field of bioorganometallic medicinal chemistry has provided 
promising alternatives to traditional organic drugs. There are many examples which 
demonstrate the advantages of using metals (such as PGMs) in drug design and development. 
For example, Ru(II) or Ir(III) metal complexes have been reported to display lower toxicity. In 
addition, the synthesis of a cyclometallated complex may aid in stabilising the metal complex 
and may introduce chemical diversity. Furthermore, enhanced activity is often observed upon 
metal complexation onto a particular pharmacophore. 
 
As already mentioned, the benzimidazole pharmacophore has been well-documented to 
display diverse biological activities. However, there is very little research on metal-based 
benzimidazoles and their antiplasmodial activity. This project therefore aims to 
explore/investigate SAR studies of cyclometallated Ru(II) and Ir(III) benzimidazole complexes 
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2. Aims and Objectives 
The aim of the project was to design and prepare a series of benzimidazole-based compounds 
for antiplasmodial evaluation. 
More specifically, the research project had two main points of focus; the first was to prepare 
a series of structurally related 2-phenylbenzimidazoles and to assess the effect of structural 
diversity on their activity as antiplasmodial agents. The second focus point was to investigate 
the effects of converting the purely organic 2-phenylbenzimidazoles to Ru and Ir 
cyclometallated complexes on activity. The specific objectives of this project are outlined 
below;     
(i) The synthesis and characterisation of 2-phenylbenzimidazole ligands; 
                  
 
(ii) The functionalisation of previously synthesised 2-phenylbenzimidazole with water-
solubilising H-bonding groups towards improving solubility; 
                  
 
 
(iii) The synthesis and characterisation of organometallic complexes containing 
platinum group metals (Ru and Ir) of the most active ligands;  
                                   
 
Where, R = H, F, Cl, CF3, CH3, OMe, SO2Me, CN, CONH2                         
R’ = CH3 or CH2CH2CH3 
 
Where, R is selected as the most active    
substituent 
 R’’=   
 
 
Where, M= Ru and Ln= p-cymene or 
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(iv) The antiplasmodial activity and cytotoxicity evaluation of all synthesised 
benzimidazole ligands and organometallic complexes; 
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Chapter 2: Synthesis and characterisation of 2-phenylbenzimidazole ligands 
and cyclometallated Ru(II)/Ir(III) benzimidazole complexes 
 
2.1. Introduction 
It is well-documented that minor structural changes, such as variation of substituents, of a 
potential drug candidate can significantly influence the overall efficacy of a compound.1, 2 
Therefore, one of the aims was to assess the effects of such changes on the 
2-phenylbenzimidazole core and investigate how these changes relate to the observed 
antimalarial activity. 2-Phenylbenzimidazoles were chosen specifically because of their known 
ability to readily form stable metal complexes through cyclometallation, which enabled an 
investigation into the effects of metal complexation on bioactivity. 
With regard to antimalarial drugs, several research articles have reported on the synthesis 
and promising antimalarial activity of various metals complexed to chloroquine.3-5 There is 
clear evidence, as demonstrated in these papers, that the introduction of a metal can be 
advantageous.3-5 Indeed, exploring the effect of metal complexation and whether or not it 
generally enhances the antiplasmodial activity of a molecule was one of the major driving 
forces for this research project. A summary of the proposed chemical modifications of the 
2-phenylbenzimidazole is outlined in Figure 2.1 below.  
 
 
Figure 2.1: Proposed SAR studies  
Several reports state that substitution at position-5 of the benzimidazole core results in 
enhanced antiplasmodial activity.6-8 The synthesis described in this chapter was thus aimed 
at producing a series of compounds, where the effects of varying the R substituent at 
Cyclometallation 
site SAR based on Craig-
plot substituents 
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position-5 of the benzimidazole moiety was investigated. Substituents were chosen based on 
the Craig Plot (Figure 2.2).  
 
Figure 2.2: The Craig Plot 
The Craig plot is often used in rational drug design, whereby variation of substituents allows 
for the probing of the electronics and steric effects of a compound. For example, often the 
size or bulkiness of a particular drug may influence its ability to approach and interact with a 
binding site. Bulky substituents may either hinder the drug from binding or may somehow aid 
in positioning the drug for maximum binding, thus increasing the activity of the drug. The 
Craig plot has a y- and x-axis. The y- and x- axis is represented by the σ- and π-constants, 
respectively. A positive π-constant indicates that the substituent is more hydrophobic, 
whereas a positive σ-constant indicates the substituent is electron-withdrawing.  
 
The Craig plot continuously informs drug-design in the sense that if groups in a particular 
quadrant are observed to have a positive effect on activity then subsequent design will 
involve making more compounds where R groups are chosen from the more active quadrant. 
The aim was therefore to efficiently and expediently synthesise compounds from the various 
quadrants. For this reason, a general synthetic sequence that would allow access to 
functionally diverse 2-phenylbenzimidazoles was considered. The sequence would 
incorporate the desired functional group (FG) by choosing an appropriate starting material 
and would then also have to tolerate and conserve different FG’s (electronically and sterically) 
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modification of the benzimidazole moiety, where the effect of the chain length could be 
investigated, where R’ (Figure 2.1) is either a methyl or propyl group. Additionally, the 
introduction of water-solubilising groups via R’, was also explored in order to evaluate the 
effects on aqueous solubility.  
 
In this chapter, the synthesis and characterisation of novel 2-phenylbenzimidazoles and 
cyclometallated Ru(II) and Ir(III) benzimidazole complexes are described. As already 
mentioned, the rationale for synthesising these benzimidazole-based compounds concerns 
the fact that the benzimidazole moiety is a known pharmacophore, highly cited in literature 
for displaying interesting biological activities.6, 9, 10 Furthermore, the concept of incorporating 
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2.2. Synthesis of 2-phenylbenzimidazoles and corresponding intermediates 
The synthesis of the N-methyl and N-propyl 2-phenylbenzimidazole ligands (35 – 50) involved 
three synthetic steps: 1) Nucleophilic aromatic substitution (SNAr) of methylamine or  
n-propylamine with either an ortho- substituted fluoro- or chloro- nitrobenzene, followed by 
2) the reduction of the nitro- moiety to the amine functionality, and lastly 3) a condensation 
cyclisation reaction to afford the desired benzimidazole ligand. The overall synthetic scheme 
is outlined below (Scheme 2.1) and the syntheses and characterisation of these compounds 
are described subsequently. 
 
                                                                  Where R’ = Me for (1 – 9)                                             18 – 34                                                                                              
                                                                                      R’ = Pr for (10 – 16)  
                                                                                      R’ = PrNH-Boc 17 
 
                                                                                                     35 – 50  
Scheme 2.1: Synthesis of intermediates and 2-phenylbenzimidazoles. Reagents and conditions: i) 
MeNH2/ DCM/ K2CO3/ rt or n-PrNH2/ DMF/ rt or N-Boc-1,3-propanediamine/ DMF/ rt; ii) Zn/ NH4Cl/ 
MeOH/ rt; iii) Benzaldehyde/ TFA/ MgSO4/ EtOH/ rt. 
 
There are several methods which describe the synthesis of benzimidazoles. However, the most 
common methodology involves the condensation of 1,2-diaminobenzenes with aromatic 
aldehydes.13, 14 Thus, the first step towards the synthesis of the 2-phenylbenzimidazole ligands 
involved forming a nitroaniline derivative, which could easily be reduced to the required 
1,2-diaminobenzene.  
 
2.2.1. Synthesis of nitroanilines (1 – 16)  
The synthesis of the N-methyl nitroaniline derivatives (1 – 9) and the N-propyl nitroaniline 
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n-propylamine was reacted with various substituted nitrobenzene compounds containing 
either a fluoro- or chloro- atom ortho- to the nitro- moiety (Scheme 2.2). 
 
                                                                                                                      1 – 16 
Scheme 2.2: Synthesis of nitroaniline compounds, where X = Cl or F; Where R’ = Me and R = H (1), 
Cl (2), OCH3 (3), CN (4), CH3 (5), CF3 (6), SO2CH3 (7), CONH2 (8), or F (9); Where R’ = Pr and R = H (10), 
Cl (11), CH3 (12), CN (13), SO2CH3 (14), OCH3 (15), CF3 (16). Reagents and conditions: i) MeNH2/ DMF/ 
rt or n-PrNH2/ DMF/ rt 
 
In most cases the reaction conditions for the synthesis of the nitroaniline compounds involved 
dissolving the nitrobenzene starting material in a polar aprotic solvent such as DMF, adding  
two equivalents of the desired amine and allowing the reaction to stir for 24 h at room 
temperature. However, in certain cases where compounds were previously reported, 
literature methods were followed. These methods varied in terms of solvent choice, reaction 
temperature and/or the addition of a base. 
A nucleophilic aromatic substitution reaction (SNAr) is described as a reaction, where the 
addition of a nucleophile to an aromatic ring, is followed by the elimination of a leaving group 
(Scheme 2.3). The alkyl amine, which acts as both nucleophile and base, attacks the aromatic 
carbon bearing the halogen, resulting in the formation of a negatively charged intermediate 
Meisenheimer complex. The Meisenheimer complex formed, is stabilised through resonance 
by the electron withdrawing nitro- group. Subsequent elimination of the halogen results in 
the production of the nitroaniline compound. The addition of two equivalents of alkyl amine 
is usually necessary as the second equivalent of amine acts as a base to neutralise the HCl or 
HF formed from the reaction. 
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In general, the synthesis of the nitroaniline compounds proceeded easily, as almost complete 
conversion of starting material was observed under mild reaction conditions. However, as 
expected the nitroaniline bearing the electron-donating methoxy substituent was found to 
be less reactive toward substitution than its EWG counterparts. As a result of this, the 
methoxy analogue was prepared in a sealed vessel at 100 ᵒC.  
Reaction progress was monitored by thin layer chromatography (TLC). In most cases after  
24 h, TLC analysis of the reaction revealed almost complete conversion of the starting material 
to a more polar product. However, the reaction time involving the synthesis of the methoxy 
analogue, was increased to 48 h, for reasons previously discussed. In general, purification of 
the nitroaniline compounds was achieved by either column chromatography or 
recrystallisation methods. In some cases, the product could not be purified by column 
chromatography, despite the optimisation of solvent ratios and flow rates. Consequently, the 
crude material was used and purified in the next step, as was the case for compounds 2 and 
11. The synthesised nitroaniline derivatives were generally isolated as either orange/yellow 
solids or oils in good to excellent yields (48 – 99%). 
 
Analysis of the 1H NMR spectra of compounds 1 – 16, supported the successful synthesis of 
these compounds. Evidence of substitution of the methylamine or n-propylamine group is 
given by the broad singlet, which appears in the aromatic region of the 1H NMR spectra and 
is assigned to the proton of the secondary amine, Hh. The appearance of a distinct doublet, 
with a J-value of 5.2 Hz, in the aliphatic region, integrating for three protons is assigned to the 
methyl of the methylamine. The resonance, Hg is observed as a doublet due to its coupling to 
the proton of the secondary amine, Hh. With respect to the synthesis of the nitroaniline 
compounds bearing a propyl chain, the appearance of three distinct signals observed as a 
triplet, multiplet and triplet, in the aliphatic region is assigned to the propyl chain and 
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Figure 2.3: 1H NMR spectra of nitroaniline compounds a) 3 and b) 4 in CDCl3. 
 
In the aromatic region of the 1H NMR spectra of the synthesised nitroaniline compounds, 
three distinct peaks are observed. The proton signal Hf, for the compound containing the 
electron-withdrawing nitrile group, is observed more downfield compared to the proton 
signal Hf of the electron-donating methoxy analogue (Figure 2.3). This clearly shows how the 
electronic effects influence the relative shifts of the aromatic protons. 
In all instances, the aromatic protons of the nitroanilines were observed as a doublet (Hf), 
doublet of doublets (Hd) and a doublet (Hc) except the fluoro- analogue, which gave a very 
interesting splitting pattern (Figure 2.4a). This is due to the protons coupling to the spin-active 
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Figure 2.4: a) 1H NMR spectrum of 9 in DMSO-d6 and b) 13C NMR spectrum of 9 in CDCl3. 
 
As a result of the 13C{1H} NMR spectra not being 19F decoupled, fluorine coupling can also be 
observed in the 1D 13C{1H} NMR. In the 13C{1H} NMR spectra of compound 9 (Figure 2.4b), 
three distinct doublets are observed. The doublets, observed at 124 and 111 ppm in the 
13C{1H} NMR spectrum, display J-values in the range of 23 – 26 Hz which is typical for that 
observed for a 2JCF coupling.  
 
The 13C{1H} NMR spectra of the nitroaniline compounds synthesised (1 – 16), generally show 
six signals in the aromatic region, of which three signals appear as relatively less intense 










2JCF = 23 Hz 
Ce Cb 
Ca 
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Furthermore, the ESI mass spectra of compounds 1 – 16 all displayed a molecular ion peak 
which corresponds to the base peak, further confirming that the desired compounds were 
obtained. 
 
2.2.2. Synthesis of 1,2-diamines (18 – 33) 
The synthesis of the 1,2-diamine compounds (18 – 33) involved the reduction of the nitro- 
group of previously prepared nitroanilines, to the amino moiety. The synthesis was achieved 
via a Zinc/ammonium chloride reduction, wherein the synthesised nitroaniline compounds 
were reacted with 10 equivalents of ammonium chloride and 20 equivalents of zinc dust  
(Scheme 2.4). TLC analysis indicated that the reaction was complete after 30 – 45 mins.  The 
diamines were then purified using column chromatography and, in general, isolated as dark 
brown oils or solids in good yields (34 – 98%).  
 
                                                                                                                    18 – 33 
Scheme 2.4: Synthesis of the 1,2-diamine compounds, Where R’ = Me and R = H (18), Cl (19), OCH3 
(20), CN (21), CH3 (22), CF3 (23), SO2CH3 (24), CONH2 (25), F (26); or Where R’ = Pr and R = H (27), Cl 
(28), CH3 (29), CN (30), SO2CH3 (31), OCH3 (32), CF3 (33). Reagents and conditions: i) Zn/ NH4Cl/ 
MeOH/ rt 
 
Compounds 18 – 33 were analysed by 1H NMR spectroscopy, which confirmed that the nitro- 
moiety was successfully reduced to the amine functionality. A representative example of the 
1H NMR spectrum of the reduced amine (compound 22) is shown in Figure 2.5b. The 1H NMR 
spectrum of 22 illustrates that upon reduction to the amine moiety, there is a general upfield 




37         Chapter 2: Synthesis and Characterisation 
 
Figure 2.5: 1H NMR spectrum of a) 5 and b) 22 in CDCl3. 
 
The signals for the aromatic proton resonances in the product spectrum appear to converge, 
which may be due to the aromatic protons experiencing similar electronic effects as expected 
from a 1,2-substituted benzenediamine. No significant change was observed in the aliphatic 
region of the product spectrum. However, the appearance of a broad singlet at 3.40 ppm, 
integrating for three protons are assigned to the primary and secondary amine protons of 22, 
thus confirming the presence of the primary arylamine. 
 
13C{1H} NMR spectroscopy was used to further corroborate the successful synthesis of the 
1,2-diamine compounds where the number of expected signals was observed in each 
spectrum. In the ESI mass spectra of 18 – 33, a molecular ion peak ([M]+) was generally 
observed, which corresponds to the base peak. Elemental analysis further confirmed the 
composition of the 1,2-diamine compounds as the data obtained was found to be consistent 
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2.2.3. Synthesis of 2-phenylbenzimidazoles (35 – 50) 
The synthesis of the 2-phenylbenzimidazole ligands (35 – 50) involved a cyclo-condensation 
reaction whereby the synthesised 1,2-diamines (18 – 33) were reacted with 1.2 equivalents 
of benzaldehyde and a catalytic amount of TFA (Scheme 2.5).  
 
                                                                                                                   35 – 50 
Scheme 2.5: Synthesis of the 2-phenylbenzimidazoles, Where R’ = Me and R = H (35), Cl (36), OCH3 
(37), CN (38), CH3 (39), CF3 (40), SO2CH3 (41), CONH2 (42), F (43); or Where R’ = Pr and R = H (44), Cl 
(45), CH3 (46), CN (47), SO2CH3 (48), OCH3 (49), CF3 (50). Reagents and conditions: i) Benzaldehyde/ 
TFA/ MgSO4/ EtOH/ rt. 
 
There are many research articles which describe the synthesis and biological evaluation of 
benzimidazoles.15, 16 However, the mechanism for the cyclo-condensation reaction by which 
benzimidazoles are formed from o-phenylenediamines is not well-described in literature. 
Insight into the mechanism of this reaction was provided by a recently reported article where 
the proposed mechanism involving the synthesis of 2-arylsubstituted benzimidazoles was 
reported.17 The reported mechanisms occur via a sequence of reactions and was catalysed 
using either ammonium acetate or tosylic acid.17, 18 The proposed mechanism for the cyclo-
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Scheme 2.6: Proposed mechanism for the cyclo-condensation reaction. 
 
Based on the reported mechanisms, the first step in this reaction is a nucleophilic addition 
promoted by acid catalysis. The secondary amine of the synthesised 1,2-diamine acts as the 
nucleophile and benzaldehyde acts as the electrophile. The addition of a catalytic amount of 
TFA is necessary for the protonation of benzaldehyde, resulting in an increase in the 
electrophilicity of benzaldehyde. 
 
The rate at which the aryl amines react is based on the basicity of the amine. It is well known 
that more substituted amines are generally more basic, for example, NEt3 (pKa = 10.8) is more 
basic compared to NH3 (pKa = 9.25), and since basicity and nucleophilicity generally follow 
the same trend, it is proposed that the secondary amine is more reactive towards the 
carbonyl. Furthermore, it is only addition of the secondary amine onto the carbonyl that 
results in the formation of the required iminium intermediate. In this way, the nucleophilic 
diamino complex condenses with the benzaldehyde to form a reactive iminium intermediate, 
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Finally, it is proposed in literature that the oxidation of the dihydrobenzimidazole precursor 
results in the formation of the benzimidazole moiety. It has been reported that oxidation can 
either be facilitated by an organocatalyst or via air.18 The mechanism described involves 
molecular oxygen reacting with the dihydrobenzimidazole to afford hydrogen peroxide and 
the oxidised benzimidazole. This is achieved through a single electron transfer (SET) 
mechanism where oxygen heterolytically abstracts the benzimidazole NH to form two radical 
products (N· and O·), which further react when the oxygen radical anion abstracts the second 
ring proton (C-2 of the ring) to form peroxide and the aromatised benzimidazole.19 Therefore, 
for the synthesis of the 2-phenylbenzimidazoles in this study, the reaction flask was left open 
to air. 
 
The reactions were monitored using TLC analysis. In general, TLC analysis indicated the 
consumption of starting material and the appearance of two new spots, one of which was 
slightly more polar than the starting material and the other relatively non-polar. After 24 h, 
there was no change in the distribution of the two spots with respect to a change in their 
relative intensities. The reaction was therefore stopped and column chromatography was 
used to isolate what was believed to be two separate products. The more non-polar product 
was isolated, albeit the 1H NMR spectrum obtained was too complicated to resolve and no 
further time was invested in elucidating the identity of the compound. The more polar and 
major product from the reaction was the 2-phenylbenzimidazole. The 
2-phenylbenzimidazoles (35 – 50) were all successfully isolated in good yields (37 – 69%) and 
characterised by spectroscopic techniques. 
 
The 1H NMR spectra of the 2-phenylbenzimidazole compounds (35 – 50) show the presence 
of additional peaks in the aromatic region, which integrate for five protons and are assigned 
to the protons of the phenyl ring. In total, there are eight protons in the aromatic region and 
the aromatic resonances appear more downfield, compared to the starting material. In 
addition, as observed in the Figure 2.6 for compound 36, the absence of the broad signal at 
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Figure 2.6: 1H NMR spectrum of 36 in CDCl3. 
 
The 13C{1H} NMR spectral data for compounds (35 – 50) further supports the formation of the 
benzimidazole ring. The number of signals observed in the 13C{1H} NMR spectra agrees with 
the number of carbon atoms present in the compounds. Infrared (IR) analysis of the  
2-phenylbenzimidazoles (35 – 50) was carried out by using attenuated total reflectance (ATR). 
In the IR spectra, a weak absorption band is observed between 1627 – 1595 cm-1, 
corresponding to the stretching frequency of the C=N bond. The appearance of the C=N 
stretch suggests that the benzimidazole ring was obtained due to the C=N stretch being 
absent in the starting material.  
 
ESI mass spectrometry data was obtained for the 2-phenylbenzimidazoles. Generally a base 
peak corresponding to either [M]+, [M-H]+ or [M+H]+ was observed, further supporting the 
integrity of the benzimidazole ligands. The 2-phenylbenzimidazole ligands were also analysed 
by elemental and LC-MS analyses. From the data obtained, it was found that the  
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2.2.4. Synthesis of 2-phenylbenzimidazoles functionalised with water-solubilising  
H-bonding groups (53 – 54) 
Prior to the synthesis of compounds 53 and 54, results from the biological evaluation of the 
substituted N-methyl and N-propyl 2-phenylbenzimidazoles (35 – 50), later discussed in 
Chapter 3 (vide infra), provided a criteria for the choice of a methyl group as the R substituent 
and the propyl chain as the preferred linker. 
The synthesis of the benzimidazole ligands containing the water-solubilising groups, involved 
five synthetic steps (Scheme 2.7). The first three steps were carried out using the same 
synthetic procedures as described previously in section 2.2.3, for the synthesis of the  
2-phenylbenzimidazole ligands containing either a methyl or propyl chain. The fourth step 
involved deprotection of the terminal amine and then finally, from the synthesised 
benzimidazole bearing the free amine (52), the synthesis of the sulfonamide (53), involved a 
SNAc reaction and the synthesis of 54 involved a basic SN2 reaction. 
 
                                                                   17                                                                            34 
 
                                                                       51                                                                        52 
 
Scheme 2.7: Synthesis of the benzimidazole ligands functionalised with water solubilising H-
bonding groups. Reagents and conditions: i) 1.1 eq. N-Boc-1,3-propanediamine/ DMF/ rt/ 24 h ii) 
Zn/ NH4Cl/ MeOH/ rt/ 30 min iii) benzaldehyde/ TFA/ MgSO4/ EtOH/ rt/ 24 h iv) TFA/ DCM/ rt/ 2 h 
v) Compound 53: MsCl/ NEt3/ DCM/ 2 h/ 0 ᵒC. Compound 54: 4-(chloroacetyl)morpholine/ K2CO3/ 
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Preceding the synthesis of the nitroaniline compound 17, N-Boc-1,3-propanediamine was 
firstly synthesised by the addition of one equivalent of Boc anhydride in 90 mL CHCl3 to an 
excess amount of 1,3-diaminopropane (60 equivalents). The 1H NMR spectrum of the product 
confirmed that only one of the primary amines were selectively protected. Successful 
synthesis of this precursor was further supported by similar shifts observed in the 1H NMR 
spectrum of the same compound previously reported in literature.20 
The synthesis of 17 involved the reaction of 1-fluoro-2-nitrotoluene with the synthesised Boc-
protected diamine. The reaction was monitored using TLC analysis, which revealed the 
formation of a more polar product. A base was not added to the reaction and despite the 
formation of HF in the reaction, the 1H NMR spectrum indicated that the Boc functionality 
was still intact.  
 
Figure 2.7: 1H NMR spectrum of 17 in DMSO-d6. 
 
Figure 2.7 displays the 1H NMR spectrum of 17. The two broad singlets in the aromatic region 
are assigned to the two secondary amines (Hg and Hk). Due to the electron-withdrawing nitro- 
group, the proton representing the amine directly attached to the aromatic ring appears to 
be more deshielded. The singlet at 1.38 ppm integrates for a total of nine protons and is 
representative of the t-butyl group. The two peaks at 3.36 and 3.03 ppm are assigned to the 
methylene protons adjacent to the secondary amines. These peaks appear as distinct quartets 
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As previously discussed, it is evident from the 1H NMR spectrum (Figure 2.8b) that the nitro- 
group was successfully reduced to the amine moiety. Upon reduction of the nitro- moiety, 
the aromatic protons shifted upfield and seem to converge due to the effects of the 
1,2-diamine substituted ring. The introduction of a broad singlet at 4.38 ppm, integrating for 
two protons, further confirmed the presence of a primary amine. Successful cyclisation of 34 
is evidenced by the observed resonances in the aromatic region of the 1H NMR spectrum of 
51 (Figure 2.8c), which integrate for a total of eight protons. The absence of the two broad 
singlets assigned to the primary amine and secondary amine directly attached to the ring 
further confirms the successful synthesis of the benzimidazole ring.  
 
Figure 2.8: 1H NMR spectra of a) 17, b) 34, c) 51 and d) 52 in DMSO-d6. 
 
Deprotection of the Boc group was obtained by reacting 52 with an excess amount of TFA. 
After 2 h, TLC analysis showed the consumption of starting material and the formation of a 
new more polar product spot. The product was isolated as a light brown oil in excellent yield 
(97%). The 1H NMR spectrum (Figure 2.8d) confirmed that the deprotection was successful. 
The distinct singlet assigned to the t-butyl group initially observed at 1.38 ppm, was no longer 
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compound 52, where a base peak at m/z 265.0131 corresponding to the molecular weight of 
the compound, was observed. 
 
The synthesis of the benzimidazole containing the sulfonamide group involved a SNAc reaction 
where the synthesised benzimidazole functionalised with a free amine (52) was reacted with 
one equivalent of methanesulfonyl chloride and 1.1 equivalents of triethylamine in DCM 
(Scheme 2.8).  
 
Scheme 2.8: Synthesis of 53. Reagents and conditions: i) MsCl/ NEt3/ DCM/ 2 h/ 0 ᵒC. 
 
After 24 h, TLC analysis indicated the formation of a new product. However, isolation of the 
product formed proved to be challenging due to the solubility of the product. After the crude 
material was washed with ammonium chloride and extracted with EtOAc, there was still 
product present in the aqueous layer. The aqueous layers were then collected and reduced 
in vacuo. The crude residue was then purified using column chromatography to afford the 
desired compound as a light brown oil in very poor yield (6%). 
 
In the 1H NMR spectrum (Figure 2.9), a sharp singlet is observed at 2.79 ppm which integrates 
for three protons. This key peak confirmed the successful substitution of the methyl sulfonyl 
moiety onto the 2-phenylbenzimidazole ligand. A broad singlet is also observed at 4.18 ppm 
which is assigned to the secondary amine of the sulfonamide. Further support that the 
sulfonamide was obtained is given by LC-MS data, which showed a molecular ion peak of m/z 




46         Chapter 2: Synthesis and Characterisation 
 
Figure 2.9: 1H NMR spectrum of 53 in CDCl3. 
 
The synthesis of 54 involved an N-alkylation of the benzimidazole ligand (52) bearing the free 
amine moiety with 4-(chloroacetyl)morpholine (Scheme 2.9). Compound 52 was dissolved in 
acetonitrile, thereafter 1.05 equivalents of K2CO3 and 4-(chloroacetyl)morpholine was added 
to the reaction flask at 0 ᵒC. Upon addition of 4-(chloroacetyl)morpholine, the reaction 
mixture turned cloudy. After 4 h, the reaction was allowed to warm to rt.  
 
Scheme 2.9: Synthesis of 54. Reagents and conditions: i) 4-(chloroacetyl)morpholine/ K2CO3/ 
MeCN/ 4 h/ 0 ᵒC. 
 
TLC analysis using a solvent system of 1:9 MeOH:EtOAc, showed the formation of two new 
product spots. The crude material was then purified using column chromatography. 
Unfortunately, only one of the products were isolated due to the other product being very 
polar. A light brown oil was obtained in moderate yield (38%). 
 
In the 1H NMR spectrum of 54 (Figure 2.10), there is evidence to suggest that the desired 
product was not obtained. In fact, the spectrum suggests the formation of a benzimidazole 
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observed between 3.42 and 3.61 ppm and integrate for a total of sixteen protons. A sharp 
singlet is also observed at 3.36 ppm and integrates for four protons.  
 
Figure 2.10: 1H NMR spectrum of 54 in CDCl3. 
 
Further proof of the formation of this unexpected product can be observed from LC-MS, 
where a molecular ion peak is observed and corresponds to the base peak. The antiplasmodial 
activity and solubility of the isolated compound was also evaluated since it was still much 





















48         Chapter 2: Synthesis and Characterisation 
3.2. Synthesis of Ru(II) and Ir(III) cyclometallated benzimidazole complexes (55 – 68)  
The cyclometallation of the selected 2-phenylbenzimidazole ligands was achieved via sodium 
acetate mediated C-H activation (Scheme 2.10). The synthesis of these complexes was 
conducted as follows: 
 
                                                                                                                             55 – 68  
Scheme 2.10: Synthesis of the cyclometallated benzimidazole complexes, where M = Ru, Ln = 
p-cymene and R’ = Me; R = H (55), Cl (56), CH3 (57), CF3 (58), SO2CH3 (59) or where M = Ir and Ln = 
Cp* and R’ = Me; R = H (60). Where M = Ru, Ln = p-cymene and R’ = Pr; R = H (61), Cl (62), CH3 (63), 
CF3 (64) or where M = Ir and Ln = Cp* and R’ = Pr; R = H (65), Cl (66), CH3 (67), CF3 (68). Reagents and 
conditions: i) Metal dimer/ NaOAc/ DCM/ rt. 
 
Selected substituted 2-phenylbenzimidazole ligands were dissolved in DCM and  
1.2 equivalents of NaOAc added to the reaction flask. After 10 min of stirring,  
0.5 equivalents of either dichloro(p-cymene)ruthenium(II) dimer or 
pentamethylcyclopentadienyliridium(III) dimer was added to the reaction flask. The 
dichloro(p-cymene)ruthenium(II) dimer and pentamethylcyclopentadienyliridium(III) dimer 
were previously synthesised and used without further purification.21, 22 
 
Generally, the synthesis of cyclometallated complexes is achieved via intramolecular C-H 
activation in the presence of a suitable base. To activate the C-H bond, harsh reaction 
conditions and a strong base are typically required.23, 24 However, the discovery made by the 
Davies group in 2003, has led to a new efficient method for C-H activation.25 The reported 
method involved the cyclometallation of nitrogen donor ligands (amines, imines and 
oxazolines) with [MCl2Cp*]2 (M = Ir/Rh) or [RuCl2-(p-cymene)]2, which occurred at room 
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Although the detailed mechanism and the role(s) of the acetate is not clear, experimental and 
theoretical studies conducted by Davies et al., have resulted in the identification of key 
intermediates. A vacant site is needed for C-H activation to occur. It is therefore proposed 
that initially the loss of an anion (Cl-) is necessary.25 Density functional theory calculations 
performed by Davies et al. on the cyclometallation of dimethylbenzylamine with [Pd(OAc)2], 
suggested that the reaction proceeds via an agostic C-H complex, where the acetate was 
found to stabilise the agostic intermediate through hydrogen bonding.26 A low-energy 
pathway was also proposed, which involved intramolecular H-bonding to the acetate 




Figure 2.11: Proposed transition state of C-H activation mechanism resulting in the formation of a 
cyclometallated complex, where Ln = p-cymene or Cp* 
 
The proposed pathway in literature was reported to occur via a single, low-energy six-
membered transition state, involving the proximal acetate arm being displaced by the 
incoming C-H bond. The H is transferred to the dissociated acetate arm and the acetate is 
coordinated through the carbonyl oxygen.27 
 
The synthesis of the Ru(II) and Ir(III) cyclometallated benzimidazole complexes (55 – 68) did 
not require any harsh reaction conditions. The ruthenium and iridium complexes were 
isolated as green or yellow solids in good to excellent yields (41 – 98%) and were stable at 
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Analysis of the 1H NMR spectra of the metal complexes (55 – 68), confirmed the successful 
synthesis of the cyclometallated complexes. The 1H NMR spectrum of the N-methyl (methyl 
substituted) Ru benzimidazole complex 57 (Figure 2.12b) is shown below.  As a result of metal 
coordination onto the phenyl ring, the aromatic signals which previously integrated for eight 
protons, now integrate for a total of seven protons. In addition, the resonances in the 
aromatic region of the 1H NMR spectrum of the metal complex appear to be more distinct 
compared to the aromatic resonances observed in the 1H NMR spectrum of the benzimidazole 
ligand (Figure 2.12a).  
 
 
Figure 2.12: 1H NMR spectra of a) benzimidazole ligand 39 and b) N-methyl (methyl) Ru 
benzimidazole complex 57 in DMSO-d6. 
 
From the 1H NMR spectra of the ruthenium complexes, four separate doublets between  
6.02 – 5.29 ppm, a multiplet at 2.15 ppm, a singlet at 1.96 ppm and two doublets between 
0.82 and 0.72 ppm, are also observed (Figure 2.12b). These resonances correspond to the  
p-cymene ligand and further confirmed the formation of the ruthenium complex. Due to the 
a) 
b) 









51         Chapter 2: Synthesis and Characterisation 
p-cymene ligand now having less freedom of rotation, the aromatic protons of the p-cymene 
moiety appear as four separate doublets (Ht, Hu, Hv, Hw) as opposed to two doublets observed 
in the free metal-dimer. Similarly, the methyl protons of the isopropyl group appear as two 
distinct doublets (Hq and Hr), due to the chirality induced by the metal centre. 
 
In the 1H NMR spectrum of the N-propyl (methyl substituted) Ru cyclometallated 
benzimidazole complex (63), two distinct peaks are observed at 4.45 and 4.31 ppm. These 
two peaks are assigned to the methylene protons adjacent to the tertiary amine. HSQC further 
confirmed that the two proton signals are assigned to one carbon peak. The change from an 
apparent triplet before complexation to two distinct signals is likely due to the methylene 
protons being diasterotopic, as a result of the stereogenic centre created through metal 
complexation. 
 
Figure 2.13: 1H NMR spectrum of N-propyl (methyl) Ru benzimidazole complex 63 in CDCl3. 
 
The 1H NMR spectrum of 62 confirmed that metal complexation was also successful. 
However, a second set of mirroring signals of relatively low intensity were observed. This was 
of concern due to the need to obtain a pure complex for biological testing. These peaks each 
integrated for 0.10 relative to the major signals. Interestingly, the observed peaks did not 
correspond to starting material (unreacted metal dimer or ligand).   
Splitting observed for H-n in the 
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The doubling of signals is generally a result of either the presence of diastereomers or 
conformational isomers (rotamers).28 Since the metal centre only contains one static 
stereogenic element, the possibility of diastereomers, which require the presence of more 
than one stereogenic element, was ruled out and thus suggested that rotamers may exist. 1H 
NMR spectroscopy was therefore performed at a higher temperature of 80 ᵒC, the peaks 
which initially integrated for 0.10 integrated for 0.01 thereafter. This phenomenon provides 
evidence that in solution, rotamers do exist. The presence of rotamers may be due to the 
rotation of the p-cymene ligand about the metal-ligand bond.  
 
Figure 2.14: 1H NMR spectrum of 62 in DMSO-d6, where a) expanded region at rt and b) at 80 ᵒC 
 
13C{1H} NMR spectroscopy was also used to confirm that complexation had been successful. 
The aromatic carbon resonances for the p-cymene ligand is observed between 75 – 90 ppm 
and 2D NMR techniques such as HSQC and COSY, were used to confirm the assignments 
made. 
The structures of the Ir(III) cyclometallated complexes were also confirmed by spectroscopic 
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benzimidazole complexes (Figure 2.15), the absence of one aromatic proton, relative to the 
benzimidazole starting material, supports metal complexation. Additionally, the appearance 
of a singlet at 1.76 ppm, which integrates for fifteen protons is assigned to the Cp* ligand and 
further confirmed that the metal is coordinated and that the Ir complexes were successfully 
synthesised. 
 
Figure 2.15: 1H NMR spectrum of 67 in CDCl3 
 
In the 13C{1H} NMR spectra of the Ir(III) complexes, a distinct peak assigned to the methyl 
substituents on the Cp* moiety is observed at approximately 9.00 ppm. 2D NMR spectroscopy 
was used to confirm the assignments made.   
In addition to 1H and 13C{1H} NMR spectroscopy, infrared (IR) spectroscopy is also a useful 
technique used to substantiate successful metal complexation. IR spectroscopy data was 
obtained for metal complexes 55 – 68. In the IR spectra of the complexes, a weak absorption 
band was observed around 1586 – 1577 cm-1, which was assigned to the imine (C=N) 
stretching frequencies. In the IR spectra (Figure 2.16), the imine stretch for the ligand is 
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Figure 2.16: Infrared spectra of the ligand 50 (dark blue) and complex 68 (light blue). 
 
A frequency shift of the imine absorption band observed for the corresponding 
benzimidazoles to lower frequencies often confirms coordination of the metal centre to the 
imine nitrogen. This phenomenon is explained by the synergistic effect that take place on 
coordination of the metal, where there is sigma donation from the benzimidazole nitrogen 
and subsequent back-donation of electron density from the metal (Figure 2.17). This effect 
results in the strengthening of the M-N bond and subsequent weakening of the C=N bond. 
Thus, the decrease in the wavenumber of the C=N band in the infrared spectrum is due to the 
weakening of the C=N bond. 
 
 
Figure 2.17: Schematic representation of the TM-N=C orbital interactions in the cyclometallated 
benzimidazole complexes. C=N → TM 𝜎- donation (top) and TM → N=C 𝜋- back-donation (bottom) 
All Ru(II) and Ir(III) complexes were analysed using high resolution ESI mass spectrometry, 
which further supported the successful synthesis of the cyclometallated benzimidazole 
complexes. In general, the mass spectrum of the complexes show base peaks which 
correspond to the molecular ion without the chloride ion, [M-Cl]+. Elemental analysis of all 
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Single crystal X-ray diffraction 
The molecular structures of the Ir(III) complexes 67 and 68 were elucidated by single crystal 
X-ray diffraction. Single crystals of each complex were obtained by the slow diffusion of a 
concentrated chloroform/ethyl acetate mixture.  The crystal data and refinement parameters 
for both complexes are summarised in Table 2.1 Compound 67 crystallised as red blocks in 
the monoclinic space group P21/c, whereas compound 68 crystallised as orange blocks in the 
triclinic space group P1̅. 
Table 2.1: Crystallographic data and refinement parameters for complexes 67 and 68. 
 Complex 67 Complex 68 
Chemical formula C27H32ClIrN2 C27H29ClF3IrN2 
Formula weight 612.22 666.19 
Crystal system monoclinic triclinic 
Space group P21/c (No. 14) P1̅ (No. 2) 




α, β, γ (˚) 90, 99.465(2), 90 82.592(1), 77.641(1), 
84.652(1) 
V (Å3) 2431.4(3) 1238.38(18 
Z 4 2 
D (g.cm-3) 1.673 1.787 
µ (mm-1) 5.618 5.540 
F (000) 1208 652 
Crystal size (mm) 0.21 x 0.26 x 0.32 0.21 x 0.26 x 0.31 
T (K) 173 173 
Scan range/ ˚ 1.9 < ϴ < 28.4 1.7 < ϴ < 28.3 
Unique reflections 6077 5949 
Rint 0.073 0.039 
Reflections used [I > 2σ(I)] 5003 5248 
R indices (all data) R 0.0253, wR2 0.0532, S 1.04 R 0.0275, wR2 0.0517, S 1.02 
Goodness-of-fit 1.040 1.021 
Max, Min Δρ (e Å-3) -0.93, 1.62 -1.30, 1.00 
 
The ORTEP diagrams of complexes 67 and 68 are shown in Figure 2.18. The crystallographic 
analysis confirmed that the Ir(III) complexes adopts a “three-legged piano-stool” structure, 
where the pentamethylcyclopentadiene (Cp*) ligand forms the seat of the piano-stool and 
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structure is also commonly observed in many other iridium, ruthenium and rhodium half-
sandwich complexes reported in literature.29-31  
              
                                                 a                                                                                b 
Figure 2.18: X-ray crystallographic ORTEP diagram of Ir Cp* cyclometallated benzimidazole 
complexes a) 67 and b) 68, where thermal ellipsoids are drawn at 50% probability level. 
 
Selected bond distances and angles are listed in Table 2.2. The crystallographic data suggests 
that the geometry around the metal centre is pseudo-tetrahedral, which is typically observed 
in piano-stool structures. The bond angles ranging between 77 and 89˚ around the metal 
centre are clearly not in agreement with the angles observed for a tetrahedral (109.5˚) or a 
square planar (90˚) geometry. The data obtained also suggests that the benzimidazole ring 
and the phenyl ring are not coplanar. 
The bond distances obtained for both complexes were comparable. The distance between 
the metal centre and the carbon atoms of the Cp* ligand ranges between 2.143 and 2.265 Å. 
The bond distance between the metal centre and the chloride ligand is approximately 2.4 Å, 
whereas the distance between the metal centre and the two chelating atoms ranges between 
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Table 2.2: Selected bond distance and bond angles. 
 Complex 67 Complex 68 
Selected bond distances (Å) 
Ir(1) – Cl(1) 2.4114(9) 2.4054(10) 
Ir(1) – N(1) 2.072(2) 2.079(2) 
Ir(1) – C(1) 2.062(3) 2.050(4) 
N(1) – C(7) 1.345(4) 1.337(4) 
Ir(1) – C(18) 2.173(3) 2.157(4) 
Ir(1) – C(19) 2.143(3) 2.159(4) 
Ir(1) – C(20) 2.177(4) 2.144(4) 
Ir(1) – C(21) 2.205(4) 2.247(4) 
Ir(1) – C(22) 2.257(3) 2.265(4) 
Selected bond angles (˚) 
Cl(1) – Ir(1 )– C(1) 89.04(9) 87.40(10) 
N(1) – Ir(1) – C(1) 77.09(12) 77.05(12) 
Cl(1) – Ir(1) – N(1) 88.86(7) 86.40(7) 
 
3.3. Summary 
A series of 2-phenylbenzimidazole ligands and corresponding Ru(II) and Ir(III) cyclometallated 
complexes were successfully synthesised. All compounds were characterised fully using 
standard spectroscopic and analytical techniques such as 1H, 13C{1H}, COSY, HSQC NMR 
spectroscopy, IR spectroscopy and ESI-mass spectrometry. Single crystal X-ray structure 
analysis of complexes 67 and 68, further confirmed the molecular structure of the iridium 
complexes in the solid state. The purity of the target compounds was supported by elemental 
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Chapter 3: Biological evaluation of 2-phenylbenzimidazoles and 
cyclometallated Ru(II)/Ir(III) benzimidazole complexes 
 
3.1. Introduction 
Malaria remains a highly prevalent disease, largely affecting developing countries of the 
sub-Saharan African region. Although there are several antimalarial drugs which have been 
developed over many years, the emergence of drug resistance underscores the need for 
researchers to search for new pharmacophores which are chemically and structurally diverse 
compared to current therapies.1 This chapter is concerned with the antiplasmodial activity 
evaluation of the previously synthesised 2-phenybenzimidazole ligands (35 – 54) and the 
cyclometallated ruthenium(II) and iridium(III) complexes (55 – 68). The benzimidazole 
pharmacophore may be a good antimalarial drug candidate as several research articles 
recently demonstrate various benzimidazole derivatives with different substitution patterns, 
possessing potent antiplasmodial activities.2-4  
 
In recent years, the synthesis and biological evaluation of cyclometallated complexes have 
been extensively investigated.5-7 Literature reports suggest the synthesis of cyclometallated 
complexes, where the chelating ring contains a strong C-M σ bond, may help prevent 
biological reduction and ligand exchange reactions.8 Moreover, structural and electronic 
properties can be fine-tuned by modifying the bidentate C-N ligand and/ or other ancillary 
ligands,8 which may result in the enhancement of the overall activity of the compound. 
Therefore, the first aim of this study was to make minor structural changes to the 2-
phenylbenzimidazole ligand. Since there has been reports of enhanced antiplasmodial activity 
upon substitution at position-5 of the benzimidazole ring,9, 10 the effect of altering 
substituents at position-5 of the 2-phenylbenzimidazole scaffold with Craig plot substituents 
was explored. This may then lead to the identification of key structural changes which are 
necessary for the antiplasmodial activity of 2-phenylbenzimidazoles.  
 
The antiplasmodial activity of the compounds was determined quantitatively using the 




61          Chapter 3: Biological evalution 
types of plasmodium strains, however since Plasmodium falciparum is prevalent and deadly, 
most drugs are generally tested against chloroquine-sensitive (CQS) and chloroquine-
resistant (CQR) strains of P. falciparum. Thus, all of the synthesised ligands and complexes 
were initially screened against the CQS NF54 strain and selected complexes screened against 
the CQR K1 strain. This may allow us to establish if the activity of the synthesised 
benzimidazole compounds is comparable to chloroquine and if the compounds are cross-
resistant (i.e. less active in the CQR strain compared to the CQS strain). 
 
3.2 In vitro antiplasmodial evaluation against P. falciparum 
3.2.1 Antiplasmodial activity against the chloroquine-sensitive NF54 strain  
A full dose-response experiment was performed on the synthesised compounds to determine 
the respective IC50 values. An IC50 value is defined as the concentration of a particular drug 
inhibiting 50% of parasite growth. The results for the 2-phenylbenzimidazole ligands are 
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Table 3.1: In vitro antiplasmodial activity of 2-phenylbenzimidazole ligands 35 – 54 against the 
chloroquine-sensitive NF54 strain of P. falciparum. 
Compound R substituent Structure  IC50 (µM) ± SD 
35 H 
 
17.96 ± 0.29 
36 Cl 8.23 ± 0.23 
37 OCH3 NA 
38 CN 30.87 ± 0.95 
39 CH3 4.13 ± 0.11 
40 CF3 10.85 ± 1.13 
41 SO2CH3 32.97 ± 0.35 
42 CONH2 NA 
43 F 19.40 ± 0.44 
44 H 
 
9.64 ± 0.16 
45 Cl NA 
46 CH3 NA 
47 CN 21.07 ± 1.02 
48 SO2CH3 NA 
49 OCH3 NA 












4.65 ± 1.17 
CQ - - 0.044 
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When comparing the biological data obtained for the 2-phenylbenzimidazole ligands with a 
methyl linker and which were substituted at position-5 (35 – 43), compounds 39, 36 and 40 
(with chloro-, methyl and trifluoromethyl substituents, respectively) were found to be the 
most active with IC50 values of 4.23, 8.23 and 10.85 µM, respectively. On the other hand, 
compounds 38 and 41, incorporating nitrile and methyl sulfonyl substituents were found to 
be significantly less active.  
Figure 3.1 illustrates the Craig plot and highlights the substituents which were investigated in 
this study. The x- and y- axis is represented by a π- or σ- constant, respectively. As already 
mentioned, a positive π-constant indicates that a substituent is more hydrophobic, whereas 
a positive σ- constant indicates the substituent is electron-withdrawing. Thus, by relating the 
activity of these compounds with their relative positions in the Craig plot, it was observed 
that the antiplasmodial activity is generally enhanced through the incorporation of 
substituents positioned in the top and bottom right-hand quadrants of the Craig plot where 
substituents have a more positive π-constant. This suggests that more lipophilic substituents 
at position-5 of the benzimidazole core is important for activity in this case. 
 
Figure 3.1: The Craig plot, highlighting the substituents chosen for this study in red. 
 
By comparing compounds 44 and 47 (N-propyl) with compounds 35 and 38 (N-methyl), 
respectively, it is evident that the compounds with a propyl chain are significantly more active 
than the corresponding methyl analogues. Based on these two cases, the activity of the 
unsubstituted N-propyl benzimidazole ligand (44) and the nitrile substituted benzimidazole 
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analogues. However, in terms of the other 2-phenylbenzimidazole ligands containing a propyl 
chain, compounds 45, 46 and 48 – 50 were found to be inactive at the tested concentration.  
Due to the enhanced activity observed for the methyl-substituted compound 39, compounds 
51 – 54 were then also functionalised with a methyl group. As previously mentioned, 
compounds 53 and 54, were synthesised in order to examine the overall solubility of the 
benzimidazole ligand and to investigate the effect of introducing a water-solubilising H-
bonding moiety on antiplasmodial activity. The intermediate benzimidazole ligands 51 and 
52, functionalised with a carbamate (Boc) group and free amine moiety, respectively, were 
also tested. Compounds 51 and 53 were found to be inactive at the tested concentration, 
whereas compound 52, functionalised with the free amine moiety proved to be more active 
when compared to the corresponding propyl analogue 46. The addition of two morpholine 
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In terms of the biological data obtained for the metal complexes, several trends can be 
observed from the results in Table 3.2 and Figure 3.2.  









0.14 ± 0.01 
56 Cl 2.69 ± 0.16 
57 CH3 2.04 ± 0.06 
58 CF3 2.31 ± 0.12 
59 SO2CH3 NA 




0.12 ± 0.01 
62 Cl 0.59 ± 0.04 
63 CH3 1.16 ± 0.02 
64 CF3 3.02 ± 0.15 
65 H 
Ir/ Cp* 
0.19 ± 0.01 
66 Cl 1.94 ± 0.04 
67 CH3 1.73 ± 0.13 
68 CF3 1.62 ± 0.04 
CQ - - - 0.044 
 
       NA = Not active at the tested concentration 
The potency of the most active 2-phenylbenzimidazole ligands (substituted with a methyl, 
chloro-, or trifluoromethyl group), is significantly enhanced upon complexation with 
ruthenium or iridium, which suggests that the metal moiety may play a role in activity. The 
enhanced activity observed upon metal complexation may be related to an increase in the 
overall lipophilicity of the compound, or the interaction of the metal complex with the target 
via an as yet unknown mechanism of action. Generally, the Ru(II) cyclometallated complexes 
exhibited better activity compared to the Ir(III) complexes. For example, the IC50 value for the 
unsubstituted ruthenium complex 55 was found to be 0.14 µM, whereas that for the 
corresponding iridium complex 60 was found to be 1.14 µM. The enhanced activity observed 
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mimic iron.12 This suggests that the Ru(II) complexes may be able to bind to proteins such as 
serum albumin and transferrin in the plasma.13 Moreover, the manner in which a Ru(II) 
compound oxidises may also be similar to an Fe(II) compound. This may give insight to the 
mechanism of action of these compounds, where they are perhaps involved in the generation 
of reactive oxygen species. 
The results for the metal complexes also show a clear trend in terms of activity and chain 
length. In general, the activity of the N-propyl metal complexes (61 – 68) was significantly 
greater compared to the N-methyl metal complexes (55 – 60).  
 
Figure 3.2: Graph depicting IC50 values of N-methyl (55 – 60) and N-propyl (61 – 68) Ru(II) and 
Ir(III) cyclometallated benzimidazole complexes. 
 
Despite a clear trend observed for the ligands, wherein the introduction of a more lipophilic 
substituent enhanced the antiplasmodial activity, the substituent did not appear to 
significantly affect the activity. The unsubstituted metal complexes (55, 61 and 65) were 
found to be more active compared to the substituted analogues. Trends therefore observed 
for the ligands were found to not necessarily be the same as that for the metal complexes. 
 
3.2.2 Antiplasmodial activity against the chloroquine-resistant K1 strain  
Since the N-propyl Ru(II) and Ir(III) cyclometallated benzimidazole complexes exhibited 
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their corresponding N-methyl analogues, compounds 61 – 68 were also tested against the 
chloroquine-resistant K1 strain of P. falciparum. The results are presented in Table 3.3 and 
Figure 3.3 is also shown, which graphically compares the results obtained for both strains. 
Table 3.3: In vitro antiplasmodial activity of N-propyl Ru(II) and Ir(III) metal complexes 61 – 68 
against CQS NF54 and CQR K1 strains of P. falciparum. 





61 (Ru) 0.12 2.68 ± 0.15 22.92 
65 (Ir) 0.19 4.31 ± 0.27 22.94 
Me  
Me  
63 (Ru) 1.16 0.97 ± 0.12 0.84 
67 (Ir) 1.73 2.25 ± 0.15 1.30 
CF3  
CF3 
64 (Ru) 3.02 1.04 ± 0.14 0.34 
68 (Ir) 1.62 1.20 ± 0.23 0.74 
Cl  
Cl  
62 (Ru) 0.59 1.85 ± 0.27 3.11 
66 (Ir) 1.94 4.20 ± 0.18 2.16 
- CQ 0.04 0.29 ± 0.04 6.54 
 
            a (IC50 K1/ IC50 NF54) 
 
From the data obtained for the K1 strain, the ruthenium complexes clearly display enhanced 
activity compared to the iridium complexes, a trend similarly observed in the NF54 strain. 
Compound 63 displayed similar activities in both the chloroquine-sensitive and resistant 
strains of P. falciparum, whereas the activity of compounds 61, 62, 65 and 66 were 
significantly lower in the K1 strain compared to the NF54 strain. This suggests that compounds 
61, 62, 65 and 66 may experience cross-resistance in a manner similar to that of chloroquine. 
Compounds 67 and 68 exhibited more or less consistent activity across both strains, while the 
activity of compound 64 increased significantly in the K1 strain compared to the NF54 strain.  
The significant difference observed in the activity across the two strains was confirmed by the 
small resistance index (RI) of 0.34 calculated for compound 64. The resistance index (RI) is a 
useful marker for the analysis of potential drugs and is calculated by dividing the IC50 value 
obtained in the resistant strain by the IC50 value obtained in the sensitive strain. A small RI 
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to the sensitive strain. In most cases, the RI values for the compounds were significantly lower 
than the RI value of chloroquine. The RI value of the unsubstituted compounds 61 and 65 
however, were much higher compared to CQ. This may suggest that substitution at position-
5 of the benzimidazole ring is crucial for the antiplasmodial activity against the resistant strain, 
which may help to overcome cross-resistance. The complexes containing the trifluoromethyl- 
and methyl- substituents seem to exhibit the best antiplasmodial activity against the CQ-
resistant K1 strain.  
 
Figure 3.3: In vitro antiplasmodial activity of N-propyl Ru(II) and Ir(III) metal complexes 61 – 68 
against NF54 and K1 strains of P. falciparum. 
 
While the results obtained for the metal complexes (55 – 68) indicated that they were more 
active than their corresponding ligands in both CQS and CQR strains, they were not as active 
as chloroquine (IC50 = 0.044 µM) or artesunate (IC50 = 0.012 µM).  
 
3.3 In vitro cytotoxicity studies 
Since the biological data obtained indicates that the metal complexes are potent against both 
strains of P. falciparum, the most active ligand and selected metal complexes synthesised, 
were screened for cytotoxicity. Although there are many advantages associated with the use 
of metals in medicine, often the toxicity of metal complexes is of great concern. It is therefore 
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display potent activity against the parasites. To determine whether the synthesised metal 
complexes are toxic to non-parasitic cells and to gain insight about the selectivity of the 
compounds towards the malaria parasites, the cytotoxicity of the compounds was tested 
against the mammalian Chinese Hamster Ovarian (CHO) cell-line, using the colorimetric 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) assay. The results 
obtained are summarised in Table 3.4 below. 
Table 3.4: IC50 values obtained for selected compounds against CHO mammalian cells. 
Compound Structure IC50 (µM) ± SD 
Selectivity 
Indexa (SI) 
39 (R = CH3) 
 
323.5 ± 4.89 78 
55 (R = H, M = Ru, Ln 
= p-cymene) 
 
74.32 ± 9.41 512 
60 (R = H, M = Ir, Ln = 
Cp*) 
92.31 ± 8.96 81 
61 (R = H, M = Ru, Ln 
= p-cymene) 
 
50.92 ± 0.81 434 
65 (R = H, M = Ir, Ln = 
Cp*) 
20.71 ± 0.23 110 
Emetine 
 
0.05 ± 0.003 - 
 
            a (IC50 CHO/ IC50 NF54) 
 
From the results obtained it is evident that most of the compounds synthesised are not very 
cytotoxic compared to the standard control (Emetine). Compound 65 appears to be the most 
cytotoxic compared to the other synthesised metal complexes. When comparing all the metal 
complexes, the iridium benzimidazole complex with a methyl chain 60 appears to be the least 
cytotoxic with an IC50 value of 92.31 µM.  
The selectivity index (SI) of each compound is also displayed in Table 3.4 and depicted in the 
graph below (Figure 3.4). As already mentioned, this value is calculated by dividing the IC50 
value obtained for the cytotoxicity tests (CHO) by the respective P. falciparum strain (NF54 or 
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a particular cell type. A large SI value suggests selectivity towards malaria parasites as 
opposed to the CHO mammalian cells. 
 
Figure 3.4: Selectivity indices 
From the calculated SI values is it evident that the Ru complexes display the best selectivity, 
with SI values of 512 and 434, respectively. The benzimidazole ligand 39 and iridium metal 
complex 60 displays lower selectively as they as less active against the malaria parasite 
compared to the ruthenium complexes.  
 
3.4 Aqueous solubility evaluation  
A further study involved investigating the effect of improving aqueous solubility. Therefore, 
the apparent solubility of selected target compounds was determined in PBS buffer at the 
more relevant physiological pH of 6.5.  The general classification of solubility ranges was 
analysed as follows: 
• Solubility >150 µM – highly soluble  
• Solubility of 50-150 µM – moderately soluble  
• Solubility <50 µM – highly insoluble  
Hydrocortisone (>150 µM) and Reserpine (<50 µM) were used as respective positive and 
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48 SO2CH3 160 
49 OCH3 115 















The strategy used to improve aqueous solubility was to introduce water-solubilising groups 
to the 2-phenylbenzimidazole moiety, such as a sulfonamide or morpholine functionality. The 
results obtained indicated that the introduction of these groups, did in fact lead to an 
improvement in solubility. Compound 53 showed moderately good solubility, while the 
dimorpholine functionalised compound (54) stood out with 200 µM solubility at physiological 
pH. 
The aqueous solubility of selected N-propyl and N-methyl 2-phenylbenizmidazoles were also 
determined. In this case, the aqueous solubility data obtained can be related to the Craig plot, 
where compounds which are more lipophilic were found to have generally low aqueous 
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benzimidazole compounds were found to be relatively insoluble with low solubility values  
(>5 µM), whereas the less lipophilic methyl sulfonyl and methoxy- substituted compounds 
displayed relatively good aqueous solubility (160 and 115 µM, respectively).  
The methyl substituted N-methyl (57) and N-propyl (63) metal complexes displayed low 
aqueous solubility (30 and 50 µM, respectively). The results suggest that the more lipophilic 
compounds are generally more active and this may be related to the compounds mechanism 
of action. Further modification of these metal complexes should therefore be made in order 
to enhance the activity and aqueous solubility of the overall compound and then assess if the 
activity of the compound is compromised. 
 
3.5 β-Haematin inhibition studies 
Several research articles have reported that compounds containing the benzimidazole moiety 
inhibit β-haematin formation. In addition, since the synthesised 2-phenylbenzimidazoles and 
corresponding metal complexes displayed promising antiplasmodial activity against both 
strains of P. falciparum and the mechanism of action of benzimidazoles remains unknown, 
β-haematin inhibition studies were also performed on selected compound in order to shed 
light on potential modes of action of the synthesised 2-phenylbenzimidazole compounds. 
As previously mentioned, quinoline-based antimalarial drugs such as chloroquine are believed 
to target the erythrocytic stage of the malaria parasites life cycle. These quinoline-based 
drugs are considered as inhibitors of haemozoin formation, where they act by binding to 
haematin (a toxic product of the haemoglobin degradation process). These drugs are then 
able to prevent further conversion of haemozoin, resulting in the death of the parasite due 
to the toxic build-up of free haematin. The inhibition of the formation of haemozoin or its 
synthetic counterpart, β-haematin, is therefore regarded as an attractive approach in drug 
development. The NP40 detergent-mediated assay, developed by Sandlin et al, was used in 
this study to determine β-haematin inhibition activity.14 This method involved the use of 
NP40, a neutral detergent, which mimics lipids and mediates the formation of β-haematin in 
this assay.  
The results obtained for the 2-phenylbenzimidazole ligand (44) and its corresponding Ru(II) 
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dose-response curves of the tested compounds and chloroquine (CQ), which were screened 
up to a concentration of 500 µM.  
 
Figure 3.5: Dose response curves, depicting the β-haematin inhibition activity of CQ, 44, 65 and 61. 
 
From the results obtained in this study, it is clear that the compounds tested did not exhibit 
any activity. Since the absorbance is proportional to the concentration of free haem, in the 
case of CQ, this compound inhibited β-haematin formation. However, in the case of the 
benzimidazole compounds, conversion of β-haematin was observed (low absorbance, hence 
no free haem present). The concentration at which the compounds are tested could be 
increased since there is a slight increase in absorbance at higher concentrations, however, 
any value obtained would not be significant. The results suggest that the compounds are not 
β-haematin inhibitors in this cell-free assay, which suggests that they are unlikely candidates 
for haemozoin inhibition in the parasite.  
 
3.6 Summary 
A series of substituted N-methyl and N-propyl 2-phenylbenzimidazole ligands as well as 
selected Ru(II) and Ir(III) cyclometallated benzimidazole complexes were screened in vitro for 
their antiparasitic activity against the CQS NF54 strain of P. falciparum. The ligands displayed 
moderate antiplasmodial activity and compounds substituted with lipophilic substituents 
(methyl, chloro- or trifluoromethyl) at position-5 of the benzimidazole core were found to be 
more active. The antiplasmodial activity of the benzimidazole ligands was significantly 
enhanced upon the incorporation of either ruthenium or iridium. The Ru(II) metal complexes 
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with a propyl chain exhibited better activity than the metal complexes with a methyl chain. 
Furthermore, despite the general trend observed for the series of 2-phenylbenzimidazole 
ligands, where compounds substituted with more lipophilic groups showed enhanced activity, 
this trend was not observed for metal complexes against the CQS strain.  
The metal complexes screened against the CQR strain, generally displayed low resistance 
index values, indicating that the complexes are not cross-resistance with chloroquine. This 
suggests that the compounds may have a different mode of action to CQ, which was also 
suggested by the β-haematin inhibition studies, where the conversion of β-haematin was not 
observed in the study. Aqueous solubility tests showed that although the introduction of 
water-solubilising groups did not have a significant effect on the antiplasmodial activity of the 
compounds, the aqueous solubility was greatly improved. 
Cytotoxicity studies indicated that the compounds had low cytotoxicity and were selective 
towards the malaria parasites.  
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Chapter 4: Conclusions and Future Work 
 
4.1. Overall Summary and Conclusions 
A series of substituted 2-phenylbenzimidazoles (35 – 50) were successfully synthesised. The 
2-phenylbenzimidazoles were substituted at position-5 of the benzimidazole ring and 
substituents were selected from each quadrant of the Craig plot, allowing for the electronic 
and steric effects to be investigated. In addition, the effect of introducing water-solubilising 
H-bonding groups was also investigated through the synthesis of a 2-phenylbenzimidazole 
tethered with either a sulfonamide (53) or morpholine moiety (54), at position-1 of the 
benzimidazole ring. Ru(II) and Ir(III) cyclometallated benzimidazole complexes (55 – 68) were 
also successfully synthesised to introduce chemical diversity. All compounds were isolated in 
moderate to good yields and fully characterised using spectroscopic and analytical techniques 
such as 1D (1H, 13C{1H}) and 2D (COSY, HSQC) NMR spectroscopy, IR spectroscopy and mass 
spectrometry (electron impact, electrospray ionisation). In addition, the molecular structure 
of the Ir(III) cyclometallated complexes 67 and 68 were confirmed by single crystal X-ray 
diffraction, corroborating a pseudo-tetrahedral geometry about the metal centre. 
Furthermore, the purity of the synthesised compounds were supported by elemental analysis 
and LC-MS data. 
The synthesised 2-phenylbenzimidazole ligands (35 – 54) and corresponding Ru(II) and Ir(III) 
metal complexes (55 – 68) were screened in vitro for their potential antiplasmodial activity 
against the chloroquine-sensitive NF54 strain. The substituted 2-phenylbenzimidazole ligands 
displayed moderate activity, where compounds with lipophilic substituents (chloro-, methyl 
and trifluoromethyl) exhibited relatively good antiplasmodial activity when compared to the 
other substituted benzimidazole ligands. The antiplasmodial activity of the 
2-phenylbenzimidazoles was enhanced significantly upon cyclometallation with ruthenium or 
iridium. The Ru(II) complexes generally displayed better antiplasmodial activity compared to 
the Ir(III) complexes. In addition, the N-propyl metal complexes (61 – 68) were relatively more 
potent than the N-methyl metal complexes (55 – 60), therefore complexes 61 – 68 were also 
screened against the chloroquine-resistant K1 strain. A similar trend was observed in the CQR 
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complexes also displayed lower resistance index values relative to CQ, which suggests that 
they are not cross-resistant with CQ. 
Since the complexes were active, they were screened against Chinese Hamster Ovarian (CHO) 
cells to measure selectivity. The complexes displayed low cytotoxicity and generally displayed 
high selectivity indices, implying that the compounds are selective towards the malaria 
parasites.  
The apparent solubility of selected compounds were also tested in aqueous PBS buffer at a 
pH of 6.5. Although the introduction of a water-solubilising H-bonding group to the 
benzimidazole moiety did not have a significant effect on the antiplasmodial activity, solubility 
studies showed that through the introduction of a sulfonamide or morpholine functionality, 
the overall solubility of the compound increased substantially. Unfortunately, the more active 
compounds displayed poor solubility at the tested pH.  
In terms of a potential mechanism of action, the benzimidazole compounds did not show 
β-haematin inhibition activity in the cell-free assay at the tested concentration of 500 µM, 
suggesting that the compounds are unlikely candidates for haemozoin inhibition in the 
parasite. 
 
4.2. Future Work 
Based on the results of this study, the benzimidazole complexes show promising 
antiplasmodial activity. Further mechanistic studies and structural modifications could be 
made in order to gain further insight to the mode(s) of action of 2-phenylbenzimidazoles and 
to enhance the efficacy and solubility of these compounds. 
4.2.1. Further mechanistic studies 
Since the benzimidazole compounds did not display β-haematin inhibition activity, it would 
be interesting to investigate other possible mechanisms of action. This may then result in 
preliminary data on how the benzimidazole compounds exerts its pharmacological effects and 
aid in the design and development of target-based antiplasmodial agents. Additional tests 
which could be performed include (but are not limited to) cysteine protease inhibition studies 
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reactive oxygen species (ROS) could also be determined by evaluating the antiplasmodial 
activity of the benzimidazole compounds in the presence of an antioxidant such as 
N-acetylcysteine (NAC). Further evaluation of the electrochemistry of the compounds may 
help in identifying compounds which are redox active as well as those which enable ROS 
generation. Through the incorporation of a fluorescent tag/marker onto the benzimidazole 
compound, the site (in the parasite) at which the compound acts may also be established. 
Since this study showed that the terminal group of the N-propyl chain did not significantly 
affect the compounds overall activity, this therefore makes it an ideal site for conjugating 
fluorescent tags. 
 
4.2.2. Structural modifications to enhance activity and solubility 
The biological results indicate that despite the synthesised compounds exhibiting promising 
antiplasmodial activity, the activity was not comparable to chloroquine. Thus, further 
modification of the benzimidazole compound should be made to enhance the efficacy and 
solubility of the compounds.  
Figure 4.1 below highlights suggested modifications, which may enhance the antiplasmodial 





Figure 4.1: Suggested structural modifications 
 
Further derivatisation of the phenyl ring could be evaluated as well as the replacement of the 
phenyl ring with a pyridyl ring, which may alter the lipophilicity of the compound. Since the 
Introduce PTA moiety to increase solubility 
Functionalise phenyl ring 
with various Craig plot 
substituents or alter 
phenyl ring to pyridyl ring 
Functionalise with a fluorescent 
tag or synthesise a bis/tris 
benzimidazole compound. 
Lipophilic substituent as 
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ruthenium complexes were generally more active compared to the iridium complexes, further 
studies could be limited to ruthenium complexes. In addition, lipophilic substituents should 
be maintained at position-5 of the benzimidazole ring. The aqueous solubility of the 
compounds may also be enhanced through the incorporation of a PTA (1,3,5-triaza-7-
phosphaadamantane) moiety. The benzimidazole compound could also be functionalised with a 
fluorescent tag, which may help determine where the compound accumulates in the parasite. 
Furthermore, through the synthesis of a bis- or tris- benzimidazole compound, we could also 
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Chapter 5: Experimental Procedures 
 
5.1. General Remarks 
All reagents and solvents were purchased from commercial sources (Sigma Aldrich or Combi 
blocks) and were used without further purification. All reactions were carried out under an 
inert nitrogen or argon atmosphere, unless otherwise stated. Reactions were monitored by 
TLC using aluminium-backed Merck precoated silica-gel 60 F254 plates, and compounds were 
visualised by ultraviolet light at 254 nm and/or were sprayed with either ninhydrin, a 2.5% 
solution of p-anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v), iodine vapour, 
or ceric ammonium sulphate solution, and then heated. Column chromatography was carried 
out using silica-gel (Fluka Silica Gel 60, 40-63 microns).   
 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Bruker XR600 MHz 
spectrometer (1H at 599.95 MHz and 13C at 151.0 MHz), a Bruker XR400 MHz spectrometer 
(1H at 399.95 MHz and 13C at 100.6 MHz) or a Bruker XR300 MHz (1H at 299.95 MHz) using 
tetramethylsilane (TMS) as the internal standard. Infrared (IR) spectroscopy was performed 
on a Perkin-Elmer Spectrum 100 FT-IR spectrometer using Attenuated Total Reflectance (ATR) 
with vibrations measured in units of cm-1.  
 
Elemental analyses for C, H, N and S were performed using a Thermo Flash 1112 series CHNS-
O Analyser. Purity was determined using an analytical Agilant HPLC 1260 equipped with an 
Agilent infinity diode array detector (DAD) 1260 UV-Vis detector, with an absorption 
wavelength range of 210 – 640 nm. The compounds were eluted using a mixture of solvent A 
(10 mM NH4OAc/H2O) and solvent B (10 mM NH4OAc/MeOH) at a flow rate of 0.9 mL min−1. The 
gradient elution conditions were as follows: 10% solvent B between 0 and 1 min, 10 – 95% solvent 
B between 1 and 3 min, 95% solvent B between 3 and 5 min. Mass Spectrometry (MS) 
determinations were carried out using Electron Impact (EI) on a JEOL GCmateII instrument or 
Electrospray Ionisation (ESI) on a Waters API Quattro Micro triple quadrupole mass 
spectrometer with data recorded using the positive mode. Melting points were obtained 
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5.2. Synthesis of intermediate compounds and 2-phenylbenzimidazole ligands 
5.1. General synthetic procedure for synthesis of nitroaniline derivatives (1 – 17) 
Method A: Commercially available substituted nitrobenzene compounds (1 eq.) were 
dissolved in anhydrous DMF (5 mL) at rt. Thereafter, methylamine hydrochloride (2 eq.) and 
K2CO3 (2 eq.) were added to the solution and left to stir for 24 h. The synthesis of 3 however, 
required the reaction to be heated to 100 o C in a sealed vessel. After 24 h, the reaction mixture 
was diluted with sat. NaCl (50 mL) and the crude product extracted with ethyl acetate  
(3 x 50 mL). The organic extracts were combined and dried over anhydrous Na2SO4 and then 
concentrated in vacuo. The crude product was then purified via column chromatography 
using EtOAc:Petroleum ether as the eluent to afford the desired compounds, 1 – 3. 
Method B: Commercially available substituted nitrobenzene compounds (1 eq.) were 
dissolved in DCM (2 mL) at rt. Thereafter, K2CO3 (2 eq.) and methylamine (40% solution in 
H2O, 2 mL) was added to the solution. The resulting biphasic solution was then left to stir 
overnight at rt. The reaction mixture was diluted with distilled H2O (30 mL) and extracted with 
DCM (3 x 30 mL). The organic layers were combined and washed with sat. NaCl (30 mL). The 
combined organic extracts were dried over anhydrous MgSO4 and concentrated in vacuo. The 
resulting residue was purified via flash chromatography using DCM:Petroleum ether as the 
eluent to afford  products, 4 – 8.1 
Method C: Methylamine (40% solution in H2O, 1.25 mL) was then added to 
2,5- difluoronitrobenzene (0.21 mL, 1.91 mmol) at 0 ᵒC. The solution was then left to cool to 
rt and allowed to stir for 2 h. The reaction mixture was then diluted with H2O (10 mL) and the 
resultant orange precipitate filtered. Recrystallisation from EtOH afforded product, 9.2 
Method D: Commercially available substituted nitrobenzene compounds (1 eq.) were 
dissolved in DMF (3 mL) at rt. N-propylamine (2 eq.) was then added to the solution and the 
solution was then left to stir for 24 h. Thereafter, the reaction mixture was diluted with 
distilled H2O (30 mL) and extracted with EtOAc (3 x 30 mL). The organic layers were combined 
and washed with sat. NaCl (30 mL). The combined organic extracts were then dried over 
anhydrous Na2SO4 and concentrated in vacuo. The resulting residue was purified via flash 
chromatography using DCM:Petroleum ether as the eluent to afford products, 10 – 12 and 14 
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in THF (4 mL) followed by N-propylamine (2 mL). The solution was left to heat at 60 ᵒC for   
4 h. Excess solvent was then concentrated in vacuo and upon addition of H2O (5 mL) a yellow 
precipitate formed and was then filtered. Recrystallisation from EtOH afforded product, 13.  
Method E: 1-Fluoro-2-nitrotoluene (0.258 g, 1.67 mmol) was dissolved in DMF (1 mL). tert-
Butyl N-(3-aminopropyl)carbamate was previously prepared according to a literature 
procedure,4 whereby a solution of Boc anhydride (0.753 g, 3.43 mmol) in chloroform (30 mL) 
was added dropwise to 1,3-diaminopropane (g, mmol) at 0 ˚ C. The previously synthesised 
tert-Butyl N-(3-aminopropyl)carbamate (0.319 g, 1.83 mmol) and K2CO3 (0.345 g, 2.50 mmol) 
were then added to the reaction flask. The reaction was warmed to 100 ˚C and left to stir for 
24 h. Thereafter, the reaction mixture was cooled to room temperature and diluted with 
water (30 mL). The aqueous layer was extracted with EtOAc (3 x 30 mL) and washed with sat. 
NaCl (30 mL). The organic layers were collected and dried over sat. Na2SO4, filtered and 
concentrated in vacuo. The crude residue obtained was purified by column chromatography 




1-Fluoro-2-nitrobenzene (1.49 mL, 14.2 mmol) was diluted with DMF (15 mL). Methylamine 
hydrochloride (1.94 g, 28.6 mmol) and K2CO3 (3.80 g, 27.5 mmol) was then added to the 
solution. Product: Orange oil (2.00 g, 93%); Rf (EtOAc/Pet. Ether, 2:8): 0.70. 1H-NMR   
(300 MHz, CDCl3) δ (ppm): 8.16 (d, 3JHH = 8.4 Hz, 1H, Hf), 8.04 (s, 1H, Hh), 7.46 (t, 3JHH = 8.4 Hz, 
1H, Hd), 6.84 (d, 3JHH = 8.7 Hz, 1H, Hc), 6.65 (t, 3JHH = 8.4 Hz, 1H, He), 3.02 (d, 3JNH = 5.8 Hz, 3H, 
Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 146.49 (Cb), 136.37 (Cd), 132.17 (Ca), 126.95 (Cf), 
115.32 (Ce), 113.47 (Cc), 29.83 (Cg). Elemental Analysis for C7H8N2O2 (152.15 g.mol-1): Found 
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4-Chloro-N-methyl-2-nitroaniline (2) 
 
1,4-Dichloro-2-nitrobenzene (0.305 mg, 1.59 mmol) was diluted with DMF (3 mL). 
Methylamine hydrochloride (0.213 g, 3.15 mmol) and K2CO3 (0.437 g, 3.16 mmol) was then 
added to the solution. Product: Orange solid (0.121 g, 42%); Rf (EtOAc:Pet. Ether, 1:9): 0.55. 
1H NMR (300 MHz, CDCl3) δ (ppm): 8.17 (d, J = 2.5 Hz, 1H, Hf), 8.05 (s, 1H, Hh), 7.41 (dd, J = 
9.2, 2.5 Hz, 1H, Hd), 6.81 (d, J = 9.2 Hz, 1H, Hc), 3.03 (d, J = 5.1 Hz, 3H, Hg). 13C{1H} NMR (101 
MHz, CDCl3) δ (ppm): 145.09 (Cb), 136.53 (Cd), 126.06 (Cf), 122.74 (Ca), 120.23 (Ce), 114.94 




4-Chloro-3-nitroanisole (0.359 g, 1.91 mmol) and methylamine (40% solution in H2O, 1.25 mL) 
was added to a sealed vessel and heated to 100 ᵒC. Product: Red solid (0.233 g, 67%); Rf 
(EtOAc:Pet. Ether, 1:9): 0.29. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.63 (d, 4JHH = 3.0 Hz, 1H, Hf), 
7.18 (dd, 3JHH = 9.3 Hz and 4JHH = 3.0 Hz, 1H, Hd), 6.83 (d, 3JHH = 9.3 Hz, 1H, Hc), 3.80 (s, 3H, Ar-
OCH3), 3.03 (s, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 149.58 (Ce), 142.38 (Cb), 
130.96 (Ca), 127.40 (Cd), 114.75 (Cc), 107.17 (Cf), 55.89 (Ar-OCH3), 29.69 (Cg). Elemental 
Analysis for C8H10N2O3 (182.07 g.mol-1): Found (%) C, 53.95; H, 5.95; N, 14.64; Calcd. (%) C, 




4-Chloro-3-nitrobenzonitrile (0.183 g, 1.00 mmol) was dissolved in DCM (1 mL). K2CO3  
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Product: Yellow solid (0.175 g, 98%); Rf (EtOAc:Pet. Ether, 1:1): 0.68. Mp: 160.6 - 165.8 ᵒC. 1H 
NMR (300 MHz, CDCl3) δ (ppm): 8.50 (d, 4JHH = 1.8 Hz, 1H, Hf), 8.39 (s, 1H, Hh), 7.63 (dd, 3JHH = 
9.0 and 4JHH = 1.8 Hz, 1H, Hd), 6.91 (d, 3JHH = 9.0 Hz, 1H, Hc), 3.09 (d, 3JNH = 5.1 Hz, 3H, Hg). 
13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 148.12 (Cb), 137.87 (Cd), 132.23 (CN), 131.71 (Cf), 
118.09 (Ca), 114.56 (Cc), 98.31 (Ce), 30.04 (Cg). FT-IR (ATR) v (cm-1): = 3384.16 (sec. amine, N-
H) and 2220.49 (C≡N). Elemental Analysis for C7H8N2O2 (177.16 g.mol-1): Found (%) C, 53.99; 




1-Fluoro-4-methyl-2-nitrobenzene (0.317 g, 2.05 mmol) was dissolved in DCM (2 mL). K2CO3 
(0.574 g, 4.15 mmol) and methylamine (40% solution in H2O, 2 mL) was then added to the 
solution. Product: Orange solid (0.338 g, 99%), Rf (EtOAc:Pet. Ether, 1:9): 0.59. Mp: 72.0 – 
80.5 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.97 (d, 4JHH = 2.2 Hz, 1H, Hf), 7.29 (dd, 3JHH = 8.7 
Hz and 4JHH = 2.2 Hz, 1H, Hd), 6.76 (d, 3JHH = 8.7 Hz, 1H, Hc), 3.01 (s, 3H, Hg), 2.27 (s, 3H, Ar-
CH3). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 144.64 (Cb), 137.77 (Cd), 131.62 (Ca), 126.04 (Cc), 
124.73 (Ce), 113.35 (Cf), 29.75 (Ci), 19.92 (Cg). Elemental Analysis for C8H10N2O2  
(166.18 g.mol-1): Found (%) C, 57.97; H, 6.03; N, 15.82; Calcd. (%) C, 57.82; H, 6.06; N, 16.86. 




4-Chloro-3-nitrobenzotrifluoride (0.230 mL, 1.54 mmol) was dissolved in DCM (1.5 mL). K2CO3 
(0.413 g, 2.99 mmol) and methylamine (40% solution in H2O, 1.5 mL) was then added to the 
solution. Product: Yellow solid (0.336 g, 99%), Rf (EtOAc:Pet. Ether, 1:9): 0.29. Mp:  
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1H, Hf), 8.26 (s, 1H, Hh), 7.64 (dd, 3JHH = 9.0 and 4JHH = 2.1 Hz, 1H, Hd), 6.93 (d, 3JHH = 9.0 Hz, 1H, 
Hc), 3.08 (d, 3JNH = 5.1 Hz, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 147.70 (s, Cb), 
132.16 (Cd), 131.08 (s, Ca), 124.87 (Cc), 122.32 (s, Ce), 117.41 (d, 2JCF = 34.0 Hz, CF3), 114.04 (s, 
Cf), 29.85 (s, Cg). 19F NMR (377 MHz, CDCl3) δ (ppm): -61.93 (s). Elemental Analysis for 
C8H7F3N2O2 (220.15 g.mol-1): Found (%) C, 43.61; H, 2.05; N, 12.29; Calcd. (%) C, 43.65; H, 3.21; 




1-Fluoro-4-methanesulfonyl-2-nitrobenzene (0.326 g, 1.49 mmol) was dissolved in DCM (1.5 
mL). K2CO3 (0.419 g, 3.03 mmol) and methylamine (40% solution in H2O, 1.5 mL) was then 
added to the solution. Product: Yellow solid (0.340 g, 99%), Rf (EtOAc:Pet. Ether, 5:5): 0.23. 
Mp: 186.1 – 190.1 ᵒC.  1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.65 (d, 3JNH = 4.2 Hz, 1H, Hh), 
8.51 (d, 4JHH = 2.1 Hz, 1H, Hf), 7.95 (dd, 3JHH = 9.0 and 4JHH = 2.1 Hz, 1H, Hd), 7.19 (d, 3JHH = 9.0 
Hz, 1H, Hc), 3.21 (s, 3H, Ar-SO2CH3), 3.04 (d, 3JHNH = 5.1 Hz, 3H, Hg). 13C{1H} NMR (101 MHz, 
DMSO-d6) δ (ppm): 148.50 (Cb), 133.96 (Cd), 130.41 (Ca), 127.24 (Cf), 126.50 (Ce), 115.97 (Cc), 
44.30 (Cg), 30.51 (Ch). Elemental Analysis for C8H10N2O4S (230.24 g.mol-1): Found (%) C, 46.98; 
H, 5.68; N, 10.45; S, 12.32; Calcd. (%) C, 41.73; H, 4.38; N, 12.17; S, 13.92. MS (EI, m/z): 




4-Chloro-3-nitrobenzamide (0.201 g, 1.00 mmol) was dissolved in DCM (1 mL). K2CO3 (0.283 
g, 2.05 mmol) and methylamine (40% solution in H2O, 1 mL) was then added to the solution. 
Product: Orange solid (0.139 g, 71%); Rf (EtOAc: 10): 0.56. Mp: 249.3 – 251.4 o C.  1H NMR (300 
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3JHH = 9.0 and 4JHH = 2.1 Hz, 1H, Hd), 7.98 (bs, 1H, CONH2), 7.25 (bs, 1H, Hh), 7.03 (d, JHH = 9.0 
Hz, 1H, Hc), 3.00 (d, JNH = 4.8 Hz, 3H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 166.60 
(C=O), 147.65 (Cb), 135.41 (Cd), 130.83 (Ca), 126.78 (Ce), 121.00 (Cf), 114.44 (Cc), 30.31 (Cg). 
Elemental Analysis for C8H9N3O3 (195.18 g.mol-1): Found (%) C, 51.94; H, 5.18; N, 10.45; S, 




2,5-difluoronitrobenzene (0.21 mL, 1.94 mmol) was added to methylamine (40% solution in 
H2O, 1.25 mL). Product: Orange solid (0.324 g, 98%), Rf (EtOAc:Pet. Ether, 3:7): 0.64. Mp: 65.5 
– 72.9 ᵒC.  1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.11 (d, 3JHH = 3.6 Hz, 1H, Hh), 7.84 (dd, 3JHF 
= 9.6 and 4JHH = 3.1 Hz, 1H, Hf), 7.54 (ddd, 3JHF = 9.6, 3JHH = 7.5 and 4JHH = 4.8 Hz, 1H, Hd), 7.05 
(dd, 3JHH = 9.6 and 4JHF = 4.8 Hz, 1H, Hc), 2.96 (d, J = 5.1 Hz, 3H, Hg). 13C{1H} NMR (101 MHz, 
CDCl3) δ (ppm): 153.62 (Ce), 151.26 (Cb), 143.48 (Ca), 124.98 (d, 2JCF = 23.8 Hz, Cd), 114.59 (d, 
3JCF = 7.2 Hz, Cc), 111.97 (d, 2JCF = 26.2 Hz, Cf), 29.95 (Cg). 19F NMR (377 MHz, CDCl3) δ (ppm): 
-128.33 (s). Elemental Analysis for C7H7FN2O2 (170.14 g.mol-1): Found (%) C, 49.34; H, 3.33; 




1-Fluoro-2-nitrobenzene (1.01 g, 7.16 mmol) was dissolved in DMF (15 mL). n-Propylamine 
(0.838 g, 14.2 mmol) was then added to the solution. Product: Orange oil (1.26 g; 99%); Rf 
(EtOAc: Pet. Ether, 1:9): 0.45. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.10 (bs, 1H, Hg), 8.08 – 
8.03 (m, 1H, Hf), 7.53 (m, 1H, Hd), 7.05 (m, 1H, Hc), 6.67 (m, 1H, He), 3.35 – 3.30 (t, 3JHH = 7.2 
Hz, 2H, Hh), 1.72 – 1.56 (sextet, JHH = 7.2 Hz, 2H, Hi), 0.95 (t, 3JHH = 7.2 Hz, 3H, Hj). 13C{1H} NMR 
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114.44 (Cc), 44.82 (Ch), 21.55 (Ci), 11.17 (Cj). Elemental Analysis for C9H12N2O2 (180.21 g.mol-
1): Found (%) C, 60.12; H, 6.46; N, 15.88; Calcd. (%) C, 59.9; H, 6.70; N, 15.50. MS (EI, m/z): 




1,4-Dichloro-2-nitrobenzene (0.425 g, 2.21 mmol) was dissolved in DMSO (4 mL). 
n-Propylamine (0.36 mL, 4.38 mmol) was then added to the solution. Product: Orange solid 
(0.452 g, 95%); Rf (EtOAc: Pet. Ether, 1:9): 0.65. Mp: 44.5 – 46.1 ᵒC. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): δ 8.17 (d, 4JHH = 2.4 Hz, 1H, Hf), 8.03 (bs, 1H, Hg), 7.37 (dd, 3JHH = 9.3, and 4JHH = 2.4 
Hz, 1H, Hd), 6.81 (d, 3JHH = 9.3 Hz, 1H, Hc), 3.27 (m, 1H, Hh), 1.85 – 1.67 (m, 1H, Hi), 1.05 (t, J = 
7.4 Hz, 1H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 144.41 (Cb), 136.46 (Cd), 131.75 (Ca), 
126.10 (Cc), 120.00 (Ce), 115.38 (Cf), 44.09 (Ch), 22.36 (Ci), 11.66 (Cj). Elemental Analysis for 
C9H11ClN2O2 (214.65 g.mol-1): Found (%) C, 52.24; H, 5.51; N, 12.04; Calcd. (%) C, 50.36; H, 




1-Fluoro-4-methyl-2-nitrobenzene (0.358 g, 2.31 mmol) was dissolved in DMF (4 mL). 
n-Propylamine (0.38 mL, 4.62 mmol) was then added to the solution. Product: Orange oil 
(0.442 g, 99%); Rf (EtOAc:Pet. Ether, 1:9): 0.76. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.97 (d, 
4JHH = 2.1 Hz, 1H, Hf), 7.30 – 7.20 (dd, 3JHH = 8.4 Hz and 4JHH = 2.1 Hz, 1H, Hd), 6.81 – 6.73 (d, 
3JHH = 8.4 Hz, 1H, Hc), 3.26 (t, JHH = 7.2 Hz, 2H, Hh), 2.26 (s, 3H, Ar-CH3), 1.85 – 1.60 (m, 2H, Hi), 
1.04 (t, JHH = 7.2 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 139.22 (Cb), 132.97 (Cd), 
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(Cj). Elemental Analysis for C10H14N2O2 (194.23 g.mol-1): Found (%) C, 62.00; H, 7.30; N, 14.16; 




4-Chloro-3-nitrobenzonitrile (0.353 g, 1.93 mmol) was dissolved in THF (4 mL). n-Propylamine 
(2.05 mL, 24.9 mmol) was then added to the solution. Product: Yellow solid (0.181, 46%); Mp: 
110.3 – 115.1 ᵒC.  1H-NMR (300 MHz, CDCl3) δ (ppm): 8.50 (d, 4JHH = 2.9 Hz, 1H, Hf), 8.40 (s, 
1H, Hg), 7.59 (dd, 3JHH = 9.0 Hz and 4JHH = 2.9 Hz, 1H, Hd), 6.91 (d, 3JHH = 9.0 Hz, 1H, Hc), 3.33 
(m, 2H, Hh), 1.90 – 1.70 (m, 2H, Hi), 1.07 (t, 3JHH = 7.4 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) 
δ (ppm): 147.27 (Cb), 137.57 (Cd), 132.24 (Cf), 131.36 (C≡N), 117.98 (Ca), 114.79 (Cc), 97.95 
(Ce), 44.97 (Ch), 22.06 (Ci), 11.42 (Cj). Elemental Analysis for C10H11N3O2 (205.22 g.mol-1): 
Found (%) C, 58.52; H, 5.23; N, 20.30; Calcd. (%) C, 58.47; H, 5.36; N, 20.46. MS (EI, m/z): 




1-Fluoro-4-methanesulfonyl-2-nitrobenzene (0.708 g, 3.23 mmol) was dissolved in DMF  
(3 mL). n-Propylamine (0.53 mL, 6.48 mmol) was then added to the solution. Product: Yellow 
solid (0.302 g, 36%); Rf (EtOAc:Pet. Ether, 5:5): 0.49. Mp: 117.7 – 119.1 ᵒC. 1H-NMR (300 MHz, 
CDCl3) δ (ppm): 8.76 (d, 4JHH = 2.4 Hz, 1H, Hf), 8.44 (bs, 1H, Hg), 7.92 – 7.84 (dd, 3JHH = 9.3 Hz 
and 4JHH = 2.4 Hz, 1H, Hd), 6.97 (3JHH = 9.3 Hz, 1H, Hc), 3.35 (m, 2H, Hh), 3.05 (s, 3H, Ar-SO2CH3), 
1.92 – 1.70 (m, 2H, Hi), 1.08 (t, 3JHH = 7.2 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 
148.08 (Cb), 133.72 (Cd), 131.18 (Ca), 128.29 (Cf), 126.82 (Ce), 114.78 (Cc), 45.25 (Ar-SO2CH3), 









4-Chloro-3-nitroanisole (0.640 g, 3.41 mmol) was dissolved in DMF (2 mL). n-Propylamine 
(0.56 mL, 6.83 mmol) was then added to the solution and the reaction mixture was left to stir 
in a sealed vessel at 100 ˚C. Product: Orange oil (0.539 g, 75%); Rf (EtOAc:Pet. Ether, 1:9): 
0.50. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.02 (bs, 1H, Hg), 7.62 (d, 4JHH = 3.0 Hz, 1H, Hf), 7.15 
(dd, 3JHH = 9.3 Hz and 4JHH = 3.0 Hz, 1H, Hd), 6.83 (3JHH = 9.3 Hz, 1H, Hc), 3.79 (s, 3H, Ar-OCH3), 
3.27 (t, 3JHH = 7.2, Hz, 2H, Hh), 1.85 – 1.65 (m, 2H, Hi), 1.05 (t, 3JHH = 7.2 Hz, 3H, Hj). 13C{1H} 
NMR (101 MHz, CDCl3) δ (ppm): 149.63 (Ce), 141.91 (Cb), 130.95 (Ca), 127.56 (Cd), 115.39 (Cc), 




4-Chloro-3-nitrobenzotrifluoride (1.51 g, 6.71 mmol) was dissolved in DMF (3 mL). 
n-Propylamine (1.1 mL, 13.4 mmol) was then added to the solution. Product: Yellow solid 
(1.42 g, 85%); Rf (EtOAc:Pet. Ether, 1:9): 0.65. Mp: 54.9 – 55.8 ᵒC. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): 8.46 (d, 4JHH = 2.1 Hz, 1H, Hf), 8.28 (bs, 1H, Hg), 7.60 (dd, 3JHH = 9.0 Hz and 4JHH = 2.1 
Hz, 1H, Hd), 6.94 (3JHH = 9.0 Hz, 1H, Hc), 3.32 (m, 2H, Hh), 1.87 – 1.71 (m, 2H, Hi), 1.07 (t, 3JHH = 
7.2 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 147.16 (Cb), 132.21 (Cd), 131.04 (Ca), 
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tert-Butyl (3-((4-methyl-2-nitrophenyl)amino)propyl)carbamate (17) 
 
1-Fluoro-4-methyl-2-nitrobenzene (0.258 g, 1.66 mmol) was dissolved in DMF (2 mL). N- Boc-
1,3-propanediamine (0.32 mL, 1.83 mmol) and K2CO3 (0.352 g, 2.55 mmol) was then added to 
the solution. Product: Yellow solid (0.470 g, 91%); Rf (EtOAc:Pet. Ether, 4:6): 0.28. Mp: 102.3 
– 104.2 ᵒC. 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.07 (s, 1H, Hg), 7.86 (d, J = 2.1 Hz, 1H, Hf), 
7.37 (dd, 3JHH = 8.7 and 4JHH 2.1 Hz, 1H, Hd), 6.96 (d, 3JHH = 8.7 Hz, 1H, Hc), 6.89 (s, 1H, Hk), 3.40 
– 3.32 (q, 2H, Hh), 3.01 (q, 2H, Hj), 2.22 (s, 3H, Ar-CH3), 1.70 (p, J = 6.6 Hz, 2H, Hi), 1.37 (s, 9H, 
Hn). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 155.66 (Cl), 143.48 (Cb), 137.99 (Cd), 130.51 
(Ca), 125.16 (Cc), 124.08 (Ce), 114.44 (Cf), 77.48 (Cm), 38.89 (Ch), 37.35 (Cj), 28.65 (Ci), 28.19 
(Cn), 19.36 (Ar-CH3). Elemental Analysis for C15H23N3O4 (309.37 g.mol-1): Found (%) C, 58.90; 
H, 7.73; N, 13.34; Calcd. (%) C, 58.24; H, 7.49; N, 13.58. MS (EI, m/z): 309.1533 (90%, [M]+). 
 
5.2. General synthetic procedure for synthesis of 1,2-diamine derivatives (18 – 34) 
Nitroaniline compounds, 1 – 17 (1.eq.) were dissolved in anhydrous MeOH, under an argon 
atmosphere at room temperature. Ammonium chloride (10 eq.) was then added to the 
solution and left to stir for 5 min. Thereafter, Zinc dust (20 eq.) was added to the reaction 
flask. The reaction was allowed to stir vigorously for 30 – 45 min. After the reaction was 
complete, the reaction mixture was filtered through Celite, and washed with copious amounts 
of MeOH. Excess solvent was concentrated in vacuo and saturated NaHCO3 (aq.) was added 
to the resultant residue and extracted with EtOAc (2 x 30 mL). The combined organic layers 
were collected, dried over anhydrous Na2SO4 and the solvent removed to afford the product 
or purified further via column chromatography using EtOAc:Petroleum ether as an eluent to 










N-Methyl-2-nitroaniline 1 (1.99 g, 13.1 mmol) was dissolved in MeOH (100 mL). NH4Cl  
(6.99 g, 131 mmol) and Zinc (17.1 g, 262 mmol) was then added to the solution. Product: 
Brown oil (1.46 g, 91%); Rf (EtOAc:Pet. Ether, 2:8): 0.29. 1H NMR (300 MHz, CDCl3) δ (ppm): 
6.95 – 6.78 (m, 1H, He), 6.79 – 6.57 (m, 3H, Hc, Hd, Hf), 3.59 – 2.98 (bs, 3H, Hh), 2.87 (s, 3H, Hg). 
13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 137.19 (Cb), 134.99 (Ca), 117.69 (Cd), 116.63 (Ce), 
113.82 (Cc), 109.11 (Cf), 30.19 (Cg). Elemental Analysis for C7H10N2 (122.17 g.mol-1): Found (%) 





4-Chloro-N-methyl-2-nitroaniline 2 (2.03 g, 10.9 mmol) was dissolved in MeOH (60 mL). NH4Cl 
(5.83 g, 109 mmol) and Zinc (14.0 g, 217 mmol) was then added to the solution. Product: 
Brown oil (0.219 g, 13%); Rf (EtOAc:Pet. Ether, 2:8): 0.19. 1H-NMR (300 MHz, CDCl3) δ (ppm): 
6.79 (dd, 3JHH = 8.4 and 4JHH = 2.3 Hz, 1H, Hd), 6.69 (d, 4JHH = 2.3 Hz, 1H, Hf), 6.55 (d, 3JHH = 8.4 
Hz, 1H, Hc), 3.21 (bs, 3H, Hh), 2.84 (s, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 137.38 
(Cb), 135.64 (Ca), 123.55 (Ce), 120.24 (Cd), 116.13 (Cf), 112.09 (Cc), 31.23 (Cg). Elemental 
Analysis for C7H10N2 (156.61 g.mol-1): Found (%) C, 55.37; H, 6.01; N, 16.46; Calcd. (%) C, 53.60; 
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4-Methoxy-N1-methylbenzene-1,2-diamine (20) 
 
4-Methoxy-N-methyl-2-nitroaniline 3 (0.230 g, 1.23 mmol) was dissolved in MeOH (50 mL). 
NH4Cl (0.655 g, 12.2 mmol) and Zinc (1.62 g, 24.8 mmol) was then added to the solution. 
Product: Dark brown solid (0.101 g, 55%); Rf (EtOAc:Pet. Ether, 4:6): 0.29. 1H-NMR (300 MHz, 
CDCl3) δ (ppm): 6.62 (d, 3JHH = 8.6 Hz, 1H, Hc), 6.37 (m, 2H, Hd, Hf), 3.74 (s, 3H, OCH3), 2.97 (bs, 
3H, Hh), 2.82 (bs, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 153.96 (Ce), 136.95 (Ca), 
132.05 (Cb), 113.30 (Cc), 104.07 (Cd), 103.43 (Cf), 55.75 (OCH3), 32.07 (Cg). Elemental Analysis 
for C8H12N2O (152.20 g.mol-1): Found (%) C, 64.01; H, 7.86; N, 17.19; Calcd. (%) C, 63.13; H, 




4-(Methylamino)-3-nitrobenzonitrile 4 (0.495 g, 2.79 mmol) was dissolved in MeOH (50 mL). 
NH4Cl (1.50 g, 27.9 mmol) and Zinc (3.64 g, 55.9 mmol) was then added to the solution. 
Product: Brown solid (0.384 g, 93%); Rf (EtOAc:Pet. Ether, 4:10): 0.29. Mp: 133.6 – 140.7 ᵒC. 
1H-NMR (300 MHz, CDCl3) δ (ppm): 7.18 (dd, 3JHH = 8.1 and 4JHH = 1.8 Hz, 1H, Hd), 6.92 (d, 4JHH 
= 1.8 Hz, 1H, Hf), 6.57 (d, 3JHH = 8.1 Hz, 1H, Hc), 3.43 (bs, 3H, Hh), 2.90 (s, 3H, Hg). 13C{1H} NMR 
(101 MHz, CDCl3) δ (ppm): 143.64 (Cb), 133.19 (Ca), 126.92 (Cd), 120.69 (Ci), 119.25 (Cf), 109.64 
(Cc), 99.47 (Ce), 31.23 (Cg). Elemental Analysis for C8H9N3 (147.18 g.mol-1): Found (%) C, 65.24; 
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N1,4-dimethylbenzene-1,2-diamine (22) 
 
N,4-Dimethyl-2-nitroaniline 5 (0.322 g, 1.94 mmol) was dissolved in MeOH (30 mL). NH4Cl 
(1.01 g, 18.8 mmol) and Zinc (2.52 g, 38.5 mmol) was then added to the solution. Product: 
Brown solid (0.220 g, 83%); Rf (EtOAc:Pet. Ether, 5:5): 0.44. Mp: 35.8 – 40.7 ᵒC. 1H-NMR (300 
MHz, CDCl3) δ (ppm): 6.66 (m, 1H, Hd), 6.60 (d, 1H, Hc), 6.58-6.54 (m, 1H, Hf), 3.20 (s, 3H, Hh), 
2.85 (s, 3H, Hg), 2.24 (s, 3H, Ar-CH3). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 136.32 (Cb), 
134.51 (Ca), 128.23 (Ce), 120.82 (Cd), 117.15 (Cf), 111.52 (Cc), 31.31 (Ar-CH3), 20.58 (Cg). 
Elemental Analysis for C8H12N2 (136.20 g.mol-1): Found (%) C, 70.95; H, 8.59; N, 19.31; Calcd. 




N-Methyl-2-nitro-4-(trifluoromethyl)aniline 6 (0.426 g, 1.93 mmol) was dissolved in MeOH  
(60 mL). NH4Cl (1.04 g, 19.4 mmol) and Zinc (2.52 g, 38.6 mmol) was then added to the 
solution. Product: Brown solid (0.234 g, 64%); Rf (EtOAc:Pet. Ether, 2:8): 0.26.  
MP: 42.4 – 47.4 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.12 (dd, 3JHH = 8.3 and 4JHH = 2.0, Hz, 
1H, Hd), 6.93 (d, 4JHH = 2.0 Hz, 1H, Hf), 6.64 (d, 3JHH = 8.2 Hz, 1H, Hc), 3.56 – 3.08 (bs, 3H, Hh), 
2.90 (s, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 141.97 (Cb), 133.26 (Ca), 124.95 (d, 
1JCF = 268.9 Hz, Ar-CF3), 119.76 (d, 2JCF = 32.2 Hz, Ce), 118.47 (d, 4JCF = 4.1 Hz, Cc), 113.04 (Cd), 
109.50 (Cf), 30.61 (Cg). Elemental Analysis for C8H9F3N2 (190.17 g.mol-1): Found (%) C, 51.61; 
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N1-Methyl-4-(methylsulfonyl)benzene-1,2-diamine (24) 
 
N-Methyl-4-(methylsulfonyl)-2-nitroaniline 7 (0.301 g, 1.31 mmol) was dissolved in MeOH  
(30 mL). NH4Cl (0.695 g, 13.0 mmol) and Zinc (1.72 g, 26.4 mmol) was then added to the 
solution. Product: Brown oil (0.193 g, 74%); Rf (EtOAc:10) 0.63. 1H-NMR (300 MHz, DMSO-d6) 
δ (ppm): 7.06 (dd, 3JHH = 8.4 and 4JHH = 2.4, Hz, 1H, Hd), 7.01 (d, 4JHH = 2.4 Hz, 1H, Hf), 6.47 (d, 
3JHH = 8.4 Hz, 1H, Hc), 5.48 (bd, 3JHH = 5.1 Hz, 1H, Hh), 4.93 (s, 2H, Hi), 2.99 (s, 3H, Ar-SO2CH3), 
2.79 (d, 3JHH = 5.1 Hz, 1H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 141.72 (Cb), 135.24 
(Ca), 127.35 (Ce), 118.15 (Cd), 111.08 (Cf), 107.75 (Cc), 45.17 (Ar-SO2CH3), 30.20 (Cg). Elemental 
Analysis for C8H12N2O2S (200.26 g.mol-1): Found (%) C, 48.22; H, 6.47; N, 13.61; S, 11.64 Calcd. 




4-(Methylamino)-3-nitrobenzamide 8 (0.204 g, 1.04 mmol) was dissolved in MeOH (30 mL). 
NH4Cl (0.557 g, 10.4 mmol) and Zinc (1.36 g, 20.8 mmol) was then added to the solution. 
Product: Brown oil (0.094 g, 54%); Rf (EtOAc:10) 0.14. 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 
7.40 (bs, 1H, Ar-CONH2), 7.15 (dd, 3JHH = 8.1 and 4JHH = 2.1 Hz, 1H, Hd), 7.09 (d, 4JHH = 2.1 Hz, 
1H, Hf), 6.70 (s, 1H, Ar-CONH2), 6.34 (d, 3JHH = 8.1 Hz, 1H, Hc), 5.08 (d, 3JHNH = 4.5 Hz, 1H, Hh), 
4.52 (bs, 2H, Hi), 2.76 (d, 3JHNH = 4.5 Hz, 3H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 
169.22 (C=O), 140.46 (Cb), 134.40 (Ca), 122.47 (Ce), 118.62 (Cd), 113.75 (Cc), 107.76 (Cf), 30.38 
(Cg). Elemental Analysis for C8H11N3O (165.20 g.mol-1): Found (%) C, 57.46; H, 7.21; N, 16.62; 
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4-Fluoro-N1-methylbenzene-1,2-diamine (26) 
 
4-Fluoro-N-methyl-2-nitroaniline 9 (0.376 g, 2.21 mmol) was dissolved in MeOH (40 mL). 
NH4Cl (1.19 g, 22.2 mmol) and Zinc (2.89 g, 44.2 mmol) was then added to the solution. 
Product: Brown solid (0.160 g, 52%); Rf (EtOAc:Pet. Ether, 2:8): 0.15. 1H-NMR (300 MHz, 
DMSO-d6) δ (ppm): 6.40 – 6.33 (m, 1H, Hf), 6.33 – 6.21 (m, 2H, Hc, Hd), 4.77 (bs, 2H, Hi), 4.38 
(bs, 1H, Hh), 2.68 (s, 3H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 155.92 (d, 1JCF = 230.0 
Hz, Ce), 137.52 (d, 3JCF = 10.7 Hz, Ca), 133.86 (Cb), 109.55 (d, 3JCF = 9.6 Hz, Cc), 102.19 (d, 2JCF = 
21.4 Hz, Cd), 100.74 (d, 2JCF = 25.8 Hz, Cf), 31.11 (Cg). Elemental Analysis for C7H9FN2 (140.16 
g.mol-1): Found (%) C, 60.42; H, 6.04; N, 19.74; Calcd. (%) C, 59.99; H, 6.47; N, 19.99. MS (EI, 
m/z): 140.0041 (100%, [M]+). 
 
N1-Propylbenzene-1,2-diamine (27) 
   
2-Nitro-N-propylaniline 10 (0.200 g, 1.11 mmol) was dissolved in MeOH (30 mL). NH4Cl (0.594 
g, 11.1 mmol) and Zinc (1.45 g, 22.2 mmol) was then added to the solution. Product: Brown 
oil (0.147 g, 88%); Rf (EtOAc: Pet. Ether, 1:3): 0.52. 1H-NMR (400 MHz, CDCl3) δ (ppm): 6.87 – 
6.82 (m, 1H, He), 6.75 – 6.66 (m, 3H, Hc, Hd, Hf), 3.25 (s, 2H, Hg), 3.10 (t, 2H, 3JHH = 7.2 Hz, Hh), 
1.77 – 1.65 (m, 2H, Hi), 1.05 (t, 3H, 3JHH = 7.4 Hz, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 
138.18 (Ca), 134.06 (Cb), 120.81 (Cd), 118.35 (Ce), 116.54 (Cc), 111.71 (Cf), 46.14 (Cg), 22.91 (Ch), 
11.77 (Ci). Elemental Analysis for C9H14N2 (150.23 g.mol-1): Found (%) C, 72.06; H, 9.57; N, 
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4-Chloro-N1-propylbenzene-1,2-diamine (28) 
 
4-Chloro-2-nitro-N-propylaniline 11 (0.739 g, 3.44 mmol) was dissolved in MeOH (100 mL). 
NH4Cl (1.84 g, 34.4 mmol) and Zinc (4.52 g, 69.1 mmol) was then added to the solution. 
Product: Brown oil (0.214 g, 34%); Rf (EtOAc: Pet. Ether, 2:8): 0.39. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): 6.76 (dd, 3JHH = 8.4 and 4JHH = 2.4 Hz, 1H, Hd), 6.69 (d, 4JHH = 2.4 Hz, 1H, Hf), 6.54 (d, 
3JHH = 8.4 Hz, 1H, Hc), 3.37 (bs, 3H, Hg), 3.04 (t, 3JHH = 6.9 Hz, 2H Hh), 1.79 – 1.58 (m, 2H, Hi), 
1.02 (t, 3JHH = 7.5 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 136.49 (Ca), 135.46 (Cb), 
123.12 (Ce), 120.03 (Cd), 116.08 (Cf), 112.56 (Cc), 46.22 (Ch), 22.78 (Ci), 11.71 (Cj). Elemental 
Analysis for C9H13ClN2 (184.67 g.mol-1): Found (%) C, 57.86; H, 6.78; N, 14.02; Calcd. (%) C, 




4-Methyl-2-nitro-N-propylaniline 12 (0.280 g, 1.44 mmol) was dissolved in MeOH (50 mL). 
NH4Cl (0.773 g, 14.5 mmol) and Zinc (1.90 g, 29.1 mmol) was then added to the solution. 
Product: Brown oil (0.228 g, 97%); Rf (EtOAc:Pet. Ether, 1:9): 0.14. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): 6.67 – 6.51 (m, 3H, Hc, Hd, Hf), 3.19 (bs, 3H, Hg), 3.05 (t, 3JHH = 7.1 Hz, 2H, Hh), 1.77 – 
1.58 (m, 2H, Hi), 1.03 (t, 3JHH = 7.4 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 135.47 
(Ca), 134.54 (Cb), 128.11 (Ce), 120.76 (Cd), 117.26 (Cf), 112.33 (Cc), 46.51 (Ch), 22.96 (Ci), 20.59 
(CH3), 11.77 (Cj). Elemental Analysis for C10H16N2 (164.25 g.mol-1): Found (%) C, 72.91; H, 9.70; 
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3-Amino-4-(propylamino)benzonitrile (30) 
 
3-Nitro-4-(propylamino)benzonitrile 13 (0.371 g, 1.83 mmol) was dissolved in MeOH (30 mL). 
NH4Cl (0.932 g, 17.4 mmol) and Zinc (2.31 g, 35.3 mmol) was then added to the solution. 
Product: Brown solid (0.299 g, 94%); Rf (EtOAc:Pet. Ether, 1:2): 0.74. 1H-NMR (300 MHz, 
CDCl3) δ (ppm): 8.50 (d, 4JHH = 2.9 Hz, 1H, Hf), 8.41 (s, 3H, Hg), 7.59 (dd, 3JHH = 9.0 Hz and 4JHH 
= 2.9 Hz, 1H, Hd), 6.91 (d, 3JHH = 9.0 Hz, 1H, Hc), 3.40-4.23 (m, 2H, Hh), 2.89-2.70 (m, 2H, Hi), 
1.07 (t, 3JHH = 7.4 Hz. 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 147.27 (Cb), 137.57 (Cd), 
132.24 (Cf), 131.36 (CN), 117.98 (Ca), 114.79 (Cc), 97.95 (Ce), 44.97 (Ch), 22.06 (Ci), 11.42 (Cj). 
Elemental Analysis for C10H13N3 (175.24 g.mol-1): Found (%) C, 68.39; H, 7.15; N, 23.72; Calcd. 




4-(Methylsulfonyl)-2-nitro-N-propylaniline 14 (0.283 g, 1.10 mmol) was dissolved in MeOH 
(50 mL). NH4Cl (0.584 g, 10.9 mmol) and Zinc (1.46 g, 22.3 mmol) was then added to the 
solution. Product: Brown solid (0.247 g, 99%); Rf (EtOAc:Pet. Ether, 1:1): 0.33. Mp: 87.9 – 95.6 
ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.40 (dd, 3JHH = 8.4 and 4JHH = 2.1 Hz, 1H, Hd), 7.22 (d, 
4JHH = 2.1 Hz, 1H, Hf), 6.64 (d, 3JHH = 8.4 Hz, 1H, Hc) 3.35 – 3.06 (bs, 3H, Hg), 3.14 (t, 3JHH = 6.9 
Hz, 2H, Hh), 2.99 (s, 3H, Ar-SO2CH3), 1.81 – 1.62 (m, 2H, Hi), 1.03 (t, 3JHH = 7.2 Hz, 3H, Hj). 
13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 143.33 (Cb), 132.78 (Ca), 127.81 (Ce), 121.78 (Cd), 
115.24 (Cf), 109.43 (Cc), 45.48 (CH3), 45.06 (Ch), 22.49 (Ci), 11.58 (Cj). Purity 98% by LC (tR 2.02 
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4-Methoxy-N1-propylbenzene-1,2-diamine (32) 
 
4-Methoxy-2-nitro-N-propylaniline 15 (0.510 g, 2.42 mmol) was dissolved in MeOH (60 mL). 
NH4Cl (1.30 g, 24.3 mmol) and Zinc (3.17 g, 48.5 mmol) was then added to the solution. 
Product: Brown oil (0.209 g, 48%); Rf (EtOAc:Pet. Ether, 3:7): 0.60. 1H-NMR (300 MHz, CDCl3) 
δ (ppm): 6.63 (d, 3JHH = 8.4 Hz, 1H, Hc), 6.35 – 6.28 (m, 2H, Hd, Hf) 3.76 (s, 3H, OCH3), 3.01 (bs, 
2H, Hg), 3.00 (m, 2H, Hh), 1.75 – 1.59 (m, 2H, Hi), 1.02 (t, 3JHH = 7.5 Hz, 3H, Hj). 13C{1H} NMR 
(101 MHz, CDCl3) δ (ppm): 154.13 (Ce), 137.41 (Ca), 131.12 (Cb), 114.83 (Cc), 104.11 (Cd), 




2-Nitro-N-propyl-4-(trifluoromethyl)aniline 16 (1.69 g, 6.79 mmol) was dissolved in MeOH 
(150 mL). NH4Cl (3.63 g, 67.9 mmol) and Zinc (8.88 g, 136 mmol) was then added to the 
solution. Product: Brown solid (1.42 g, 96%); Rf (EtOAc:Pet. Ether, 2:8: 0.33. Mp:  
41.2 – 43.1 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.10 (m, 1H, Hd), 6.93 (d, 4JHH = 2.1 Hz, 1H, 
Hf), 6.63 (d, 3JHH = 8.4 Hz, 1H, Hc) 3.42 (bs, 3H, Hg), 3.12 (t, 3JHH = 6.9 Hz, 2H, Hh), 1.82 – 1.64 
(m, 2H, Hi), 1.04 (t, 3JHH = 7.2 Hz, 3H, Hj). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 141.43 (Cb), 
133.21 (Ca), 125.13 (d, 1JCF = 271.39 Hz, Ar-CF3), 119.60 (d, 2JCF = 32.42 Hz, Ce), 118.61 (Cc), 








99            Chapter 5: Experimental Procedures 
tert-Butyl (3-((2-amino-4-methylphenyl)amino)propyl)carbamate (34) 
 
tert-Butyl (3-((4-methyl-2-nitrophenyl)amino)propyl)carbamate 17 (0.463 g, 1.50 mmol) was 
dissolved in MeOH (60 mL). NH4Cl (0.801 g, 15.0 mmol) and Zinc (1.96 g, 30.0 mmol) was then 
added to the solution. Product: Purple solid (0.337 g, 81%); Rf (EtOAc:Pet Ether, 5:5): 0.58. 
Mp: 110.6 – 112.6 ᵒC. 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 6.83 (bs, 1H, Hg), 6.37 (s, 1H, 
Hf), 6.35 – 6.25 (m, 2H, Hd, Hc), 4.38 (bs, 2H, Ho), 4.12 (bs, 1H, Hk), 3.00 (m, 4H, Hh, Hi), 2.08 (s, 
3H, CH3), 1.83 – 1.54 (m, 2H, Hi), 1.39 (s, 9H, Hn).  13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 
155.65 (Cl), 135.34 (Ca), 133.66 (Cb), 125.18 (Ce), 117.73 (Cd), 115.03 (Cf), 110.21 (Cc), 77.37 
(Cm), 41.28 (Ch), 38.02 (Cj), 29.16 (Ci), 28.24 (Cn), 20.39 (CH3).  Elemental Analysis for 
C15H25N3O2 (279.38 g.mol-1): Found (%) C, 64.35; H, 9.04; N, 14.77; Calcd. (%) C, 64.49; H, 9.02; 
N, 15.04. MS (EI, m/z): 279.1597 (90%, [M]+). 
 
5.3. General synthetic procedure for 2-phenylbenzimidazole ligands (35 – 53) 
The synthesised 1,2-diamines (18 – 34) (1 eq.) were dissolved in EtOH. Benzaldehyde (1.2 eq.), 
TFA (0.1 eq.) and MgSO4 (6 eq.) was added to the reaction flask, under an argon atmosphere 
at 25 ᵒC. The reaction was then left to stir, open to air, for 24 h. The reaction mixture was 
filtered and the solvent reduced in vacuo. The resultant residue was dissolved in DCM (30 mL) 
and washed with H2O (2 x 20 mL) and sat. NaCl (20 mL). The organic layers were collected, 
dried with anhydrous Na2SO4 and concentrated in vacuo. The crude product was then purified 




N-Methylbenzene-1,2-diamine 18 (0.410 g, 3.36 mmol) was dissolved in EtOH (30 mL). 
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20.1 mmol) was then added to the reaction flask. Product: Yellow solid (0.265 g, 38%); Rf 
(EtOAc:Pet. Ether, 5:5): 0.63. Mp: 94.3 – 95.4 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.87-
7.81 (m, 1H, Hf), 7.80 – 7.73 (m, 2H, Hj), 7.58 – 7.47 (m, 3H, Hk), 7.43 – 7.36 (m, 1H, Hc), 7.35 
– 7.29 (m, 2H, Hd,He), 3.87 (s, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 153.91 (Ch), 
143.06 (Ca), 136.71 (Cb), 130.36 (Ci), 129.88 (Ck’), 129.61 (Ck), 128.82 (Cj), 122.95 (Ce), 122.62 
(Cd), 120.00 (Cf), 109.74 (Cc), 31.79 (Cg). FT-IR (ATR) v(cm-1) = 1603 (imine, C=N). Elemental 
Analysis for C14H12N2 (208.26 g.mol-1): Found (%) C, 80.26; H, 5.72; N, 13.78; Calcd. (%) C, 




4-Chloro-N-methylbenzene-1,2-diamine 19 (0.201 g, 1.28 mmol) was dissolved in EtOH  
(15 mL). Benzaldehyde (0.16 mL, 1.57 mmol), TFA (0.015 g, 0.127 mmol) and MgSO4 (0.932 g, 
7.74 mmol) was then added to the reaction flask. Product: Brown solid (0.128 g, 41%); Rf 
(EtOAc:Pet. Ether, 4:6): 0.68. Mp: 128.4 – 134.7 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.81 
– 7.27 (m, 1H, Hf), 7.78 – 7.27 (m, 2H, Hj), 7.57 – 7.49 (m, 3H, Hk), 7.31 – 7.27 (m, 2H, Hc, Hd), 
3.85 (s, 3H, Hg). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 155.05 (Ch), 143.70 (Ca), 135.32 (Cb), 
130.24 (Ck’), 129.81 (Ci), 129.59 (Ck), 128.93 (Cj), 128.30 (Ce), 123.41 (Cd), 119.70 (Cc), 110.54 
(Cf), 31.98 (Cg). FT-IR (ATR) v(cm-1) = 1610 (imine, C=N).  Elemental Analysis for C14H11ClN2 
(242.71 g.mol-1): Found (%) C, 69.01; H, 4.54; N, 11.25; Calcd. (%) C, 69.30; H, 4.60; N, 11.50. 




4-Methoxy-N1-methylbenzene-1,2-diamine 20 (76.2 mg, 0.501 mmol) was dissolved in EtOH 
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(0.362 g, 3.00 mmol) was then added to the reaction flask. Product: Yellow solid (0.081 g, 
68%); Rf (EtOAc: 10): 0.67. Mp: 118.1 – 121.4 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.79 – 
7.72 (m, 2H, Hj), 7.57 – 7.48 (m, 3H, Hk), 7.32 (d, 4JHH = 2.4 Hz, 1H, Hf), 7.27 (d, 3JHH = 8.7 Hz, 
1H, Hc), 6.98 (dd, 3JHH = 8.7 and 3JHH = 2.4 Hz, 1H, Hd), 3.89 (s, 3H, Hg), 3.85 (s, 3H, OCH3). 13C{1H} 
NMR (101 MHz, CDCl3) δ (ppm): 156.46 (Ce), 153.91 (Ch), 143.61 (Ca), 131.30 (Ci), 130.28 (Cb), 
129.65 (Ck’), 129.37 (Ck), 128.67 (Cj), 112.91 (Cc), 109.97 (Cd), 101.98 (Cf), 55.87 (OCH3), 31.76 
(Cg). FT-IR (ATR) v(cm-1) = 1618 (imine, C=N).  Elemental Analysis for C15H14N2O  
(238.29 g.mol-1): Found (%) C, 74.47; H, 6.17; N, 10.71; Calcd. (%) C, 75.61; H, 5.92; N, 11.76. 




3-Amino-4-(methylamino)benzonitrile 21 (0.358 g, 2.43 mmol) was dissolved in EtOH (20 mL). 
Benzaldehyde (0.30 mL, 2.95 mmol), TFA (27.7 mg, 0.243 mmol) and MgSO4 (1.76 g, 14.6 
mmol) was then added to the reaction flask. Product: White solid (0.227 g, 40%); Rf 
(EtOAc:Pet. Ether, 4:6): 0.32. Mp: 185.8 – 191.3 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.13 
(m, 1H, Hf), 7.77 (m, 2H, Hj), 7.61 – 7.53 (m, 3H, Hk), 7.46 (m, 1H, Hc), 3.91 (s, 3H, Hg). 13C{1H} 
NMR (101 MHz, CDCl3) δ (ppm): 156.45 (Ch), 142.63 (Cb), 139.37 (Ca), 130.67 (Ck’), 129.61 (Ck), 
129.25 (Ci), 129.07 (Cj), 126.34 (Cd), 124.95 (Cf), 119.99 (CN), 110.85 (Cc), 105.94 (Ce), 32.14 
(Cg). Elemental Analysis for C15H11N3 (233.27 g.mol-1): Found (%) C, 76.50; H, 4.68; N, 17.72; 




N1,4-dimethylbenzene-1,2-diamine 22 (0.225 g, 1.65 mmol) was dissolved in EtOH (10 mL). 
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9.92 mmol) was then added to the reaction flask. Product: Orange solid (0.145 g, 51%); Rf 
(EtOAc:Pet. Ether, 4:6): 0.48. Mp: 114.7 – 120.7 ᵒC.   1H-NMR (300 MHz, DMSO-d6) δ (ppm): 
7.84 (m, 1H, Hj), 7.64 – 7.52 (m, 3H, Hk, Hk’), 7.49 (m, 2H, Hc. Hd), 7.17 – 7.09 (m, 1H, Hf), 3.86 
(s, 3H, Hg), 2.45 (s, 3H, Ar-CH3). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 152.85 (Ch), 142.78 
(Ca), 134.77 (Cb), 130.87 (Ce), 130.24 (Ci), 129.48 (Ck’), 129.20 (Ck), 128.58 (Cj), 123.73 (Cd), 
118.69 (Cf), 110.03 (Cc), 31.61 (Cg), 21.18 (Ar-CH3). FT-IR (ATR) v(cm-1) = 1614 (imine, C=N). 
Elemental Analysis for C15H14N2 (222.29 g.mol-1): Found (%) C, 80.17; H, 6.07; N, 11.10; Calcd. 




N1-methyl-4-(trifluoromethyl)benzene-1,2-diamine 23 (0.210 g, 1.10 mmol) was dissolved in 
EtOH (10 mL). Benzaldehyde (0.13 mL, 1.33 mmol), TFA (12.6 mg, 0.110 mmol) and MgSO4 
(0.798 g, 6.63 mmol) was then added to the reaction flask. Product: Brown solid (0.145 g, 
58%); Rf (EtOAc:Pet. Ether, 5:5): 0.47. Mp: 156.7 – 158.5 ᵒC. 1H-NMR (300 MHz, DMSO-d6) δ 
(ppm): 8.16 – 8.11 (m, 1H, Hd), 7.84 – 7.76 (m, 2H, Hj), 7.64 – 7.55 (m, 4H, Hk, Hk’, Hc), 7.50 (d, 
1H, Hf), 3.93 (s, 3H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 150.87 (Ch), 137.37 (Cb), 
133.64 (Ca), 125.59 (Ck’), 124.73 (Ck), 124.60 (Ci), 124.13 (Cj), 121.64 – 118.55 (d, 1JCF = 270 Hz, 
CF3), 120.39 (d, 2JCF = 32.2 Hz, Ce), 115.01 (d, 3JCF = 3.2 Hz, Cd), 112.72 (d, 4JCF = 3.8 Hz, Cc), 
105.32 (Cf), 27.20 (Cg). FT-IR (ATR) v(cm-1) = 1621 (imine, C=N). Elemental Analysis for 
C15H11F3N2 (276.26 g.mol-1): Found (%) C, 65.30; H, 3.64; N, 9.78; Calcd. (%) C, 65.22; H, 4.01; 
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1-Methyl-5-(methylsulfonyl-2-phenyl-1H-benzo[d]imidazole (41) 
 
N1-Methyl-4-(methylsulfonyl)benzene-1,2-diamine 24 (0.168 g, 0.838 mmol) was dissolved in 
EtOH (10 mL). Benzaldehyde (0.10 mL, 1.01 mmol), TFA (9.56 mg, 0.0838 mmol) and MgSO4 
(0.606 g, 5.03 mmol) was then added to the reaction flask. Product: White solid (0.107 g, 
45%); Rf (EtOAc:10): 0.61. Mp: 192.2 – 196.2 ᵒC.  1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.23 
– 8.18 (m, 1H, Hc), 7.99 – 7.70 (m, 4H, Hj, Hd, Hf), 7.71 – 7.45 (m, 3H, Hk. Hk’), 3.95 (s, 3H, Hg), 
3.24 (s, 3H, CH3). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 156.45 (Ch), 142.24 (Cb), 140.12 
(Ca), 135.12 (Ce), 130.72 (Ck’), 129.92 (Ck), 129.84 (Ci), 129.24 (Cj), 121.26 (Cd), 119.08 (Cc), 
112.06 (Cf), 44.76 (Cl), 32.60 (Cg). FT-IR (ATR) v(cm-1) = 1609 (imine, C=N). Elemental Analysis 
for C15H14N2O2S (286.35 g.mol-1): Found (%) C, 62.80; H, 5.12; N, 9.22; S, 10.18; Calcd. (%) C, 




3-Amino-4-(methylamino)benzamide 25 (0.110 g, 0.666 mmol) was dissolved in EtOH (6 mL). 
Benzaldehyde (0.080 mL, 0.799 mmol), TFA (7.59 mg, 0.0666 mmol) and MgSO4 (0.481 g,  
3.99 mmol) was then added to the reaction flask. Product: Brown solid (0.0581 g, 35%); Rf 
(EtOAc:10): 0.32. Mp: 259.6 – 261.4 ᵒC. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 8.31 – 8.25 
(m, 1H, Hf), 8.00 (bs, 1H, Ar-CONH2), 7.91 – 7.84 (m, 3H, Hj, Hc), 7.67 (dd, JHH = 8.6, 0.6 Hz, 1H, 
Hd), 7.64 – 7.54 (m, 3H, Hk, Hk’), 7.26 (bs, 1H, Ar-CONH2), 3.92 (s, 3H, Hg). 13C{1H} NMR (101 
MHz, DMSO-d6) δ (ppm): 168.80 (C=O), 154.93 (Ch), 142.45 (Cb), 139.06 (Ca), 130.34 (Ck’), 
129.82 (Ck), 129.17 (Cj), 128.80 (Ci), 122.74 (Cd), 119.15 (Cf), 110.55 (Cc), 32.35 (Cg). Elemental 
Analysis for C15H13N3O (251.29 g.mol-1): Found (%) C, 71.43; H, 5.53; N, 15.17; Calcd. (%) C, 








4-Fluoro-N1-methylbenzene-1,2-diamine 26 (0.144 g, 1.027 mmol) was dissolved in EtOH  
(6 mL). Benzaldehyde (0.13 mL, 1.23 mmol), TFA (11.7 mg, 0.0103 mmol) and MgSO4  
(0.742 g, 6.16 mmol) was then added to the reaction flask. Product: Brown solid (0.127 g, 
55%); Rf (EtOAc:Pet. Ether, 3:7): 0.38. Mp: 106.8 – 112.6 ᵒC.  1H-NMR (300 MHz, DMSO-d6) δ 
(ppm): 7.90 – 7.81 (m, 2H, Hj), 7.68 – 7.62 (m, 1H, Hc), 7.61 – 7.55 (m, 3H, Hk), 7.49 (m, 1H, 
Hf), 7.17 (m, 1H, Hd), 3.33 (s, 3H, Hg). 13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 159.16 (d, 
1JCF = 234.4 Hz, Ce), 155.09 (Ch), 143.21 (d, 3JCF = 12.9 Hz, Ca), 133.85 (Cb), 130.30 (Ci), 130.21 
(Ck’), 129.75 (Ck), 129.15 (Cj), 111.87 (d, 3JCF = 10.4 Hz, Cc), 110.84 (d, 2JCF = 25.9 Hz, Cd), 104.91 
(d, 2JCF = 23.8 Hz, Cf), 32.34 (Cg). FT-IR (ATR) v(cm-1) = 1623 (imine, C=N). Elemental Analysis 
for C14H11FN2 (226.25 g.mol-1): Found (%) C, 74.19; H, 4.83; N, 12.00; Calcd. (%) C, 74.32; H, 




N1-Propylbenzene-1,2-diamine 27 (96.0 mg, 0.639 mmol) was dissolved in EtOH (6 mL). 
Benzaldehyde (0.078 mL, 0.767 mmol), TFA (7.29 mg, 0.0639 mmol) and MgSO4 (0.385 g,  
3.20 mmol) was then added to the reaction flask. Product: Brown oil (0.0730 g, 49%); Rf 
(EtOAc: Pet. Ether, 2.5:7.5): 0.27. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.86 – 7.81 (m, 1H, Hf), 
7.74 – 7.68 (m, 2H, Hj), 7.55 – 7.48 (m, 3H, Hk, Hk’), 7.44 – 7.39 (m, 1H, Hc), 7.34 – 7.27 (m, 2H, 
Hd, He), 4.23 – 4.17 (t, 2H, J = 7.6 Hz, Hg), 1.90 – 1.80 (m, 2H, Hl), 0.89 – 0.85 (t, 3H, J = 7.2 Hz, 
Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 153.75 (Ch), 143.08 (Ca), 135.65 (Cb), 130.76 (Ci), 
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(Cg), 23.16 (Cl), 11.21 (Cm). FT-IR (ATR) v (cm-1) = 1611 (imine, C=N).  Elemental Analysis for 
C16H16N2 (236.32 g.mol-1): Found (%) C, 78.58; H, 7.02; N, 11.41; Calcd. (%) C, 81.40; H, 6.80; 




4-Chloro-N1-propylbenzene-1,2-diamine 28 (0.190 g, 1.03 mmol) was dissolved in EtOH  
(10 mL). Benzaldehyde (0.13 mL, 1.23 mmol), TFA (11.7 mg, 0.103 mmol) and MgSO4 (0.743 
g, 6.17 mmol) was then added to the reaction flask. Product: Brown solid (0.174 g, 62%); Rf 
(EtOAc:Pet. Ether, 5:5): 0.63. Mp: 84.8 – 88.6 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.79 (d, 
4JHH = 1.8 Hz, 1H, Hf), 7.72 – 7.65 (m, 2H, Hj), 7.56 – 7.48 (m, 3H, Hk), 7.32 (d, 3JHH = 8.6 Hz, 1H, 
Hc), 7.26 (dd, 3JHH = 8.6 and 4JHH = 1.8 Hz, 1H, Hd), 4.26 – 4.08 (m, 2H, Hg), 1.93 – 1.71 (m, 2H, 
Hl), 0.85 (t, 3JHH = 8.6 Hz, 3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 155.12 (Ch), 144.06 
(Ca), 134.43 (Ce), 130.45 (Cb), 130.09 (Ci), 129.43 (Ck’), 128.92 (Ck), 128.05 (Cj), 123.20 (Cd), 
119.85 (Cf), 110.99 (Cc), 46.61 (Cg), 23.28 (Cl), 11.30 (Cm). FT-IR (ATR) v (cm-1) = 1595 (imine, 




4-Methyl-N1-propylbenzene-1,2-diamine 29 (0.206 g, 1.25 mmol) was dissolved in EtOH   
(10 mL). Benzaldehyde (0.15 mL, 1.50 mmol), TFA (14.3 mg, 0.125 mmol) and MgSO4 (0.905 
g, 7.52 mmol) was then added to the reaction flask. Product: Brown oil (0.126 g, 40%); Rf 
(EtOAc:Pet. Ether, 5:5): 0.63. 1H-NMR (300 MHz, CDCl3) δ (ppm): 7.74 – 7.65 (m, 2H, Hj), 7.61 
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(m, 2H, Hg), 1.93 – 1.73 (m, 2H, Hl), 0.85 (t, J = 7.4 Hz, 3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) 
δ (ppm): 153.72 (Ch), 143.47 (Ca), 133.79 (Ce), 131.96 (Cb), 130.92 (Ci), 129.55 (Ck’), 129.34 (Ck), 
128.65 (Cj), 124.10 (Cd), 119.74 (Cf), 109.62 (Cc), 46.34 (Cg), 23.16 (Cl), 21.56 (CH3), 11.21 (Cm). 
FT-IR (ATR) v(cm-1) = 1518 (imine, C=N). Elemental Analysis for C17H18N2 (250.35 g.mol-1): 
Found (%) C, 77.87; H, 7.40; N, 10.34; Calcd. (%) C, 81.56; H, 7.25; N, 11.19. MS (EI, m/z): 




3-Amino-4-(propylamino)benzonitrile 30 (0.282 g, 1.61 mmol) was dissolved in EtOH (10 mL). 
Benzaldehyde (0.20 mL, 1.93 mmol), TFA (18.4 mg, 0.161 mmol) and MgSO4 (1.16 g, 9.67 
mmol) was then added to the reaction flask. Product: Yellow solid (0.157 g, 37%); Rf 
(EtOAc:Pet. Ether, 5:5): 0.75. Mp: 173.7 – 178.9 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.15 
(dd, 4JHH = 1.4, 0.6 Hz, 1H, Hf), 7.80 – 7.64 (m, 2H, Hj), 7.61 – 7.52 (m, 4H, Hk, Hk’, Hd), 7.49 (dd, 
3JHH = 8.4, 0.6 Hz, 1H, Hc), 4.35 – 4.11 (m, 2H, Hg), 1.98 – 1.73 (m, 2H, Hl), 0.87 (t, 3JHH = 7.4 Hz, 
3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 156.30 (Ch), 142.39 (Ca), 138.39 (Cb), 130.68 
(Ck’), 129.49 (Ci), 129.44 (Ck), 129.13 (Cj), 126.31 (Cd), 124.96 (Cf), 119.91 (CN), 111.35 (Cc), 
105.98 (Ce), 46.81 (Cg), 23.29 (Cl), 11.27 (Cm). FT-IR (ATR) v(cm-1) = 1614 (imine, C=N).  
Elemental Analysis for C17H15N3 (261.33 g.mol-1): Found (%) C, 75.83; H, 5.52; N, 14.45; Calcd. 
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5-(Methylsulfonyl)-2-phenyl-1-propyl-1H-benzo[d]imidazole (48) 
 
4-(Methylsulfonyl)-N1-propylbenzene-1,2-diamine 31 (0.231 g, 1.01 mmol) was dissolved in 
EtOH (10 mL). Benzaldehyde (0.12 mL, 1.21 mmol), TFA (11.5 mg, 0.101 mmol) and MgSO4 
(0.731 g, 6.07 mmol) was then added to the reaction flask. Product: Brown solid (0.155 g, 
49%); Rf (EtOAc:Pet. Ether, 4:6): 0.15. Mp: 145.8 – 148.9 ᵒC.  1H-NMR (400 MHz, CDCl3) δ 
(ppm): 8.42 (s, 1H, Hf), 7.89 (d, 3JHH = 8.8 Hz, 1H, Hc), 7.77 – 7.66 (m, 2H, Hj), 7.62 – 7.50 (m, 
4H, Hd, Hk, Hk’), 4.25 (t, 3JHH = 7.6 Hz, 2H, Hg), 3.10 (s, 3H, CH3), 1.94 – 1.76 (m, 2H, Hl), 0.87 (t, 
3JHH = 7.2 Hz, 3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 156.79 (Ch), 142.81 (Ca), 139.13 
(Cb), 135.05 (Ce), 130.60 (Ck’), 129.85 (Ci), 129.49 (Ck), 129.11 (Cj), 121.66 (Cd), 120.50 (Cc), 
111.02 (Cf), 46.88 (Cg), 45.27 (Ar-SO2CH3), 23.32 (Cl), 11.28 (Cm). FT-IR (ATR) v(cm-1) = 1604 




4-Methoxy-N1-propylbenzene-1,2-diamine 32 (82.0 mg, 0.455 mmol) was dissolved in EtOH 
(10 mL). Benzaldehyde (0.055 mL, 0.546 mmol), TFA (5.18 mg, 0.0455 mmol) and MgSO4 
(0.164 g, 1.36 mmol) was then added to the reaction flask. Product: Brown oil (0.0746 g, 62%); 
Rf (EtOAc:Pet. Ether, 3:7): 0.32. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.73 – 7.66 (m, 2H, Hj), 
7.55 – 7.47 (m, 3H, Hk, Hk’), 7.31 (d, 4JHH = 2.4 Hz, 1H, Hf), 7.29 (d, 3JHH = 8.4 Hz, 1H, Hc), 6.96 
(dd, J = 8.4, 2.4 Hz, 1H, Hd), 4.17 (t, 3JHH = 7.6 Hz, 2H, Hg), 3.88 (s, 3H, Ar-OCH3), 1.85 – 1.75 (m, 
2H, Hl), 0.86 (t, 3JHH = 7.2 Hz, 3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 156.53 (Ce), 
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(Cc), 110.62 (Cd), 102.29 (Cf), 56.02 (Ar-OCH3), 46.60 (Cg), 23.38 (Cl), 11.32 (Cm). FT-IR (ATR) 




N1-propyl-4-(trifluoromethyl)benzene-1,2-diamine 33 (1.26 g, 5.79 mmol) was dissolved in 
EtOH (10 mL). Benzaldehyde (0.71 mL, 6.95 mmol), TFA (65.9 mg, 0.579 mmol) and MgSO4 
(4.15 g, 34.7 mmol) was then added to the reaction flask. Product: Off-white solid (0.814 g, 
46%); Rf (EtOAc:Pet. Ether, 2:8): 0.33. Mp: 64.7 – 66.0 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 
8.12 – 8.08 (m, 1H, Hd), 7.75 – 7.66 (m, 2H, Hj), 7.60 – 7.52 (m, 4H, Hf, Hk, Hk’), 7.49 (d, 3JHH = 
8.4 Hz, 1H, Hc), 4.27 – 4.19 (t, 3JHH = 7.8 Hz, 2H, Hg), 1.94 – 1.76 (m, 2H, Hl), 0.87 (t, 3JHH = 7.2 
Hz, 3H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 155.89 (Ch), 142.78 (Ca), 136.79 (Cb), 
130.32 (Ci), 130.28 (Ck’), 129.47 (Ck), 129.01 (Cj), 126.39 – 123.69 (d, 1JCF = 270.1 Hz, Ar-CF3), 
125.22 – 124.90 (d, 2JCF = 32.1 Hz, Ce), 119.66 (Cc), 117.87 (Cd), 110.60 (Cf), 46.70 (Cg), 23.31 
(Cl), 11.30 (Cm). 19F NMR (377 MHz, CDCl3) δ (ppm): -60.67 (s). FT-IR (ATR) v(cm-1) = 1627 
(imine, C=N), 1323 (Ar amine, C-N). Purity 100% by LC (tR 3.56 min); MS (m/z): 305.1 (100%, 
[M+H]+). 
 
tert-Butyl (3-(5-methyl-2-phenyl-1H-benzo[d]imidazol-1-yl)propyl)carbamate (51) 
 
tert-Butyl (3-((2-amino-4-methylphenyl)amino)propyl)carbamate 34 (83.0 mg, 0.297 mmol) 
was dissolved in EtOH (10 mL). Benzaldehyde (0.036 mL, 0.357 mmol), TFA (3.39 mg,  
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White solid (56.6 mg, 52%); Rf (EtOAc:Pet. Ether, 5:5): 0.56. Mp: 84.2 – 86.8 ᵒC. 1H-NMR   
(300 MHz, DMSO-d6) δ (ppm): 7.75 (m, 2H, Hj), 7.61 – 7.55 (m, 3H, Hk), 7.55 – 7.49 (m, 1H, 
Hd), 7.48 (s, 1H, Hf), 7.12 (dd, 3JHH = 8.1, 0.9 Hz, 1H, Hc), 6.86 (bs, 1H, Hq), 4.31-4.19 (t, 3JHH = 
7.5 Hz, 2H, Hg), 2.89 (m, 2H, Hm), 2.44 (s, 3H, CH3), 1.92 – 1.73 (m, 2H, Hl), 1.35 (s, 9H, Hp). 
13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 156.07 (Cn), 153.19 (Ch), 143.45 (Ca), 134.26 (Ce), 
131.46 (Cb), 130.96 (Ci), 130.03 (Ck’), 129.52 (Ck), 129.19 (Cj), 124.28 (Cd), 119.38 (Cf), 110.76 
(Cc), 78.07 (Co), 42.62 (Cg), 37.88 (Cm), 30.28 (Cl), 28.68 (Cp), 21.65 (CH3). FT-IR (ATR) v(cm-1) = 
1676 (imine, C=N), 1364 (Ar amine, C-N). Elemental Analysis for C22H27N3O2 (365.48 g.mol-1): 
Found (%) C, 72.79; H, 7.83; N, 10.43; Calcd. (%) C, 72.30; H, 7.45; N, 11.50. MS (EI, m/z): 
365.1413 (85%, [M]+).  
 
5.4. Synthetic procedure for Boc deprotection of 51 
Synthesised tert-Butyl (3-(5-methyl-2-phenyl-1H-benzo[d]imidazol-1-yl)propyl)carbamate 51 
(0.103 g, 0.274 mmol) was dissolved in DCM (3 mL). TFA (1 mL) was then added to the reaction 
flask under an Argon atm and the reaction was left to stir for 2 h at rt. The solvent was 
removed in vacuo. The crude material was stirred in a solution of 1M NaOH (10 mL) and 
thereafter extracted with EtOAc (2 x 20 mL). The organic extracts were collected, washed with 




Brown oil (0.0719 g, 97%), Rf (EtOAc:10): 0.06. 1H-NMR (400 MHz, DMSO-d6) δ (ppm): 7.81 – 
7.73 (m, 2H, Hj), 7.61 – 7.51 (m, 4H, Hk, Hd), 7.47 (m, 1H, Hc), 7.11 (dd 3JHH = 8.4, 1.6, 1H, Hf), 
4.39-4.20 (t, 3JHH = 7.2 Hz, 2H, Hg), 2.46 (t, 2H, Hl), 2.43 (s, 3H, CH3), 1.87 – 1.67 (m, 2H, Hm). 
13C{1H} NMR (101 MHz, DMSO-d6) δ (ppm): 153.28 (Ch), 143.44 (Ca), 134.37 (Ce), 131.39 (Cb), 
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(Cg), 39.04 (Cm), 33.21 (Cl), 21.65 (CH3). FT-IR (ATR) v(cm-1) = 3158 (primary amine, N-H), 1618 
(imine, C=N), 1327 (Ar amine, C-N). MS (EI, m/z): 265.0131 (85%, [M]+).  
 
5.5. Synthetic procedure for nucleophilic acyl substitution of 53 
52 (0.0720 g, 0.271 mmol) was dissolved in DCM (3 mL). Triethylamine (0.04 mL, 1.1 eq.) and 
methanesulfonyl chloride (0.02 mL, 0.271 mmol) was added dropwise to the reaction mixture 
at 0 ˚C. The reaction allowed to stir for 2 h at rt. Thereafter it was then warmed to rt and left 
to stir for 24 h at rt. Thereafter, the crude material obtained was purified via column 
chromatography using EtOAc (100%) as an eluent to afford the desired product.8 
N-(3-(5-Methyl-2-phenyl-1H-benzo[d]imidazol-1-yl)propyl)methanesulfonamide (53) 
 
Brown oil (5.51 mg, 6.0%); Rf (EtOAc:10): 0.47. 1H-NMR (400 MHz, CDCl3) δ (ppm): 7.71 (m, 
2H, Hj), 7.63 (s, 1H, Hf), 7.58 – 7.48 (m, 3H, Hk, Hk’), 7.31 (d, 3JHH = 8.4 Hz, 1H, Hc), 7.17 (dd, J = 
8.4, 1.2 Hz, 1H, Hd), 4.43 – 4.32 (t, 3JHH = 7.2 Hz, 2H, Hg), 4.18 (bs, 1H, NH), 2.97 (m, 2H, Hl), 
2.82 (s, 3H, SO2CH3), 2.50 (s, 3H, Ar-CH3) 2.00 (m, 2H, Hm). 13C{1H} NMR (101 MHz, CDCl3) δ 
(ppm): 153.19 (Ch), 142.76 (Ca), 133.36 (Ce), 133.05 (Cb), 130.39 (Ck’), 129.98 (Ci), 129.48 (Ck), 
129.26 (Cj), 125.04 (Cd), 119.83 (Cf), 109.67 (Cc), 41.90 (Cg), 40.41 (SO2CH3) 30.42 (Cm), 29.85 
(Cl), 21.69 (Ar-CH3). Purity 100% by LC (tR 2.36 min); MS (m/z): 343.9 (100%, [M]+). 
 
5.6. Synthetic procedure for N-alkylation of 52 
52 (0.101 g, 0.380 mmol) was dissolved in anhydrous acetonitrile (2 mL). Potassium carbonate 
(0.0551 g, 1 eq.) was added to the brown solution and was allowed to stir for 5 min.  
4-(Chloroacetyl)morpholine (0.0653 g, 0.399 mmol) was then added dropwise to the reaction 
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the crude material was concentrated in vacuo and purified via column chromatography using 





Brown solid (0.0741 g, 38%); Rf (MeOH:EtOAc, 1:9): 042. Mp: 62.2 – 68.3 ᵒC.  1H-NMR  
(400 MHz, CDCl3) δ (ppm): 7.72 (m, 2H, Hj), 7.62 (s, 1H, Hf), 7.55 – 7.46 (m, 3H, Hk, Hk’), 7.35 
(d, 3JHH = 8.4 Hz, 1H, Hc), 7.13 (dd, 3JHH = 8.4, 1.6 Hz, 1H, Hd), 4.40 – 4.28 (t, 3JHH = 7.2 Hz, 2H, 
Hg), 3.59 (m, 12H, Ho/p), 3.43 (m, 4H, Ho/p), 3.37 (s, 4H, Hn), 2.64 (t, 3JHH = 6.8 Hz, 2H, Hm) 2.50 
(s, 3H, Ar-CH3), 1.87 (m, 2H, Hl). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 168.88 (C=O), 153.44 
(Ch), 143.17 (Ca), 133.83 (Ce), 132.47 (Cb), 130.69 (Ci), 129.90 (Ck’), 129.46 (Ck), 128.95 (Cj), 
124.52 (Cd), 119.82 (Cf), 109.90 (Cc), 67.00 (Co/p), 66.75 (Co/p), 55.40 (Cn), 51.89 (Cm), 
45.63(Co/p), 42.85 (Cg), 42.07 (Co/p), 27.57 (Cl), 21.69 (CH3). FT-IR (ATR) v(cm-1) = 2920 (C-H), 
1635 (imine, C=N). Purity 94% by LC (tR 2.71 min); MS (m/z): 520.3 (100%, [M+H]+). 
 
5.3. Synthesis of cyclometallated benzimidazole complexes (55 – 68) 
5.3.1. General synthetic procedure for Ru and Ir cyclometallated complexes 
The selected 2-phenylbenzimidazole (1 eq.) was dissolved in dry DCM (6 mL) under argon. 
Sodium acetate (1.2 eq.) was then added, and the reaction mixture left to stir at rt for 10 min. 
Thereafter, the appropriate metal dimer (2 eq.) was added, in one portion. The reaction 
mixture was allowed to stir at rt, under argon, for 24 h, after which the reaction mixture was 
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(10 mL) was added to the residue. The mixture was then cooled to 0 ᵒC and left to stir for 10 
min. The precipitate that formed was filtered by suction and dried under vacuum.7 
 
N-Methyl Ru benzimidazole complex (55) 
 
1-Methyl-2-phenyl-1H-benzo[d]imidazole 35 (81.6 mg, 0.392 mmol) was dissolved in DCM  
(5 mL). Sodium acetate (38.6 mg, 0.470 mmol) and dichloro(p-cymene)ruthenium(II) dimer 
(120 mg, 0.195 mmol) was then added to the solution. Product: Green solid (0.101 g, 54%); 
Mp: 250.9 – 257.9 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.34 (d, 3JHH = 7.6 Hz, 1H, Hi), 7.92 
(d, 3JHH = 8.0 Hz, 1H, Hf), 7.73 (d, 3JHH = 7.8 Hz, 1H, Hl), 7.45 – 7.27 (m, 3H, Hc, Hd, He), 7.20 (td, 
3JHH = 7.4, 1.3 Hz, 1H, Hk), 7.04 (td, 3JHH = 7.7, 1.2 Hz, 1H, Hj), 5.85 (d, 3JHH = 5.7 Hz, 1H, Hx), 5.71 
(d, 3JHH = 5.8 Hz, 1H, Ht), 5.38(d, 3JHH = 5.9 Hz, 1H, Hw), 5.15 (d, 3JHH = 5.8 Hz, 1H, Hu), 3.99 (s, 
3H, Hn), 2.29 (m, 1H, Hp), 2.08 (s, 3H, Ho), 0.93 (d, 3JHH = 6.9 Hz, 3H, Hq), 0.79 (d, 3JHH = 6.9 Hz, 
3H, Hr). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 183.22 (Ch), 157.41 (Cm), 141.41 (Cg), 140.53 
(Ci), 136.30 (Cx), 134.19 (Cu), 128.86 (Ck), 124.36 (Cl), 123.13 (Cd), 123.01 (Ce), 122.43 (Cj), 
117.00 (Cf), 109.88 (Cc), 101.07 (Ca), 99.02 (Cb), 89.30 (Ct), 88.81 (Cx), 81.76 (Cu), 81.31 (Cw), 
31.93 (Cn), 30.89 (Cp), 22.60 (Cr), 21.91 (Cq), 18.95 (Co). FT-IR (ATR) v (cm-1) = 1577 (imine, 
C=N). Elemental Analysis for C24H25ClN2Ru (478.07 g.mol-1): Found (%) C, 59.26; H, 5.41; N, 
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N- Methyl (chloro-) Ru benzimidazole complex (56) 
 
5-Chloro-1-methyl-2-phenyl-1H-benzo[d]imidazole 36 (60.3 mg, 0.248 mmol) was dissolved 
in DCM (4 mL). Sodium acetate (24.5 mg, 0.298 mmol) and dichloro(p-cymene)ruthenium(II) 
dimer (76.1 mg, 0.124 mmol) was then added to the solution. Product: Yellow solid (0.061 g, 
48%); Mp: Decomp. 251.9 – 259.0 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.34 (d, J = 7.5 Hz, 
1H, Hi), 7.86 (s, 1H, Hf), 7.73 (d, 3JHH = 7.8 Hz, 1H, Hl), 7.27 (d, J = 1.2 Hz, 2H, Hd, Hc), 7.22 (td, 
3JHH = 7.5 and 4JHH 1.2 Hz, 1H, Hj), 7.06 (td, 3JHH = 7.5, 1.2 Hz, 1H, Hk), 5.85 (d, 3JHH = 6.0 Hz, 1H, 
Hx), 5.72 (d, 3JHH = 5.7 Hz, 1H, Ht), 5.39 (d, 3JHH = 6.0 Hz, 1H, Hw), 5.15 (d, 3JHH = 5.7 Hz, 1H, Hu), 
3.99 (s, 3H, Hn), 2.30 (m, 1H, Hp), 2.09 (s, 3H, Ho), 0.93 (d, 3JHH = 6.9 Hz, 3H, Hq), 0.81 (d, 3JHH = 
6.9 Hz, 3H, Hr). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 183.57 (Ch), 159.56 (Cm), 142.20 (Cg), 
140.64 (Ci), 134.97, 133.70, 129.25 (Cj), 128.99, 124.57 (Cl), 123.43 (Cc), 122.58 (Ck), 116.80 
(Cf), 110.77 (Cd), 101.50, 98.98, 89.60 (Ct), 88.68 (Cx), 81.94 (Cw), 81.19 (Cu), 32.25 (Cn), 30.93 
(Cp), 22.60 (Cq), 21.93 (Cr), 18.99 (Co). FT-IR (ATR) v (cm-1) = 1577 (imine, C=N). Elemental 
Analysis for C24H24Cl2N2Ru · H2O: Found (%) C, 53.26; H, 4.97; N, 4.51; Calcd. (%) C, 54.34; H, 
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N- Methyl (methyl-) Ru benzimidazole complex (57) 
 
1,5-Dimethyl-2-phenyl-1H-benzo[d]imidazole 39 (54.5 mg, 0.245 mmol) was dissolved in DCM 
(3 mL). Sodium acetate (24.1 mg, 0.294 mmol) and dichloro(p-cymene)ruthenium(II) dimer 
(75.1 mg, 0.123 mmol) was then added to the solution. Product: Green solid (0.0301 g, 25%); 
Mp: 222.8 – 225.1 ᵒC. 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.31 (dd, 3JHH = 7.5, 1.2 Hz, 1H, 
Hi), 7.87 (dd, 3JHH = 7.8, 1.2 Hz, 1H, Hl), 7.72 (s, 1H, Hf), 7.61 (d, 3JHH = 8.4 Hz, 1H, Hd), 7.22 (d, 
3JHH = 8.4 Hz, 1H, Hc), 7.13 (td, 3JHH = 7.5, 1.2 Hz,  Hj), 7.05 (td, 3JHH = 7.8, 1.2 Hz, 1H, Hk), 6.02 
(d, 3JHH = 5.7 Hz, 1H, Hx), 5.79 (d, 3JHH = 5.7 Hz, 1H, Ht), 5.59 (d, 3JHH = 5.7 Hz, 1H, Hw), 5.29 (d, 
3JHH = 5.7 Hz, 1H, Hu), 4.13 (s, 1H, Hn), 2.60 (s, 3H, Ar-CH3), 2.15 (m, 1H, Hp), 1.96 (s, 3H, Ho), 
0.82 (d, 3JHH = 6.9 Hz, 3H, Hq), 0.72 (d, 3JHH = 6.9 Hz, 3H, Hr). 13C{1H} NMR (101 MHz, DMSO-
d6) δ (ppm): 183.68 (Ch), 158.24 (Cm), 141.63 (Cg), 141.13 (Ci), 134.78, 134.64, 132.71, 128.18 
(Cj), 124.72 (Cl), 124.65 (Cc), 122.34 (Ck), 117.22 (Cf), 110.82 (Cd), 101.31, 97.56, 89.74 (Ct), 
88.75 (Cx), 82.81 (Cw), 81.13 (Cu), 32.40 (Cn), 30.96 (Cp), 22.67 (Cq), 22.07 (Cr), 21.81 (Ar-CH3), 
19.01 (Co). FT-IR (ATR) v (cm-1) = 1579 (imine, C=N). Elemental Analysis for C25H27ClN2Ru · 
CH2Cl2: Found (%) C, 54.13; H, 4.73; N, 4.90; Calcd. (%) C, 54.13; H, 5.07; N, 4.86. MS (HR-ESI, 
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N- Methyl (trifluoromethane-) Ru benzimidazole complex (58) 
 
1-Methyl-2-phenyl-5-(trifluoromethyl)-1H-benzo[d]imidazole 40 (66.9 mg, 0.242 mmol) was 
dissolved in DCM (3 mL). Sodium acetate (23.8 mg, 0.291 mmol) and dichloro(p-
cymene)ruthenium(II) dimer (74.2 mg, 0.121 mmol) was then added to the solution. Product: 
Yellow solid (0.0548 g, 41%); Mp: Decomp. 248.5 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.36 
(dd, 3JHH = 7.5, 0.9 Hz, 1H, Hi), 8.18 (s, 1H, Hf), 7.76 (dd, 3JHH = 7.8, 0.9 Hz, 1H, Hl), 7.56 (d, 3JHH 
= 8.7 Hz, 1H, Hd), 7.44 (d, 3JHH = 8.7 Hz, 1H, Hc), 7.23 (m, 1H, Hj), 7.12 – 7.04 (m, 1H, Hk), 5.85 
(d, 3JHH = 5.7 Hz, 1H, Hx), 5.77 (d, 3JHH = 5.7 Hz, 1H, Ht), 5.34 (d, 3JHH = 5.7 Hz, 1H, Hw), 5.16 – 
5.10 (d, 3JHH = 5.7 Hz, 1H, Hu), 4.04 (s, 1H, Hn), 2.36 (m, 1H, Hp), 2.08 (s, 3H, Ho), 0.98 (d, 3JHH = 
6.9 Hz, 3H, Hq), 0.83 (d, 3JHH = 6.9 Hz, 3H, Hr). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 184.14, 
160.43, 140.91, 140.70, 138.29, 133.46, 129.51, 125.79 – 125.46 (d, 2JCF = 32.7 Hz, Ce), 124.83, 
122.66, 120.03, 114.30, 110.43, 100.91, 100.43, 89.52, 88.88, 81.66, 81.21, 32.31, 30.95, 
22.47, 21.97, 18.93. FT-IR (ATR) v (cm-1) = 1581 (imine, C=N). Elemental Analysis for 
C25H24ClF3N2Ru (546.00 g.mol-1): Found (%) C, 63.55; H, 5.84; N, 6.34; Calcd. (%) C, 55.00; H, 
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N- Methyl (methylsulfonyl-) Ru benzimidazole complex (59) 
 
1-Methyl-2-phenyl-1H-benzo[d]imidazole 41 (70.1 mg, 0.245 mmol) was dissolved in DCM  
(4 mL). Sodium acetate (24.1 mg, 0.294 mmol) and dichloro(p-cymene)ruthenium(II) dimer 
(75.0 mg, 0.122 mmol) was then added to the solution. Product: Yellow solid (0.0531 g, 39%); 
Mp: Decomp. 258.0 ᵒC. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.53 (d, 4JHH = 2.0 Hz, 1H, Hi), 8.37 
(dd, 3JHH = 7.6, 0.8 Hz, 1H, Hf), 7.90 – 7.86 (dd, 3JHH = 8.4, 1.6 Hz, 1H, Hj), 7.81 – 7.78 (dd, 3JHH = 
8.4, 1.2 Hz, 1H, Hd), 7.52 (d, 3JHH = 8.4 Hz, 1H, Hc), 7.24 (m, 1H, Hk), 7.11 – 7.06 (m, 1H, Hl), 5.89 
(dd, 3JHH = 6.0, 0.4 Hz, 1H, Hx), 5.79 (dd, 3JHH = 5.6, 0.8 Hz, 1H, Ht), 5.39 (dd, 3JHH = 6.0, 0.8 Hz, 
1H, Hw), 5.15 (dd, 3JHH = 6.0, 1.2 Hz, 1H, Hu), 4.10 (s, 3H, Hn), 3.18 (s, 3H, Ar-SO2CH3) 2.35 (m, 
1H, Hp), 2.08 (s, 3H, Ho), 0.98 (d, 3JHH = 6.8 Hz, 3H, Hq), 0.83 (d, 3JHH = 6.8 Hz, 3H, Hr). 13C{1H} 
NMR (101 MHz, CDCl3) δ (ppm): 184.81 (Ch), 161.36 (Cm), 141.14 (Cg), 140.82 (Ci), 139.62, 
135.60, 133.20, 129.74 (Cj), 129.49, 128.92, 125.03 (Cl), 122.75 (Cc), 121.82 (Ck), 121.56, 
117.17 (Cf), 110.75 (Cd), 101.21, 100.57, 89.66 (Ct), 89.05 (Cx), 81.98 (Cw), 81.30 (Cu), 45.06 
(SO2CH3), 32.52 (Cn), 31.00 (Cp), 22.46 (Cq), 21.99 (Cr), 18.93 (Co). FT-IR (ATR) v (cm-1) = 1580 
(imine, C=N). Elemental Analysis for C25H27ClN2O2RuS (556.08 g.mol-1): Found (%) C, 59.72; H, 
5.17; N, 6.05; Calcd. (%) C, 54.00; H, 4.89; N, 5.04. MS (HR-ESI, m/z): 601.0997 (60%, [M+2Na-
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N-Methyl Ir benzimidazole complex (60) 
 
1-Methyl-2-phenyl-1H-benzo[d]imidazole 35 (62.7 mg, 0.301 mmol) was dissolved in DCM  
(6 mL). Sodium acetate (29.7 mg, 0.362 mmol) and pentamethylcyclopentadienyliridium(III) 
chloride dimer (120 mg, 0.151 mmol) was then added to the solution. Product: Yellow solid 
(0.130 g, 76%); Mp: Decomp. 339.2 – 342.9 ᵒC. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.01 (d, 
3JHH = 7.6 Hz, 1H, Hi), 7.80 (d, 3JHH = 7.7 Hz 1H, Hf), 7.69 (m, 1H, Hl), 7.41 – 7.28 (m, 3H, Hc, Hd, 
He), 7.20 (t, 3JHH = 7.1 Hz, 1H, Hk), 7.05 (t, 3JHH = 7.6 Hz, 1H, Hj), 4.14 (s, 3H, Hn), 1.77 (s, 15H, 
Hp). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 165.48, 139.85, 137.24, 136.50, 134.64, 130.73, 
129.18, 124.19, 123.22, 123.08, 122.02, 116.79, 110.00, 88.14 (Cq), 31.88 (Cn), 9.87 (Cr). FT-IR 
(ATR) v (cm-1) = 1580 (imine, C=N). Elemental Analysis for C24H26ClIrN2 (570.15 g.mol-1): Found 
(%) C, 49.96; H, 4.66; N, 4.54; Calcd. (%) C, 50.56; H, 4.60; N, 4.91. MS (HR-ESI, m/z): 535.1729 
(100%, [M-Cl]+), requires 535.1725. 
 
N- Propyl Ru benzimidazole complex (61) 
 
2-Phenyl-1-propyl-1H-benzo[d]imidazole 44 (77.2 mg, 0.327 mmol) was dissolved in DCM  
(6 mL). Sodium acetate (32.1 mg, 0.392 mmol) and dichloro(p-cymene)ruthenium(II) dimer 
(100 mg, 0.0.163 mmol) was then added to the solution. Product: Green solid (77.0 mg, 46%). 
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(d, 3JHH = 7.8 Hz, 1H, Hf), 7.63 (d, 3JHH = 7.8 Hz, 1H, Hl), 7.45 – 7.29 (m, 3H, Hc, Hd, He), 7.20 (td, 
3JHH = 7.2, 1.2 Hz, 1H, Hk), 7.12 – 7.03 (td, 3JHH = 7.8, 1.2 Hz, 1H, Hj), 5.86 (d, 3JHH = 5.7 Hz, 1H, 
Hz), 5.67 (d, 3JHH = 5.4 Hz, 1H, Hv), 5.37 (d, 3JHH = 6.0 Hz, 1H, Hy), 5.14 (d, 3JHH = 5.7 Hz, 1H, Hw), 
4.49 (m, 1H, Hn), 4.36 (m, 1H, Hn’), 2.33 – 2.21 (m, 1H, Hr), 2.10 (s, 3H, Hq), 1.98 (m, 2H, Ho), 
1.03 (t, 3JHH = 7.5 Hz, 3H, Hp), 0.90 (d, 3JHH = 6.9 Hz, 3H, Hs), 0.76 (d, 3JHH = 6.9 Hz, 3H, Ht). 
13C{1H}-NMR (101 MHz, CDCl3) δ (ppm): 183.78 (Ch), 157.85 (Cm), 141.46 (Cg), 140.66 (Ci), 
136.08 (Cx), 133.91 (Cu), 128.77 (Ck), 123.95 (Cl), 123.15 (Cd), 123.00 (Ce), 122.49(Cj), 117.20 
(Cf), 109.97 (Cc), 101.52 (Ca), 98.49 (Cb), 89.30 (Cv), 89.10 (Cz), 81.96 (Cw), 81.30 (Cy), 46.22 (Cn), 
31.24 (Cr), 23.07 (Co), 22.59 (Ct), 21.72 (Cs), 18.94 (Cq), 11.24 (Cp). FT-IR (ATR) v (cm-1) = 1577 
(imine, C=N). Elemental Analysis for C26H29ClN2Ru (506.054 g.mol-1): Found (%) C, 60.73; H, 
5.46; N, 5.78; Calcd. (%) C, 61.70; H, 5.20; N, 5.50. MS (HR-ESI, m/z): 471.1377 (100%, [M-Cl]+), 
requires 471.1374.  
 
N- Propyl (chloro-) Ru benzimidazole complex (62) 
 
5-Chloro-2-phenyl-1-propyl-1H-benzo[d]imidazole 45 (93.5 mg, 0.345 mmol) was dissolved in 
DCM (6 mL). Sodium acetate (33.9 mg, 0.414 mmol) and dichloro(p-cymene)ruthenium(II) 
dimer (106 mg, 0.173 mmol) was then added to the solution. Product: Orange solid (77.5 mg, 
42%). Mp: Decomp. 197.7 ᵒC. 1H-NMR (300 MHz, DMSO-d6) δ (ppm): 8.32 (d, 3JHH = 7.2 Hz, 
1H, Hi), 7.88 (d, 4JHH = 1.8 Hz, 1H, Hf), 7.83 (d, 3JHH = 8.7 Hz, 1H, Hl), 7.79 (d, 3JHH = 8.7 Hz, 1H, 
Hc), 7.42 (d, 3JHH = 8.7, 1.8 Hz, 1H, Hd), 7.11 (m, 2H, Hj, Hk), 6.04 (d, 3JHH = 6.0 Hz, 1H, Hv), 5.76 
(d, 3JHH = 6.0 Hz, 1H, Hz), 5.63 (d, 3JHH = 6.0 Hz, 1H, Hy), 5.30 (d, 3JHH = 6.0 Hz, 1H, Hw), 4.62 (t, 
3JHH = 6.9 Hz 2H, Hn), 2.19 – 2.04 (m, 1H, Hr), 1.97 (s, 3H, Hq), 1.80 (m, 2H, Ho), 0.87 (t, 3JHH = 
7.2 Hz, 3H, Hp), 0.78 (d, 3JHH = 6.9 Hz, 3H, Hs), 0.69 (t, 3JHH = 6.9 Hz, 3H, Ht). 13C{1H} NMR (101 
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129.25 (Cd), 129.08 (CAr), 124.33 (Cj), 123.56 (Cl), 122.78 (Ck), 117.01 (Cf), 111.10 (Cc), 102.00 
(CAr), 98.52 (CAr), 89.70 (Cv), 89.10 (Cz), 82.34 (Cw), 81.34 (Cy), 46.47 (Cn), 31.05 (Cr), 23.12 (Co), 
22.72 (Ct), 21.88 (Cs), 19.12 (Cq), 11.31 (Cp). FT-IR (ATR) v (cm-1) = 1578 (imine, C=N). Elemental 
Analysis for C26H28Cl2N2Ru (540.49 g.mol-1): Found (%) C, 57.18; H, 5.32; N, 5.12; Calcd. (%) C, 
57.78; H, 5.22; N, 5.18. MS (HR-ESI, m/z): 541.0596 (50%, [M+H]+), requires 541.0751. 
 
N- Propyl (methyl-) Ru benzimidazole complex (63) 
 
5-Methyl-2-phenyl-1-propyl-1H-benzo[d]imidazole 46 (102 mg, 0.406 mmol) was dissolved in 
DCM (6 mL). Sodium acetate (39.0 mg, 0.487 mmol) and dichloro(p-cymene)ruthenium(II) 
dimer (124 mg, 0.202 mmol) was then added to the solution. Product: Green solid (0.101 g, 
48%). Mp: Decomp. 212.0 – 214.9 ᵒC. 1H-NMR (400 MHz, CDCl3) δ (ppm): 8.33 (d, 3JHH = 7.6 
Hz, 1H, Hi), 7.70 (s, 1H, Hf), 7.62 (d,3 JHH = 8.0 Hz, 1H, Hl), 7.24 (d, 3J = 8.4 Hz, 1H, Hc), 7.22 – 
7.13 (m, 2H, Hd, Hj), 7.06 (t, 3JHH = 7.6 Hz  1H, Hk), 5.86 (d, 3JHH = 5.6 Hz, 1H, Hv), 5.66 (d, 3JHH = 
6.0 Hz, 1H, Hz), 5.39 (d, 3JHH = 6.0 Hz, 1H, Hy), 5.13 (d, 3JHH = 5.6 Hz, 1H, Hw), 4.47 (m, 1H, Hn), 
4.32 (m, 1H, Hn’), 2.59 (s, 3H, CH3), 2.26 (m, 1H, Hr), 2.11 (s, 3H, Hq), 1.96 (m, 2H, Ho), 1.02 (t, 
3JHH = 7.6 Hz, 3H, Hp), 0.89 (d, 3JHH = 7.2 Hz, 3H, Hs), 0.76 (d, 3JHH = 6.8 Hz, 3H, Ht). 13C{1H} NMR 
(101 MHz, CDCl3) δ (ppm): 183.48 (Ch), 157.61 (Cm), 141.71 (Cg), 140.61 (Ci), 134.23 (Ca), 
134.02 (CAr), 132.96 (Cb), 128.64 (Cd), 124.49 (Cj), 123.81 (Cl), 122.47 (Ck), 117.04 (Cf), 109.60 
(Cc), 101.70 (CAr), 98.05 (CAr), 89.46 (Cz), 88.90 (Cv), 82.15 (Cy), 81.11 (Cw), 46.23 (Cn), 30.88 
(Cr), 29.70 (Co), 22.58 (Cs), 21.90 (CH3), 21.77 (Ct), 18.98 (Cq), 11.26 Cp). Elemental Analysis for 
C27H31ClN2Ru (520.08 g.mol-1): Found (%) C, 62.01; H, 6.04; N, 5.37; Calcd. (%) C, 62.36; H, 
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N- Propyl (trifluoromethane-) Ru benzimidazole complex (64) 
 
2-Phenyl-1-propyl-5-(trifluoromethyl)-1H-benzo[d]imidazole 50 (95.0 mg, 0.312 mmol) was 
dissolved in DCM (6 mL). Sodium acetate (38.1 mg, 0.464 mmol) and dichloro(p-
cymene)ruthenium(II) dimer (95.6 mg, 0.156 mmol) was then added to the solution. Product: 
Green solid (71.2 mg, 40%). Mp: Decomp. 214.4 – 218.7 ᵒC. 1H-NMR (400 MHz, CDCl3) δ 
(ppm): 8.36 (m, 1H, Hi), 8.19 (s, 1H, Hf), 7.63 (m, 1H, Hl), 7.55 (dd, 3JHH = 8.8, 1.2 Hz, 1H, Hd), 
7.44 (d, 3JHH = 8.4 Hz, 1H, Hc), 7.23 (td, 3JHH = 7.6, 1.2 Hz  1H, Hj), 7.09 (td, 3JHH = 7.2, 1.2 Hz, 1H, 
Hk), 5.86 (dd, 3JHH = 6.0, 0.8 Hz, 1H, Hv), 5.73 (dd, 3JHH = 6.0, 1.2 Hz, 1H, Hz), 5.33 (dd, 3JHH = 6.0, 
1.2 Hz, 1H, Hy), 5.12 (dd, 3JHH = 6.0, 1.2 Hz, 1H, Hw), 4.50 – 4.26 (m, 2H, Hn, Hn’), 2.31 (m, 1H, 
Hr), 2.10 (s, 3H, Hq), 1.96 (m, 2H, Ho), 1.01 (t, 3JHH = 7.6 Hz, 3H, Hp), 0.95 (d, 3JHH = 7.2 Hz, 3H, 
Hs), 0.79 (d, 3JHH = 7.2 Hz, 3H, Ht). 13C{1H} NMR (101 MHz, CDCl3) δ (ppm): 184.85 (CAr), 160.04 
(CAr), 141.12 (CAr), 140.96 (Ci), 138.27 (Ca), 133.37 (Cb), 129.52 (Cj), 126.18, 125.95, 125.64, 
124.59 (Cl), 122.87 (Ck), 120.13 (Cd), 114.62 (Cf), 110.75 (Cc), 101.45 (Cu), 100.12 (Cx), 89.65 
(Cz), 89.35 (Cv), 82.03 (Cy), 81.40 (Cw), 46.65 (Cn), 31.10 (Cr), 23.14 (Co), 22.61 (Cs), 21.94 (Ct), 
19.06 (Cq), 11.30 Cp). FT-IR (ATR) v (cm-1) = 1580 (imine, C=N). Elemental Analysis for 
C27H28ClF3N2Ru (574.05 g.mol-1): Found (%) C, 56.32; H, 5.15; N, 4.94; Calcd. (%) C, 56.49; H, 
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N- Propyl Ir benzimidazole complex (65) 
 
2-Phenyl-1-propyl-1H-benzo[d]imidazole 44 (59.3 mg, 0.251 mmol) was dissolved in DCM  
(6 mL). Sodium acetate (24.7 mg, 0.301 mmol) and pentamethylcyclopentadienyliridium(III) 
chloride dimer (100 mg, 0.126 mmol) was then added to the solution. Product: Yellow solid 
(76.0 mg, 51%). Mp: 312.2 – 315.9 °C. 1H-NMR (300 MHz, CDCl3) δ (ppm): 8.00 (dd, 3JHH = 7.5, 
0.9 Hz, 1H, Hi), 7.71 – 7.62 (m, 2H, Hf, Hl), 7.40 – 7.27 (m, 3H, Hc, Hd, He), 7.19 (td, 3JHH = 7.5, 
1.2 Hz, 1H, Hk), 7.06 (td, 3JHH = 7.5, 1.2 Hz, 1H, Hj), 4.60 – 4.35 (m, 2H, Hn, Hn’), 2.14 – 1.95 (m, 
2H, Ho), 1.76 (s, 15H, Hr), 1.09 (t, 3JHH = 7.5 Hz, 3H, Hp). 13C{1H}-NMR (101 MHz, CDCl3) δ (ppm): 
165.80 (Ch), 161.91 (Cm), 139.78 (Cg), 137.36 (Ci), 136.25(Ca), 134.26 Cb), 130.63 (Ck), 123.76 
(Cf), 123.17 (Ce), 123.04 (Cd), 122.04 (Cj), 116.89 (Cl), 110.19 (Cc), 46.36 (Cn), 23.37 (Co), 11.47 
(Cp), 9.84 (Cr). FT-IR (ATR) v (cm-1) = 1578 (imine, C=N). Elemental Analysis for C26H30ClIrN2 
(598.212 g.mol-1): Found (%) C, 51.73; H, 4.51; N, 4.21; Calcd. (%) C, 52.20; H, 5.05; N, 4.73. 
MS (HR-ESI, m/z): 563.2047 (100%, [M-Cl]+), requires 563.2038.  
 
N- Propyl (chloro-) Ir benzimidazole complex (66) 
 
5-Chloro-2-phenyl-1-propyl-1H-benzo[d]imidazole 45 (93.7 mg, 0.346 mmol) was dissolved in 
DCM (6 mL). Sodium acetate (36.5 mg, 0.445 mmol) and 
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added to the solution. Product: Yellow solid (0.198 g, 90%). Mp: 304.2 – 305.3 °C. 1H-NMR 
(600 MHz, CDCl3) δ (ppm): 8.00 (dd, 3JHH = 7.8, 1.2 Hz, 1H, Hi), 7.67 – 7.65 (m, 1H, Hf), 7.63 (dd, 
3JHH = 7.8, 0.6 Hz, 1H, Hl), 7.28 – 7.25 (m, 1H, Hc), 7.24 (m, 1H, Hd), 7.20 (td, 3JHH = 7.8, 1.2 Hz, 
1H, Hj), 7.10 – 7.03 (td, 3JHH = 7.8, 1.2 Hz, 1H, Hk), 4.48 – 4.40 (m, 1H, Hn), 4.36 (m, 1H, Hn’), 
2.06 – 1.97 (m, 2H, Ho), 1.76 (s, 15H, Hr), 1.06 (t, 3JHH = 7.8 Hz, 3H, Hp). 13C{1H} NMR (151 MHz, 
CDCl3) δ (ppm): 166.28 (Ch), 163.08 (Cm), 140.53 (Cg), 137.39 (Ci), 134.92 (Ca), 133.71 Cb), 
131.01 (Cj), 129.08 (Ce), 124.01 (Cl), 123.41 (Cd), 122.21 (Ck), 116.70 (Cf), 111.16 (Cc), 88.30 
(Cq), 46.53 (Cn), 23.30 (Co), 11.42 (Cp), 9.84 (Cr). FT-IR (ATR) v (cm-1) = 1579 (imine, C=N). 
Elemental Analysis for C27H32Cl2IrN2 · H2O: Found (%) C, 48.21; H, 4.58; N, 4.41; Calcd. (%) C, 
48.71; H, 5.15; N, 4.21. MS (HR-ESI, m/z): 670.1050 (10%, [M-Na]+), requires 670.1470. 
 
N- Propyl (methyl-) Ir benzimidazole complex (67) 
 
5-Methyl-2-phenyl-1-propyl-1H-benzo[d]imidazole 46 (62.8 mg, 0.251 mmol) was dissolved 
in DCM (6 mL). Sodium acetate (26.8 mg, 0.327 mmol) and 
pentamethylcyclopentadienyliridium(III) chloride dimer (100 mg, 0.126 mmol) was then 
added to the solution. Product: Yellow solid (0.126 g, 80%). Mp: 280.1 – 281.5 °C. 1H-NMR 
(600 MHz, CDCl3) δ (ppm): 7.99 (dd, 3JHH = 7.8, 1.2 Hz, 1H, Hi), 7.64 (d, 3JHH = 7.8 Hz, 1H, Hl), 
7.48 (s, 1H, Hf), 7.24 (d, 3JHH = 8.4 Hz, 1H, Hc), 7.17 (td, 3JHH = 7.2, 0.6 Hz, 1H, Hj), 7.14 – 7.10 
(dd, , 3JHH = 7.8, 1.2 Hz, 1H, Hd), 7.08 – 7.01 (td, 3JHH = 7.8, 1.2 Hz, 1H, Hk), 4.50 (m, 1H, Hn), 
4.40 (m, 1H, Hn’), 2.53 (s, 3H, Ar-CH3), 2.04 (m, 2H, Ho), 1.76 (s, 15H, Hr), 1.07 (t, 3JHH = 7.8 Hz, 
3H, Hp). 13C{1H} NMR (151 MHz, CDCl3) δ (ppm): 165.50 (Ch), 161.65 (Cm), 140.01 (Cg), 137.29 
(Ci), 134.37 (Ca), 132.96 Cb), 130.48 (Cj), 124.43 (Cd), 123.61 (Cl), 122.02 (Ck), 116.84 (Cf), 
109.82 (Cc), 88.07 (Cq), 46.36 (Cn), 23.38 (Co), 21.77 (Ar-CH3), 11.47 (Cp), 9.85 (Cr). FT-IR (ATR) 
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C, 53.29; H, 5.31; N, 4.68; Calcd. (%) C, 53.61; H, 5.62; N, 4.47. MS (HR-ESI, m/z): 577.2216 
(100%, [M-Cl-CH3]+), requires 577.2195. 
 
N- Propyl (trifluoromethane-) Ir benzimidazole complex (68) 
 
2-Phenyl-1-propyl-5-(trifluoromethyl)-1H-benzo[d]imidazole 50 (76.5 mg, 0.251 mmol) was 
dissolved in DCM (6 mL). Sodium acetate (25.3 mg, 0.308 mmol) and 
pentamethylcyclopentadienyliridium(III) chloride dimer (100 mg, 0.126 mmol) was then 
added to the solution. Product: Yellow solid (0.112 g, 67%). Mp: 309.4 – 310.2 °C. 1H-NMR 
(300 MHz, CDCl3) δ (ppm): 8.03 (dd, 3JHH = 7.8, 0.9 Hz, 1H, Hi), 7.99 (s, 1H, Hf), 7.65 (dd, 3JHH = 
8.1, 1.2 Hz, 1H, Hl), 7.50 (dd, 3JHH = 8.7, 1.2 Hz, 1H, Hd), 7.43 (d, 3JHH = 8.7 Hz, 1H, Hc), 7.23 (td, 
3JHH = 7.5, 1.2 Hz, 1H, Hk), 7.13 – 7.05 (td, 3JHH = 7.8, 1.2 Hz, 1H, Hj), 4.40 (m, 2H, Hn), 2.14 – 
1.91 (m, 2H, Ho), 1.77 (s, 15H, Hr), 1.06 (t, 3JHH = 7.5 Hz, 3H, Hp). 13C{1H} NMR (101 MHz, CDCl3) 
δ (ppm): 166.63 (Cg), 164.07 (Cm), 139.36 (Cb), 138.24 (Ca), 137.37(Ci), 133.51 Ch), 131.27 (Ck), 
126.13 (CAr), 125.81 (CAr), 125.49 (Ce), 124.33 (Cl), 122.30 (Cj), 119.98 (Cd), 114.44 (Cf), 110.87 
(Cc), 88.45 (Cq), 46.59 (Cn), 23.28 (Co), 11.37 (Cp), 9.79 (Cr). FT-IR (ATR) v (cm-1) = 1586 (imine, 
C=N). Elemental Analysis for C28H32Cl2F3IrN2 (681.24 g.mol-1): Found (%) C, 49.05; H, 4.48; N, 
4.26; Calcd. (%) C, 49.37; H, 4.73; N, 4.11. MS (HR-ESI, m/z): 707.2049 (45%, [M-
Cl+IsoProp+H]+), requires 707.2800. 
 
5.4. Single-crystal X-ray crystallography 
Suitable single crystals of iridium complexes 67 and 68 were grown from a mixture of 
chloroform and EtOAc which were allowed to evaporate over 3 – 5 days. Single-crystal X-ray 
data were collected on a Bruker KAPPA APEX II DUO diffractometer using graphite-
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K. Temperature was controlled by an Oxford Cryostream cooling system (Oxford Cryostat). 
Cell refinement and data reduction were performed using the program SAINT.9 The data were 
scaled and absorption correction performed using SADABS.10 The structure was solved by 
direct methods using SHELXS-97 and refined by full-matrix least-squares methods based on F 
using SHELXL-2014 and using the graphics interface program X-Seed.10, 11 The programs X-
Seed and POV-Ray were both used to prepare molecular graphic images.  
 
5.5. Pharmacological activity and solubility testing protocols 
5.5.1. In vitro antiplasmodial activity 
The test samples were tested in triplicate on one or two separate occasions against 
chloroquine-sensitive (NF54) strain of P. falciparum. Continuous in vitro cultures of asexual 
erythrocyte stages of P. falciparum were maintained using a modified method of Trager and 
Jensen.12 Quantitative assessment of antiplasmodial activity in vitro was determined via the 
parasite lactate dehydrogenase assay using a modified method described by Makler.13 The 
test samples were prepared to a 20 mg/mL stock solution in 100% DMSO. Samples were 
tested as a suspension if not completely dissolved. Stock solutions were stored at -20 °C. 
Further dilutions were prepared on the day of the experiment. Chloroquine (CQ) was used as 
the reference drug in all experiments. A full dose-response was performed for all compounds 
to determine the concentration inhibiting 50% of parasite growth (IC50 value). Test samples 
were tested at a starting concentration of 100 μg/mL, which was then serially diluted 2-fold 
in complete medium to give 10 concentrations; with the lowest concentration being 0.2 
μg/mL. The same dilution technique was used for all samples. The IC50 values were obtained 
using a non-linear dose response curve fitting analysis via Graph Pad Prism v.4.0 software. 
 
5.5.2. Cytotoxicity  
Compounds were tested for in vitro cytotoxicity against the mammalian cell-line, Chinese 
Hamster Ovarian (CHO), using the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) assay. The MTT assay is used as a colorimetric assay for 
cellular growth and survival, and compares well with other available assays.14, 15 The test 
samples were tested in triplicate on one occasion. The test samples were prepared to a 2 
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completely dissolved. Test compounds were stored at -20 °C until use. Emetine was used as 
the reference drug in all experiments. The initial concentration of emetine was 100 μg/mL, 
which was serially diluted in complete medium with 10-fold dilutions to give 6 concentrations, 
the lowest being 0.001 μg/mL. The same dilution technique was applied to all the test 
samples. The highest concentration of solvent to which the cells were exposed had no 
measurable effect on cell viability. IC50 values were obtained from full dose-response curves 
using a non-linear dose-response curve fitting analysis via GraphPad Prism V.4 software. 
 
5.5.3. Beta-hematin inhibition assay 
The β-haematin formation assay was modified from the method described by Sandlin et al.16 The 
stock solutions of the compounds tested were prepared at 10 mM in DMSO. The compounds were 
delivered to a 96-well plate in triplicate and were tested at a starting concentration of 500 μM, 
where the lowest drug concentration was 5 μM. The stock solution was serially diluted to give 12 
concentrations in the 96-well flat-bottom assay plate. NP-40 detergent was then added to mediate 
the formation of β-haematin (30.55 μM, final concentration). A 25 mM stock solution of haematin 
was prepared by dissolving hemin (16.3 mg) in dimethyl sulfoxide (1 mL). A 177.76 μL aliquot of 
haematin stock was suspended in 20 mL of a 2 M acetate buffer, pH 4.7. The haematin suspension 
was then added to the plate to give a final haematin concentration of 100 μM. The plate was then 
incubated for 16 h at 37 °C. The compounds were analysed using the pyridineferrochrome method 
developed by Ncokazi and Egan.17 32 μL of a solution of 50% pyridine, 20% acetone, 20% water, 
and 10% 2 M HEPES buffer (pH 7.4) was added to each well. To this, 60 μL acetone was then added 
to each well and mixed. The UV-Vis absorbance of the resulting complex was measured at 405 nm 
on a SpectraMax 340PC plate reader. The IC50 values were obtained using a non-linear dose-
response curve fitting analysis via Graph Pad Prism v.5.0 software.18 
 
5.5.4. Kinetic solubility assay 
The kinetic solubility assay was performed using a miniaturised shake flask method.19 10 mM 
stock solutions of each of the test compounds were used to prepare calibration standards (10 
– 220 µM) in DMSO, and to spike (1:50) duplicate aqueous samples of phosphate buffered 
saline (pH 6.5), 0.01 M HCl (pH 2) and FaSSIF (simulating fasting state biorelevant media, pH 
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were filtered and analysed by means of HPLC-DAD (Agilent 1200 Rapid Resolution HPLC with 
a diode array detector). Best fit calibration curves were constructed using the calibration 
standards, which were used to determine the aqueous samples’ solubility.  
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